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1. Summary 
 
Biologically functional molecules with desired properties have proven to be invaluable 
tools for investigating biological systems. Moreover, the identification of those 
functional molecules is a crucial task in modern drug discovery. These goals can be 
achieved by two major approaches: “screening” and “selection”. 
 
Chapter 2 introduces one attractive method for “screening” to identify small molecule 
inhibitors of a given protein target from a small organic chemical library. 
The reverse transcriptase (RT) plays a crucial role in the early steps of the life cycle of 
HIV. Therefore HIV-1 RT serves as one of the major drug targets in anti-HIV therapy. 
Although current therapy for HIV-infected patients involving a combination of three or 
more of the following drugs: RT inhibitors, protease inhibitors, and/or viral entry 
inhibitors, has been highly successful, its long-term efficacy is severely limited by the 
emergence of drug-resistant variants of HIV. One way to address this problem is to 
identify new type of drugs with different inhibitory mechanisms to combat HIV. Thus, 
HIV-1 RT served a valuable target in the herein depicted screening approach. 
Protein-dependent alosteric ribozymes (or reporter ribozymes) are powerful tools which 
are able to sense molecular interactions, e.g. protein-protein, protein-nucleic acid, or 
protein-metabolite interactions in real-time. The expedience of this assay format makes 
it applicable to and suitable for high throughput screening in order to search for new 
molecules which disrupt such interactions. Reporter ribozyme FK-1 is a rationally 
engineered hammerhead ribozyme in a fusion construct with anti-RT aptamer, which 
can detect the presence of HIV-1 RT selectively in a domain specific manner. Thus, 
FK-1 enables to identify compounds via FRET-based fluorescence readout, which 
compete for the binding to HIV-1 RT with aptamer sequences inserted in the ribozyme 
construct.  
Through screening of 2500 small molecules using the reporter ribozyme (FK-1)-based 
assay, three potential inhibitors (28F6, 3E4 and 2E10) of HIV-1 RT were identified 
with in vitro inhibitory concentration that gave half-maximal activity (IC50) of 2-5 µM 
on DNA-dependent DNA polymerase activity. The three compounds were 
re-synthesized and further investigated to evaluate their selectivity and to elucidate the 
inhibitory mechanism. The selectivity was determined by testing inhibitory effect of the 
compound on other RTs (AMV and MMLV) and DNA polymerases from both 
prokaryotic (Klenow Fragment) and eukaryotic (human DNA polymerase β) sources. 
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Among the three compounds, 3E4 showed not only the lowest IC50 value for HIV-1 RT 
(2.1 µM) but the highest discrimination from all the other RT and DNA polymerases 
(10~50 fold) in terms of DNA-dependent DNA polymerase activity. The selectivity of 
3E4 with the cognate RT from HIV-2 was a factor of approximately 4.5. In addition, the 
interaction between 3E4 and HIV-1 RT was observed by a surface plasmon 
resonance-based biosensor. 
Moreover, a cell-based assay for phenotypic analysis of sensitivity of HIV-1 to the three 
inhibitors using a self-inactivating virus vector system demonstrated that 3E4 inhibited 
marker gene expression in concentration dependent manner with a IC50 value of 5.3 µM. 
The effect of 3E4 was further confirmed with the similar reduction of HIV-1 replication 
and infectivity in vivo using a HIV wild type strain. 
In summary, the data strongly indicates that the small molecule 3E4 identified by 
reporter ribozyme-based screening is a highly specific and cellular active HIV-1 RT 
inhibitor, which has significant potentiality as novel type of anti-HIV drug. Furthermore, 
the approach using a reporter ribozyme assay could be broadly applicable as screening 
format. 
 
In chapter 3, the challenge of a “selection” approach has been performed with the aim to 
evolve functional proteins from a random sequence protein library. 
Prior to the selection, the protein library consisting of a random 88 amino acid sequence 
was constructed by short cassettes ligations to avoid stop codons and frameshift 
mutations. The design of secondary structural patterns like α-helix and β-strand was 
introduced into the random regions. 
A display technology called mRNA-display was exploited to prepare protein library, 
where each protein sequence was covalently linked through its carboxy terminus to the 
3’ end of its encoding mRNA. Starting with a library that contained 1 × 1011 - 5 × 1012 
different proteins, three in vitro selections were attempted to identify protein binders to 
small molecules such as cibacron blue 3GA and coenzymes (NADP and CoA). The 
selection against cibacron blue 3GA yielded enriched fractions retaining on the column 
matrix after the ninth cycle. These sequences could not be eluted by NAD, the structural 
analogue of cibacron blue 3GA, even at higher concentration. The small fractions eluted 
with NAD from this column have been cloned and sequenced, resulting in unexpectedly 
high frequency of frameshifts and internal stop codons. The alignment of full length 
intact sequences exhibited no conserved motif but the most appearance of αβαβ type of 
cassette. The remaining column fractions were able to be eluted with free cibacron blue 
3GA, implying those sequences might be specific cibacron blue binders. Other 
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selections against both NADP and CoA did not enrich protein binders. 
The observed problems through the experiment concerning poor solubility and fold 
instability of mRNA-displayed proteins should be improved for further investigations. 
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2. Reporter Ribozyme toward Screening of Small Molecule 
Inhibitors of Human Immunodeficiency Virus Type-1 Reverse 
Transcriptase with anti-Viral Activity 
 
 
2.1. Introduction 
 
2.1.1. High Throughput Screening towards Drug Discovery 
 
Efficient identification of biologically active molecules, ranging from small molecules 
to macromolecules such as nucleic acids and proteins, can greatly enhance the 
efficiency to explore biological systems in genomics and proteomics as well as the 
development of desired therapeutic agents in drug discovery. To pursue this basic goal, 
a number of innovative approaches have been evolved. Additionally, these technologies 
are fuelled by an expanded number of targets derived by molecular biology and an 
increased number of compounds generated by combinatorial chemistry. Since Szostak[1] 
and Gold[2] have developed a method to chemically synthesize a large pool of random 
nucleotide sequences with a complexity of approximately 1015 to isolate molecules with 
highly specific ligand-binding properties, the concepts of combinatorial chemistry have 
been extended to biological macromolecules including nucleic acids and proteins (see 
chapter 3). All the current advances in chemistry and biology principally increase the 
capability for researchers to obtain any types of molecules which fulfill desired 
properties through proper designing of the selection strategy or assay manipulations. 
One dominant approach to identify interesting molecules within large combinatorial 
libraries is “screening”, pioneered by the idea of systematically searching for drugs 
advocated by Paul Ehrlich.[3] The underlying concept of this technique is described in 
Figure 1A. In general, this strategy requires individual assessment of all members from 
the library in a biological assay and functional detection of hit compounds against a 
large background. Pharmaceutical industries exhaustively exploit the great advantage of 
high throughput screening (HTS) to identify reasonable starting points of small 
molecules (lead compounds) for further elaboration towards effective drugs. A series of 
improvements in the areas of automation and miniaturization have largely accomplished 
to screen compound libraries with the number of 104-105 entities per day.[4] Not only to 
screen small molecule libraries, HTS technologies can streamline the rapid 
identification of interesting protein variants.[5] 
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In contrast, another fascinating approach called “selection” has been developed by 
mimicking the culling process associated with true Darwinian evolution (see chapter 3 
for a detailed discussion). Initially this approach has been applied for isolation of 
nucleic acids with high affinity and specificity, alternatively referred as SELEX 
(systematic evolution of ligands by exponential enrichment).[2, 6-9] The strategy is 
nowadays routinely utilized for combinatorial libraries of nucleic acids and proteins or 
peptides. As described in Figure 1B, selection strategies exploit conditions favoring the 
exclusive survival of desired variants, eliminating negative samples, thereby lead to 
isolate only the characteristic product. Darwinian evolution is able to be achieved via 
consecutive rounds of selection and amplification. The major advantage of selection is 
that more library members can be analyzed simultaneously and homogeneously. 
Usually protein libraries with the diversity up to 1010-13 and nucleic acids libraries up to 
1015 are accessible within a single experiment.[10] 
 
 
 
Figure 1. Different search modes for finding nectar-producing flowers (marked with +). Random 
screening (A): The bumblebee must check each flower individually to differentiate producers from 
the large number of non-producers (marked with -). Selection (B): The bee only encounters the 
desired flowers because nectar production was a prerequisite for plant growth in this case. The figure 
is reproduced from Taylor et al..[10] 
 
As mentioned above, any drug discovery procedure requires that in an individual assay 
the difference between a “positive” and “negative” is recorded in an output signal in a 
reliable fashion (Figure 1). To identify appropriate ligands for a protein target, the 
desired protein-small molecule interaction has to be detected. A number of biochemical 
assays feasible for HTS to measure molecular interactions have been established and are 
listed in Table 1. 
The choice of an assay for screening needs to be guided by the goal of the screening 
endeavor and the practical constraints for the target of interest. These constrains include 
amount of proteins available, substrate requirements for the enzyme and capacity for 
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follow-up chemistry and biology after the screen is completed. 
Drug screening assays can be divided into two types: those that use labeled proteins 
and/or ligands and those that are label-free (a label is a reporter moiety e.g. a fluorescent 
or radioactive group).[11] Although labels make protein–ligand interactions easier to 
observe, they can also be difficult to introduce, which increases the time and expense 
associated with the preparation and/or measurement. Additionally, introductions of 
labels can perturb native properties of the substrates which hamper the detection of 
meaningful interactions. Label-free detection methods are therefore preferred because 
they obviate the disadvantages described above. However, such measurements can be 
more difficult to perform: without a label, a larger amount of both protein and 
compound have to be produced, and often the analysis in label-free measurements is 
slower. 
Although a variety of methods to detect a molecular-binding event are available for 
HTS formats (Table 1), a generic method which can meet all desired conditions is not 
yet available. Each has advantages and disadvantages. The following points should be 
considered for preferable screening assays: 1) homogeneous formats, 2) no labeling on 
small molecules and proteins, 3) in situ production of the proteins to skip purifications 
in large parallel quantities, and 4) the possibility for automation without modifications 
to each system.[11] 
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Method Label Throughput Phase  Protein 
amount 
Description 
Fluorescence 
polarization 
Yes High 
 
Solution 
 
High 
 
Measures the change in tumbling rate for a compound 
when it is bound to a protein using loss-of-polarization 
of incident light. 
Fluorescence 
perturbation 
No Low Solution 
 
High 
 
Measures the change in fluorescence (usually of  
tryptophan residues) on a protein caused by proximity 
of a bound compound. 
Fluorescence 
correlation 
Spectroscopy 
Yes High Solution 
 
Medium 
 
Measures the correlated changes in fluorescence 
properties that occur when a labeled compound is 
bound to a labeled protein. 
Radioligand 
binding assay 
Yes High Solid 
 
High 
 
Measures retention of a compound on a surface 
holding a protein. Detection is by means of a 
radioactive isotope that is incorporated into the 
compound. 
Nuclear magnetic 
resonance 
No Low Solution 
 
High 
 
Measures changes in the nuclear spin of protons on a 
protein that occur when a compound is bound nearby.
Mass 
spectrometry 
No Medium 
 
Solution 
 
Medium 
 
Measures the change in molecular weight observable 
in a mass spectrometer when a compound is bound to 
a protein. 
Surface plasmon 
resonance 
No Low/Medium 
 
Solid 
 
High 
 
Measures the change in refractivity of a metal surface 
when a compound binds to a protein that is 
immobilized on that surface. 
Isothermal titration 
calorimetry 
No Low Solution 
 
High 
 
Measures the amount of heat produced when a 
compound binds to a protein. 
Differential 
scanning 
calorimetry 
No Low Solution 
 
High 
 
An alternative method of measuring the heat released 
when a compound binds to a protein. 
Small-molecule 
microarray 
Yes High Solid 
 
Medium 
 
Compounds are immobilized on a surface. A protein is 
incubated with the surface and localizes to where the 
protein-interacting compounds are bound. 
Protein microarray Yes High Solid 
 
Low/none Proteins are immobilized on a surface and a labeled 
compound is incubated with the surface. The 
compound localizes to where the compound-binding 
proteins are bound. 
Three-hybrid 
system 
Yes High In cells None 
 
A target is covalently linked to an adaptor moiety that 
interacts with a DNA-binding protein. If the test 
compound can bind to a test protein that is fused to a 
DNA activation domain, transcription of a reporter 
gene is initiated.  
 
Table 1. Methods for measuring the affinity of small molecules to proteins. The table is reproduced 
from Stockwell et al..[11] All the references for every method are listed there. 
 
 
2.1.2. Allosteric Ribozyme Sensing Molecular Interactions 
 
RNA is a highly sophisticated biomolecule that can serve for sequence specific 
recognition, fold into three dimensionally structures, catalyze chemical reactions, and 
control gene expression.[12-15] This multifunctionality, additionally driven by the simple 
production via both enzymatic and chemical synthesis, has been extensively applied to 
design and engineer a diverse range of novel biological RNA tools.[16, 17] 
Ribozymes are naturally occurring RNAs that catalyze phosphordiester 
cleaving/forming or peptide-bond-forming reactions.[14, 18, 19] So far, nine classes of 
natural ribozymes have been discovered. Among them, the hammerhead ribozyme has 
been well characterized for its functional properties[20-23] as well as for its 
three-dimensional structure.[24-26] The secondary structure of a natural hammerhead 
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ribozyme is shown in Figure 2. 
 
 
Figure 2. Secondary and tertiary structure of a hammerhead ribozyme. Universally conserved bases 
are shown as letters. Dashed lines and dots represent non–Watson-Crick interactions between bases; 
solid lines represent Watson-Crick base pairs. The site of cleavage is marked with an arrow. The 
figure is reproduced from Doherty et al..[18] 
 
Such detailed structural information provides a solid conceptual foundation for 
manipulating the hammerhead ribozyme and an invaluable resource for engineering 
ribozymes that function by various mechanisms of allosteric regulation. Allosteric 
ribozymes usually carry an effector-binding site (binding domain) that is separate from 
its active site (reporter domain) (Figure 3). Ligand binding to this allosteric site induces 
a conformational change in the adjoining enzyme domain that enhances or inhibits 
catalytic reaction. Because of its multifaceted functions, allosteric ribozymes can adopt 
versatile ligands as effectors to modulate catalytic event. Allosteric ribozymes 
dependent on metal ion,[27] nucleic acids,[28] small molecules,[29-31] and proteins[32-35] 
have been generated. Concerning the effector-binding site, aptamer sequences, ssRNA 
owing ligand specificity and affinity, can be generally engineered to incorporate into the 
ribozyme context. Aptamers commonly demonstrate adaptive binding in which a 
conformational change in the aptamer accompanies ligand interaction,[36] transmitting 
dynamic conformational change to catalytically active site. Currently two strategies are 
applied to develop such allosteric ribozymes: rational design or combinatorial 
techniques (selection). 
Intriguingly, after considerable endeavors for engineering allosteric ribozymes have 
been spent, the concept of allosteric ribozymes was recently discovered in natural 
systems, so-called “riboswitches”.[37] Bacteria exploit non-coding regions of mRNA to 
control gene expression. Riboswitches can capture the target metabolite and undergo 
allosteric change in the structure. In the case of GlcN6P riboswitch, the glmS ribozyme 
can cleave off a portion of the 5’ UTR of the glmS gene, which encodes for 
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glutamine-fructose-6-phosphate amidotransferase, upon binding of 
glucosamine-6-phosphate (GlcN6P), the product of the amidotransferase.[38] The 
feedback mechanism leads to reduced expression of the GlmS protein, serving as a 
novel metabolite-responsive ribozyme. 
Recently, new aspects of allosteric ribozymes are emerging as novel biologically 
functional tools for various applications. Two years before the discovery of the GlcN6P 
riboswitch Thompson et al. have created an artificial gene regulatory switch in which a 
Group I ribozyme dependent upon theophyline was conjugated to thymidylate synthase 
gene.[39] Exogeneously added theophyline was able to control in vivo splicing in a target 
specific manner. The most straightforward application of allosteric ribozymes is their 
engineering to biosensors due to the dynamic conversion of binding event into catalytic 
reaction, which is easily detectable. In an approach to prepare a prototype biosensor 
array, seven different allosteric ribozymes, each engineered from hammerhead 
ribozymes to be triggered by the corresponding ligand (such as metal ions, cofactors), 
were immobilized onto gold surface, that report the presence and concentrations of 
targets even in complex chemical or biological mixtures.[40] Another example using an 
allostericly controlled Class I ligase for diagnostic purpose have been reported.[41] The 
authors constructed a “half-ribozyme” for ultra-sensitive detection of virus RNA from 
hepatitis C virus (HCV) in zeptomole concentration. This system has been investigated 
for its compatibility with an immunodiagnostic platform with equivalent sensitivity.[42] 
Allosteric ribozymes can even monitor post-translational modifications of proteins in 
cell lysate, through engineering of the ribozymes to be activated specifically upon 
binding to either the unphosphorylated form of the protein or the phosphorylated 
form.[43] More lately, highly sophisticated design of allosteric ribozymes lead to the 
construction of  computational systems, including AND, OR, YES and NOT Boolen 
logic functions.[44] 
As discussed above, the concept of allosteric ribozymes is highly compatible to high 
throughput screening (HTS) assays. Recent studies report the elaborate design of assay 
setups that make it possible to identify protein inhibitors via allosteric ribozyme-based 
signaling. Srinivasan used a ADP responsive allosteric ribozyme (“RiboReporter”) to 
monitor the enzymatic reaction of a protein kinase.[45] Thereby, new protein kinase 
inhibitors or compounds that modulate the activity of any enzyme which is involved in 
ADP metabolism can in principle be identified. The authors demonstrated that 
RiboReporter was able to rediscover a known protein kinase inhibitor through screening. 
Another approach of HTS of protein inhibitors is to convert the inherent properties of an 
aptamer, such as specific binding, domain recognition and functional inactivation, into 
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small molecules using competitive assay formats.[46] 
 
Figure 3 describes the concept of competitive screening assays via allosteric ribozymes 
(reporter ribozymes). Hartig et al. applied a human immunodeficiency virus type-1 
(HIV-1) Rev dependent hammerhead reporter ribozyme to screen an 96-membered 
antibiotics library for the molecules that can disrupt the interaction between Rev and its 
cognate aptamer.[46] They also prepared a conversely regulated reporter ribozyme 
through incorporating a Rev binding element (RBE) into an effector binding site. Both 
reporter ribozymes were able to identify the same inhibitor Coumemycine A1, which 
efficiently suppressed HIV-1 replication in vivo as well. 
Besides the topics discussed above, reporter ribozyme-based assays provide several 
additional advantages compared to conventional screening approaches: real-time signal 
detection, no requirements of labeling of proteins and their possible interaction partners, 
homogeneous performance, and target-independent assay development.[47-49] As 
discussed in §2.1.1, screening often requires to setup independent technology platforms 
for every distinct purpose. Based on the diverse acceptability for effector molecules and 
the facility of engineering both rationally and combinatorially, allosteric ribozymes hold 
the potential to establish general HTS assay formats with fewer obstacles and force to 
obtain highly specific inhibitors. Lately, the rational design of hairpin allosteric 
ribozymes to generate sensors for detecting microRNA[50] and metabolite[51] has been 
reported. These concepts would also increase the flexibility of designing for the 
ribozyme-based assay formats. 
 
2. Reporter Ribozyme toward Screening of Small Molecule Inhibitors of Human Immunodeficiency Virus 
Type-1 Reverse Transcriptase with anti-Viral Activity 
11 
 
 
 
Figure 3 Schematic of an allosteric ribozyme and reporter ribozyme. The allostric ribozyme is 
illustrated by the combination of effector binding domain (B; orange) and reporter domain (R; blue). 
In the upper equation, the ligand (L; gray) addition induces a conformational change of the reporter 
domain, resulting in the inhibition of substrate (black line) cleavage. The lower equation represents a 
reporter ribozyme used in a competitive assay. The small molecule (SM; pink), which interferes with 
the interaction of ligand-ribozyme, restores the active conformation of ribozyme. Then, the substrate 
cleavage can be observed. 
 
 
2.1.3. HIV and AIDS 
 
Since the isolation of human immunodeficiency virus type-1 (HIV-1),[52, 53] efforts and 
studies of biology, biochemistry, and structural biology have been focused to control the 
AIDS (acquired immunodeficiency syndrome) epidemic. Modern drug discovery and 
development have markedly reduced the morbidity and mortality due to infection with 
HIV-1 in the past few years. HIV infection is characterized by a prolonged 
asymptomatic period of years to decades, which is followed by the fatal illness of AIDS 
including wasting, neurological impairment, and opportunistic infections and 
malignancies. 
HIV is a member of the lentivirus genus and classified into retroviruses that possess 
complex genomes and exhibit cone-shaped capsid core particles. HIV’s genome is 
encoded by RNA, which is reverse-transcribed to viral DNA by the viral reverse 
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transcriptase (RT) upon entering a new host cell. The virus consists of 15 proteins and 
9.7 kb of RNA.[54, 55] The general features of the HIV replication cycle is shown in 
Figure 4. The early phase begins with the recognition of the target cell CD4 receptor by 
the mature virion and involves all processes leading to the inclusion and integration of 
the proviral DNA into the chromosome of the host cell. The late phase includes all the 
events from transcription of the integrated proviral DNA to virus budding and 
maturation. 
Although all steps in the HIV life cycle are potential targets for anti-retroviral agents, 
current anti-retroviral therapy mainly uses three classes of drugs targeting RT, protease 
(PR), and viral fusion.[56] The most promising approach is termed “highly active 
antiretroviral therapy (HAART)” and contains a combination of RT and PR inhibitors. 
The administration of this kind of drug cocktail can reduce viral loads to undetectable 
levels for longer periods like two years. However, HAART cannot completely eradicate 
HIV from the body. This can result in long-term toxicity and eventually leads to the 
emergence of new drug-resistant strains.[57, 58] Thus, it is of outmost importance to 
define better drugs by new approaches.[59, 60] For example, one promising virally 
encoded target is the integrase.[61] Another attractive approach is to block the entry of 
HIV-1 through chemokine receptors.[62, 63] Other HIV-1 regulatory and accessory 
proteins are also gaining new interest, such as Vif.[64-66] Even cellular factors involved 
in HIV replication can serve as new targets to inhibit the viral replication, as 
demonstrated with an inhibitor against ataxia-talengiectasia-mutated (ATM) kinase.[67] 
Furthermore, the recent advantages in gene therapy provide RNA decoys, aptamers, and 
RNA interference technologies towards potential anti-HIV-1 agents.[68, 69] 
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Figure 4. HIV-1 life cycle. The figure is reproduced from Pomerantz et al..[56] 
 
 
2.1.4. RT as a Major Drug Target 
 
As discussed above, RT is one of the major drug targets for anti-HIV-1 therapy. This 
enzyme catalyzes the synthesis of proviral DNA using the viral RNA as a template in 
the early phase. HIV-1 RT[55, 70] catalyzes three enzymatic reactions: RNA-dependent 
DNA polymerase activity (RDDP), DNA-dependent DNA polymerase activity (DDDP), 
and degradation of the RNA part of a DNA/RNA hybrid (RNase H activity). These 
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catalytic activities are confined only to p66/p51 heterodimeric forms (66kDa and 51 
kDa respectively). Crystal structures[71, 72] of HIV-1 RT indicate that both subunits share 
four subdomains in common, which are termed “finger”, “palm”, thumb”, and 
“connection”, while an extra C-terminal domain required for RNase H activity exists 
only in p66 subunit (Figure 5). Highly conserved regions were found in the finger and 
palm subdomains of p66, providing the positions for primer/template binding as a helix 
clamp.[71] The most important feature of the RT is the lack of a proofreading function, 
resulting in 100-fold lower fidelity than the cellular DNA polymerases. The severe 
menace of drug resistance of HIV-1 is caused by this intrinsic property. 
 
 
 
Figure 5. The crystal structure of the HIV-1 RT catalytic complex. The domains of p66 are in color: 
fingers (red), palm (yellow), thumb (orange), connection (cyan), and RNase H (blue); p51 is in gray. 
The DNA template strand (light freen) contains 25 nucleotides, and the primer strand (dark green) 
contains 21 nucleotides. The dNTP is in gold. The figure is reproduced form Huang et al..[72] 
 
As already indicated by the first approved anti-HIV-1 drug AZT (zidovudine), RT 
serves as an excellent target for anti-viral strategies because RT is virus-specific, 
essential for virus replication, and acting in the early phase. The present RT inhibitors[57, 
70] include nucleoside analogue RT inhibitors (NRTIs) and non-nucleoside RT inhibitors 
(NNRTIs). NRTIs act, after intracellular phosphorylation by cellular kinases, as 
competitive inhibitors with respect to the dNTP substrates. On the other hands, NNRTIs 
bind allosterically to a hydrophobic pocket located 10-15 Å from the active site.[73] The 
examples of NRTIs and NNRTIs are listed in Figure 6. Although a number of RT 
inhibitors with higher anti-viral effects have been identified, the currently used anti-viral 
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treatment results in the emergence of drug resistant HIV-1 strains. Therefore, new 
classes of inhibitors acting with different mechanisms are still needed to be developed 
to combat HIV. 
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Figure 6. The structures of approved NRTIs and NNRTIs. 
 
 
 
2. Reporter Ribozyme toward Screening of Small Molecule Inhibitors of Human Immunodeficiency Virus 
Type-1 Reverse Transcriptase with anti-Viral Activity 
16 
2.2. Aim of Study 
 
Screening of low molecular weight compounds in massive parallel fashion is the 
state-of-the-art methodology for the identification of biologically functional molecules 
and thus, spurs endeavors in drug discovery. However, for every screening project a 
suitable assay format has to be developed. 
Recently, effector-dependent reporter ribozymes have proven to be powerful tools 
which can report molecular interactions, e.g. protein-protein, protein-aptamer, or 
protein-metabolite interactions, in real-time. The assays are broadly applicable to and 
suitable for high throughput screening (HTS) to search for new molecules which disrupt 
such interactions. Reporter ribozyme FK-1 is a rationally engineered allosteric ribozyme, 
which contains an aptamer sequence that binds to an enzyme namely HIV-1 RT 
selectively in domain specific manner. The molecular interaction between HIV-1 RT 
and an aptamer sequence inserted into the ribozyme construct are detectable through the 
generation of a fluorescent signal. 
The aim of this study is the development of HTS based on the reporter ribozyme FK-1 
as an assay format to demonstrate its general utility in screening for new drug like 
molecules. First, the assay has to be applicable to automation of liquid handling with 
sufficient reliability and sensitivity, which is a prerequisite of HTS. Of particular 
interest is to identify novel types of HIV-1 RT inhibitors, inheriting the inhibitory 
properties of the aptamer, by using the ribozyme-based screening assay. Subsequent 
studies of the identified active hit compounds would include hit validation and 
characterization. For this undertaking, the re-synthesis of the hit compounds is essential 
for the chemical identification of hit compounds. Further characterization for selectivity 
and inhibitory elucidation should be performed with those synthesized compounds. 
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2.3. Results 
 
2.3.1. Principle of Reporter Ribozyme-Based Screening Assay 
 
The reporter ribozyme construct FK-1 (see Figure 7), which is regulated by HIV-1 RT, 
was previously published by Hartig et al..[32] FK-1 is a rationally designed allosteric 
ribozyme, which is able to detect the presence of HIV-1 RT selectively in a domain 
specific manner. Allosteric regulation of ribozyme cleavage activity results from the 
insertion of an aptamer sequence into stem II of the hammerhead ribozyme. The RNA 
aptamer sequence[74] was isolated by the SELEX procedure (Systematic Evolution of 
Ligands by Exponential Enrichment) and subsequent analysis of the aptamer revealed 
highly specific binding to HIV-1 RT with an extraordinarily low Kd value of 25 pM and 
the characteristic folding into a pseudoknot structure.[75] The allosteric construct FK-1 
can fold into two structures depending of HIV-1 RT; the ribozyme-based structure and 
the pseudoknot aptamer-based structure (see Figure 7). The ribozyme-based structure of 
FK-1 is preferred in the absence of HIV-1 RT by the stable hairpin loop conformation 
of the inserted aptamer sequence in the ribozyme fusion construct. While the 
pseudoknot structure is induced by the addition of HIV-1 RT, and subsequent disruption 
of stem II leads to inhibition of cleavage activity of the hammerhead ribozyme. 
Additionally, highly selective detection of HIV-1 RT by FK-1 was demonstrated. Only 
HIV-1 RT showed significant inhibition of ribozyme activity, compared with several 
noncognate proteins. Noteworthy is that no inhibition was observed with the 
homologous RT of HIV-2 in the same assay. FK-1 functions in protein selective as well 
as in a domain specific manner. The detection of interaction between FK-1 and HIV-1 
RT was competitively influenced with primer/template complex due to the fact that free 
RNA aptamer sequence locates in the primer/template binding site of HIV-1 RT as 
indicated by the crystal structure.[76] This effect was not observed with nevirapine, one 
of the NNRTIs, which binds to the site near to, but distinct from, the polymerase active 
site.[73] All the features of FK-1 evidenced that the functions derived from the free 
aptamer were maintained in the fusion ribozyme context. 
Those intriguing findings inspired us to use FK-1 as a high throughput screening (HTS) 
format for identification of inhibitors of HIV-1 RT, which can bind to HIV-1 RT in a 
domain specific fashion. Figure 7 describes the principle of reporter ribozyme 
(FK-1)-based screening assay. 
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Figure 7. Structural interchange and cleavage activity of reporter ribozyme (FK-1).[32] Aptamer 
sequences inserted into the hammerhead ribozyme are highlighted in boldface italics. 
FRET-substrates carry 5’-fluorophore (F) and 3’-quencher (Q). The arrow indicates the 
FRET-substrate cleavage site. In the presence of HIV-1 RT (yellow), the aptamer sequence adopts a 
pseudoknot, disrupting the formation of stem II (left). Addition of a potential HIV-1 RT inhibitor 
(orange), which interferes with the interaction between HIV-1 RT and the aptamer by binding to 
HIV-1 RT, induces the active conformation of the hammerhead ribozyme (middle). Subsequent 
cleavage of the FRET-labeled substrate results in the generation of a fluorescent signal increase that 
can be detected in real time (right). 
 
The inactive state of FK-1 in the presence of HIV-1 RT is restored by the addition of a 
potential HIV-1 RT inhibitor, which is able to bind to HIV-1 RT by competing with the 
binding site of the aptamer inserted into FK-1. The structural conversion of FK-1 to the 
active form results in the hammerhead ribozyme cleavage activity. 
In the reporter ribozyme assay, the catalytic cleavage reaction of ribozyme can be 
detected by using the substrate oligonucleotides labeled with two fluorescent dyes at 
both ends; one end with fluorophore and the other with quencher.[77] The spatial 
proximity of the two dyes causes fluorescence quenching of the donor fluorophore by 
fluorescence resonance energy transfer (FRET). The cleavage of the FRET-labeled 
substrates can then be monitored by time-dependent increase of fluorescence in 
real-time. 
Moreover, the reporter ribozyme-based assay has no requirement for labeling of 
compounds or proteins and allows simple establishment of automatization.[46, 78] In 
particular, FK-1 serves enhanced sensitivity which arose from the low picomolar range 
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affinity of the aptamer-HIV-1 RT complex in addition to the signal amplification by 
catalytic cleavage reaction via the ribozyme. These features should render FK-1 to be a 
highly suitable format for employment of HTS assays, which had to be investigated 
within this thesis. 
 
 
2.3.2. Demonstration of FK-1 Ribozyme-Based Assay for Drug Screening 
 
To test the suitability to employ FK-1 in screening assays, competition experiments 
with the known HIV-1 RT inhibitor (-)-epigallocatechin gallate were carried out (Figure 
8). This compound is a natural product, and its inhibitory effect on HIV-1 RT have been 
reported by Nakane et al.[79] Inhibition of HIV-1 RT by (-)-epigallocatechin gallate was 
observed by the authors at a concentration required for 50 % inhibition (IC50) of 0.045 
µM. As illustrated in Figure 8, the inhibitory effects of (-)-epigallocatechin gallate were 
detected in a proof of principle experiment by exploiting FK-1. However, as reported by 
Nakane et al. other RTs and DNA polymerases such as eukaryotic DNA polymerase α, 
β, and γ were also inhibited but at more than five-fold higher values of IC50. The 
detailed mechanism of HIV-1 RT inhibition by the compound is unclear. However, 
having observed the competitive mode of inhibition with respect to the primer/template 
complex by (-)-epigallocatechin gallate and the slight inhibition on DNA polymerase γ, 
the authors suggested catechin binding to HIV-1 RT through the recognition of the 
primer/template complex binding site. 
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Figure 8. Competition of reporter ribozyme FK-1 from HIV-1 RT by increasing concentrations of 
the inhibitor (-)-epigallocatechin gallate. Black columns: reactivation of the FK-1-catalyzed cleavage 
activity by increasing amounts of (-)-epigallocatechin gallate in the presence of HIV-1 RT. White 
columns: control reactions for full cleavage activity of FK-1 alone and in the presence of 
(-)-epigallocatechin gallate at the indicated concentrations. The structure is shown in the right side. 
The mean values and the error bars are from duplicate measurements. 
 
As shown in Figure 8, the sensitivity of FK-1 depending on HIV-1 RT was evidently 
supported in the absence of the catechin compound. The reactivation of FK-1 cleavage 
activity was observed with the addition of catechin compound in a concentration 
dependent manner. With 100 µM of the compound, half of the ribozyme activity was 
restored by interfering with the interaction between HIV-1 RT and the aptamer. These 
results strongly indicate that the compound is most likely to bind to HIV-1 RT, and 
demonstrate that the assay can be suitably used to identify inhibitors of HIV-1 RT. 
Furthermore, this model system implies how to evaluate potential hit compounds in the 
screening assay. The relative activity (Arel) of FK-1 at a certain concentration of a 
compound can be expressed by the proportion of ribozyme activity in the presence of 
HIV-1 RT versus full ribozyme activity in the absence of HIV-1 RT. Thus, by 
comparison of the value of Arel with compound to Arel without compound (usually the 
solvent DMSO was added in the assay for 0 µM of compound), the inhibitory effects of 
a given compound can be accessed. For example, the Arel for 100 µM of 
(-)-epigallocatechin gallate was found to be 0.5, while Arel for DMSO addition was 0.1. 
Theoretically, the value of Arel should vary from 0 to 1. Hit compounds can be 
identified by values of Arel that are higher than Arel of DMSO and possibly near to 1. 
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2.3.3. Optimization of Robot Manipulation 
 
Prior to perform HTS, the FK-1 assay was applied to automated liquid handling system 
using a robotic manipulation. The reaction mixtures and small molecule compounds 
from the library were mixed by a robot automatic liquid handling system before 
initiation of the ribozyme reaction. Primary test operations resulted in considerably 
varying data output under the same assay conditions. It turned out that several plastic 
materials (e.g. reservoir, tubes) available for robot manipulations seemed to have 
affinity either to RNA or to proteins. All these problems were successfully 
circumvented through employment of equipment that contains ceramic multiple tips for 
the robot autosampler and the preparation of reaction mixtures in glass vials. 
 
 
2.3.4. High Throughput Screening of Small Molecule Library 
 
A small molecule library derived from 2500 compounds (Comgenex I), each at 100 µM 
concentration, were screened using the FK-1 ribozyme-based assay with optimized 
robot manipulations. The relatively high concentration was used because it permits 
observation of even weak effects of compounds in an initial evaluation of the library. To 
identify hit compounds, the ribozyme relative activity (Arel; see §2.3.1 and §4.6.2) was 
evaluated by comparison to Arel obtained with DMSO. 
Figure 9 describes an example of screening results. Most of the library members yielded 
averaged Arel values within in the range of Arel from DMSO (ca. 0.2 ± 0.1). In the 
primary screening, the compound showing a value of Arel > 0.4 were identified as 
potential hit compounds, which were marked in black in Figure 9. Applying this rule to 
the primary screening, a frequent occurrence of hit compounds (ca. 8 % of the total 
number of the library compounds) was observed. Subsequently, in a secondary 
screening all selected compounds identified in the primary screening with a Arel > 0.4 
were re-screened at 50 µM concentration. This compels to identify more active 
compound and less fault-positive output. Finally, 67 molecules were identified as active 
compounds by employing the FK-1 reporter ribozyme-based assay. This marks 2.7 % of 
hit occurrence. 
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Figure 9. Arel values of library compounds. Each bar represents the mean value from duplicate 
measurement for one compound from the library. The assay was performed in the presence of 100 
µM of compound (white bars). The controls with the addition of DMSO were shown in gray bars. 
The bars with relative values (Arel) higher than 0.4 were marked in black. 
 
Several of the identified componds were examined in the FK-1 assay to see whether 
they recover the ribozyme cleavage activity in a concentration dependent manner. For 
instance, two hit compounds (2E10 and 28F6), which were identified after the 
secondary screening, recovered fluorescence generation of FK-1 depending on the 
concentration increment (Figure 10). On the other hand, the compound 16A3, which is 
one of the inactive compounds selected randomly from the library members, did not 
influence the ribozyme cleavage activity. These results indicate that the FK-1 based 
assay format is suitable to monitor inhibition in a concentration dependent manner. 
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Figure 10. Concentration dependent reactivation of FK-1 ribozyme activity by the hit compounds 
identified in the screening. 2E10 and 28F6 were identified as hit compounds, and 16A3 was 
randomly chosen from inactive compounds by hit evaluation in the same library. 
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2.3.5. in vitro HIV-1 RT Inhibition by Hit Compounds 
 
In general, the affinity of the ligand to its target correlates with inhibition of enzyme 
activity. Thus, an activity-based assay to evaluate the final 67 hit molecules was 
designed to examine their ability to inhibit the DNA polymerase activity of HIV-1 RT. 
According to the crystal structure of HIV-1 RT in the complex with pseudoknot RNA 
aptamer sequence, it was shown that the position of the pseudoknot RNA overlapped 
the binding surface of duplex DNA substrate.[76] 
Taking into account this information, the 67 hit compounds were initially evaluated for 
the in vitro inhibitory activity towards the DNA-dependent DNA polymerase reaction of 
HIV-1 RT using a 5’-[32P]-DNA primer/DNA template complex. The effect of the 
compound was analyzed in the range of the concentration of 5 nM-50 µM, as shown in 
Figure 11. Seven molecules out of 67 resulted in strong inhibition of DNA-dependent 
DNA polymerase activity. 
 
 
 
Figure 11. Inhibition of DNA polymerase activity of HIV-1 RT by small molecule inhibitors. In the 
presence of HIV-1 RT, 5’-end labeled primer is extended employing either DNA or RNA template 
(second lane from the left; +RT). The control lane in the absence of HIV-1 RT shows the primer 
position (left lane; -RT). Polymerization reactions were inhibited by the addition of increasing 
concentrations of inhibitors (right lanes), which were able to be detected by radioactive intensity of 
elongated products. In this example, the lanes including inhibitor shows the inhibition by 28F6 at the 
concentration of 0.5-50 µM. 
 
The idioms and structures of the seven hit compounds are shown in  
Figure 12. Interestingly, partial structural similarity was observed with some 
compounds. The compounds had more than 70 % purity by HPLC analysis except 1B11, 
which yielded 2 major peaks. 
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Figure 12. The structures of seven compounds, which showed evident inhibition on DNA-dependent 
DNA polymerase activity of HIV-1 RT in vitro. The colored groups (yellow and gray) represent 
structural similarity among several compounds. 
 
To compare the effects of the compounds on HIV-1 RT action, the inhibitory 
concentrations that gave half-maximal activity (IC50) for the above seven compounds 
were determined from the dose-dependent inhibition curves by using the method shown 
in Figure 11 (Table 2). Specific inhibitory effects with those molecules were confirmed 
by control experiment, where 18B11, which was selected arbitrarily from the library, 
exhibited no inhibition on RT under the same assay condition. Three potential inhibitors 
(3E4, 2E10, and 28F6) which gave relatively low IC50 in the range of 3-4 µM were 
chosen for further analysis and characterization. 
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compound IC50 [µM] 
3E4 3.11 
2E10 3.49 
28F6 3.99 
1B11* 5.12 
28E2 5.97 
5A11 5.98 
25B9 9.33 
1B11* 10.3 
 
Table 2. Inhibition of DNA-dependent DNA polymerase activity of HIV-1 RT by seven inhibitors. 
*: two major compounds derived from 1B11 by HPLC separation. 
 
 
2.3.6. Synthesis of 28F6, 3E4, and 2E10 
 
To pursue the process of stage-by-stage drug development, the activity of the hit 
compounds has to be followed up with an identity and purity evaluation. Re-synthesis 
of the authentic samples permits to confirm the activity and validity of the 
corresponding hits. The compounds ensured through this objective assessment are able 
to progress into the subsequent investigations. 
For those reasons, the three most promising compounds (28F6, 3E4, and 2E10) were 
re-synthesized to yield sufficient quantities in high purity. 
First, the coupling of amine 1 and benzoylchloride 2 in the presence of triethylamine 
gave 28F6 in one step (Scheme 1). 
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Scheme 1. Synthesis of 28F6. Conditions: (a) Et3N, CH2Cl2; 18%. 
 
The synthetic strategy of 3E4 is outlined in Scheme 2. The amide 5 was prepared by the 
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coupling of benzoic acid 3 and the benzylamine 4 in the presence of EDAC. Subsequent 
treatment of 5 with piperidine yielded 6. Catalytic hydrogenation of the nitro group in 6 
was required to generate amine substituted product 7, which was then condensed with 
3-chloro-4-fluorophenylisocyanate. The reaction proceeded smoothly in the polar 
aprotic solvent THF at room temperature, giving the final product 3E4. 
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Scheme 2. Synthesis of 3E4. Conditions: (a) EDAC, DMF; 35%. (b) pyridine, reflux; 88%. (c) Pd/C, 
H2, EtOH; 89%. (d) THF, rt; 65%. 
 
Target 2E10 was able to be synthesized using a similar procedure as employed for 3E4 
(Scheme 3). O-tolylacetic acid (8) was coupled with piperazine 9 in the presence of 
N-hydroxybenzotriazole and EDAC to yield amide 10. The amino group in 11 was 
introduced by catalytic hydrogenation of the nitro group in 10 using Pd/C. Final 
condensation of 11 and 4-nitrophenyl isocyanate gave assymmetric diphenyl urea 2E10. 
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Scheme 3. Synthesis of 2E10. Conditions: (a) EDAC, N-hydroxybenzotriazole, DMF, CH2Cl2; 82%. 
(b) Pd/C, H2, EtOH; 86% (c) THF, DMSO, rt; 82%.  
 
Having all the synthetic compounds in hand, their inhibitory effects on DNA-dependent 
DNA polymerase activity of HIV-1 RT were re-examined and compared the effects of 
synthesized compounds to those of the library samples. IC50 values for both library and 
synthetic compounds are listed in Table 3. The obtained data indicates that the 
synthesized 28F6, 3E4, and 2E10 exhibit approximately equivalent activities as the 
library samples. 
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IC50 [µM] 28F6 3E4 2E10 
Comgenex I 
library 
3.99 ± 0.27 3.11 ± 0.55 3.49 ± 0.15 
synthesized 
compound 
5.01 ± 0.19 2.10 ± 0.58 3.72 ± 0.07 
 
Table 3. Inhibition of DNA-dependent DNA polymerase activity of HIV-1 RT by both library and 
re-synthesized compounds. IC50 values are the average of duplicate analyses. The structures of 28F6, 
3E4, and 2E10 are also shown. 
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2.3.7. Selectivity of 28F6, 3E4, and 2E10 in vitro 
 
The selectivity of the small molecule inhibitors was evaluated by testing their inhibitory 
effects on various reverse transcriptases (HIV-2, avian myeloblastosis virus (AMV), 
and moloney murine leukemia virus (MMLV)) and DNA polymerases from both 
prokaryotic (Klenow Fragment (KF)) and eukaryotic (human DNA polymerase β (pol 
β)) sources. It was of interest to know if the small molecules identified via the FK-1 
assay maintain the selective inhibitory property as the anti-HIV-1 RT aptamer, which 
was incorporated into a part of reporter ribozyme sequence. It is reported that the free 
anti-HIV-1 RT aptamer is capable of discriminating HIV-1 RT from other RTs such as 
HIV-2, AMV, and MMLV RTs.[74, 75] HIV-1 and HIV-2 are classified as lentivirus, 
while AMV and MMLV are in C-type retroviruses, depending upon the particle shapes. 
The selectivity of the pseudoknot aptamer towards HIV-1 is remarkable, because HIV-2 
has 60 % sequence homology to HIV-1. Noteworthy, HIV-2 RT shows resistance to 
NNRTIs due to the structural difference in the NNRTI binding pocket.[80] 
DNA polymerases were also investigated because their inhibition by the compound is 
prone to lead to the cell toxicity. Additionally, from amino acid sequence comparisons 
as well as crystal structure analyses, E. coli DNA polymerase I (Pol I), whose large 
fragment is KF, pol β, and RTs belong to different families. However, all DNA 
polymerases and RTs utilize an identical two metal ion catalyzed mechanism.[81-83] The 
results might provide a clue to understand the inhibitory mechanism of the identified 
compounds. 
Figure 13 describes the inhibition of the three compounds on DNA-dependent DNA 
polymerase activity (DDDP) of RTs (HIV-1, HIV-2, AMV, MMLV) and DNA 
polymerases (KF, pol β) as well as the inhibition of three compounds on 
RNA-dependent DNA polymerase activity (RDDP) of RTs. IC50 values obtained from 
the dose-response curves in Figure 13 are summarized in Table 4. 
 
 
Figure 13 (see p.29). Effects of the indicated compounds on DDDP and RDDP activities of various 
DNA polymerases and reverse transcriptases. Dose-response curves for DDDP inhibition by 28F6 
(A), 3E4 (C), and 2E10 (E) as well as dose-response curves for RDDP inhibition by 28F6 (B), 3E4 
(D), and 2E10 (F) are represented. The DDDP activity was assayed by using [α-32P]-labeled DNA 
primer/DNA template, while RDDP activity was assayed by using [α-32P]-labeled DNA primer/RNA 
template. The symbols used in the graphs are as follows; HIV-1 RT (■), HIV-2 RT (●), AMV RT 
(▲), MMLV RT (▼), Klenow fragment 3’-5’ exo- (◄), and human DNA polymerase β (►). The 
mean values and the error bars are the results from two independent experiments. 
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As a result, 28F6 showed moderate selectivity (4-10 fold) to HIV-1 (IC50 = 4.99 µM) 
and HIV-2 RT (6.21 µM) over other RTs and DNA polymerases to inhibit DDDP 
(Figure 13A, Table 4). While higher concentration of 28F6 (IC50 > 30 µM) was required 
to inhibit RDDP activities even with no selectivity (Figure 13B, Table 4). 
Considerably enhanced selectivity was observed with 3E4 to inhibit DDDP (Figure 13C, 
Table 4). Compared to the IC50 value for HIV-1 RT (IC50 = 2.1 µM), AMV RT, MMLV 
RT, KF, and pol β were inhibited with 10-50 fold higher IC50 values. Moreover, 3E4 
exhibited selectivity to HIV-1 RT over HIV-2 RT in the respect to DDDP inhibition. 
The difference between HIV-1 and HIV-2 in the observed IC50 values is a factor of 
about 4.5. IC50 values for RDDP inhibition by 3E4 were in the range of 40-160 µM with 
slightly stronger inhibition for AMV and MMLV compared to HIV-1 and 2 (Figure 13D, 
Table 4). 
2E10 inhibited DDDP of all the tested polymerase and RTs with less selectivity and 
with IC50 values of 3.7-22.8 µM (Figure 13E, Table 4), and thus, turned out to be the 
inhibitor with the lowest selectivity among the tested three compounds. In contrast to 
28F6 and 3E4, RDDP activities of all RTs were inhibited with lower IC50 (10-30 µM) 
by 2E10 (Figure 13F, Table 4) with slightly less effect on DDDP for each RT tested. 
The control compound 20H3 showed considerably higher IC50 values or no inhibition 
on DDDP and RDDP of all the enzymes used in this assay (data not shown). 
Overall, the data presented in Figure 13 and Table 4 indicates that all three compounds 
identified as hits exhibited effects to inhibit DDDP stronger than RDDP activities. With 
respect to inhibition of DDDP, 3E4 showed not only the lowest IC50 value for HIV-1 
RT but the highest discrimination from all the other RT and DNA polymerases which 
were investigated. 
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28F6 3E4 2E10 
HIV-1  DD 5.01 ± 0.19 2.10 ± 0.58 3.72 ± 0.07 
RT RD 38.4 ± 0.94 145 ± 5.06 10.8 ± 0.89 
HIV-2  DD 6.21 ± 0.18 9.41 ± 0.21 5.09 ± 0.07 
RT RD 71.2 ± 1.48 160 ± 19.1 10.3 ± 0.50 
AMV DD 50.8 ± 1.70 64.1 ± 2.64 7.29 ± 0.18 
RT RD > 100 63.7 ± 7.79 32.0 ± 4.79 
MMLV DD 35.6 ± 1.06 21.2 ± 0.93 12.2 ± 0.06 
RT RD 59.2 ± 1.78 42.5 ± 1.23 16.4 ± 0.39 
KF- DD 48.9 ± 2.60 99.7 ± 3.25 22.8 ± 0.53 
Pol β DD 24.2 ± 0.23 30.4 ± 0.77 12.3 ± 0.08 
 
Table 4. IC50 values of 28F6, 3E4, and 2E10 for different DNA polymerases and reverse 
transcriptases. The structures of 28F6, 3E4, and 2E10 are also represented. DD; DNA-dependent 
DNA polymerase activity, RD; RNA-dependent DNA polymerase activity. 
 
 
2.3.8. Binding Analysis of 28F6, 3E4, and 2E10 via SPR 
 
Although DDDP activity of HIV-1 RT was nicely inhibited by 28F6, 3E4, and 2E10 
with acceptable selectivity, all the data obtained so far are not able to support direct 
interaction between the small molecules and HIV-1 RT. The possible inhibition mode 
could be the intercalation of the compounds into the primer/template DNA double helix 
or binding to the major or minor groove of the DNA helix. In order to eliminate this 
hypothesis, inhibitor binding to the immobilized primer/template complex was 
investigated via surface plasmon resonance (SPR) (Figure 14). As a control, the known 
DNA double helix binder SYBR green was used to observe a binding response with the 
primer/template complex (Figure 14D). The concentration dependent binding signals 
were indeed obtained through SYBR green injection to the chip. In contrast, Figure 
14A-C clearly show that none of the three inhibitors bind to the primer/template 
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complex immobilized on the chip surface in the range of 50 nM – 5 µM. Theses results 
strongly support a mechanistic model that inhibitions results from binding of the 
compounds to HIV-1 RT or the HIV-1 RT-primer/template ternary complex. 
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Figure 14. BIAcore sensorgrams showing no binding or binding of small molecules to the 
primer/template complex immobilized on the chip surface. 28F6 (A), 3E4 (B), and 2E10 (C) were 
injected onto the surface at the concentrations from 50 nM to 5 µM. While SYBR green (D) was 
injected at the concentrations from 50 pM to 5 µM. The SA chip surface was prepared by 
immobilization with 300 RU of the 12-mer primer sequence, followed by subsequent annealing (500 
RU) of the 18-mer template at a flow rate of 5 µl/min. The compounds were injected to the surfaces 
including a reference cell at a flow rate of 30 µl/min. 
 
In another examination using SPR, HIV-1 RT was coupled on the chip surface to 
observe interactions with the inhibitors. As shown in Figure 15, the injection of 3E4 
over the RT immobilized resulted in a concentration dependent signal enhancement. 
This observation demonstrated the direct interaction between HIV-1 RT and 3E4.  
However, inherent poor solubility seems common to the identified compounds and 
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hampered to obtain reproducible binding signals with 28F6 and 2E10. The accurate 
dissociation constants (Kd) was not be accessible due to the same reason. 
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Figure 15. BIAcore sensorgrams showing reproducible binding curves of 3E4 to HIV-1 RT 
immobilized on the chip surface. 3E4 was injected onto the surface at the concentrations at 1, 2, and 
2.5 µM at a flow rate of 30 µl/min in running buffer including 1% DMSO. The chip surface was 
prepared by immobilization with 2000 RU of HIV-1 RT at a flow rate of 5 µl/min. The curves were 
normalized with the reference cell. 
 
 
2.3.9. A Cell-Based Assay using a Self-Inactivating HIV Vector System 
 
Conventional phenotypic analysis of HIV to antiviral therapy is time-consuming and 
requires to culture infectious viruses. The so-called self-inactivating virus vector system 
allows to determine the sensitivity of HIV to RT, protease (PR) and integrase inhibitors 
rapidly (approximately in 10 working days) at reduced biosafety levels (Figure 17).[84] 
Having shown the in vitro specific inhibition of HIV-1 RT with the three inhibitors 
28F6, 3E4, and 2E10, their initial characterization in vivo was carried out by the group 
of Prof. Dr. T. Restle, University of Luebeck, using a self-inactivating HIV vector 
system. 
The design of this assay requires two plasmids; one chimeric vector pGJ3 and the 
second plasmid containing the vesicular stomatitis virus G glycoprotein (VSV-G) gene. 
The pGJ3 vector plasmid includes the minimum essential sequences of a HIV 
laboratory virus, including the gag-pol and rev sequences as well as the rev responsive 
element (RRE), and a reporter gene. The plasmid lacks the HIV env, vif, vpu, vpr, tat 
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and nef genes and contains a deletion in the 3’ U3 region (Figure 16). Cotransfection of 
the plasmid pGJ3 with VSV-G resulted in the production of replication incompetent 
virus vectors that contain a rudimentary HIV RNA genome with a marker gene, RT and 
PR proteins from the virus surrounded by capsid and matrix protein of the HIV. The 
vector nucleocapsid is enveloped by a VSVG-containing membrane. Infection of 
susceptible cells with the vectors leads to marker gene expression. The active inhibitors 
for RT, PR, or integrase represent reduced marker gene expression in a dose-dependent 
manner (Figure 17). In addition, RT and PR gene segments of the plasmid could be 
replaced by the corresponding region of an HIV test specimen, which permits to 
determine the sensitivity of drug resistant HIV isolate to inhibitors using the same 
system. 
 
 
 
Figure 16. The self-inactivating replication-defective test vector. Plasmids pGJ3 (B) were 
constructed from a proviral clone of HIV-1 (A). The vector plasmid contains a chimeric 
cytomegalovirus promoter (CMVp) that regulates expression of the vector genome after transfection. 
The consecutive deletion processes of the env, nef, vpu, tat, vif, and vpr genes resulted in plasmid 
pGJ3 (B). Reporter genes driven by an internal promoter (SFFVp) were inserted in the region of the 
deleted nef gene. As reporter, either the E. coli lacZ or the firefly luciferase genes were selected. RT 
and PR sequences from laboratory or patient isolates, or from proviral clones can be alternatively 
inserted in the vector plasmid at the sites indicated to obtain chimeric test vector plasmids (B). 
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Figure 17. Cotransfection of a plasmid containing minimal HIV genome sequences (pGJ3) with a 
plasmid providing the vesicular stomatitis virus glycoprotein (VSV-G) leads to production of 
replication incompetent chimeric virus vectors which are then used to infect susceptible cells, 
resulting in marker gene expression. Inhibitors of the HIV-1 reverse transcriptase, protease and 
integrase can be analyzed in this cell-based assay system. Their inhibitory potential is reflected in a 
decrease of marker gene expression. 
 
Figure 18 shows the result of the susceptibility of HIV to the identified inhibitors in the 
cell-based assay, where 293 cells were infected with the chimeric vector particles in the 
presence of 28F6, 3E4, and 2E10 as well as the negative control (20H3) and the 
positive control (AZT). The control compound 20H3 was identified to require 
significantly higher amounts to observe the inhibition of HIV-1 RT in vitro, compared 
to the other three inhibitors. One of the NRTIs, azidothymidine (AZT) was used as a 
positive control. Among the three compounds identified in the screening, 3E4 showed 
substantial reduction of reporter gene expression in concentration dependent manner. 
However, the other two inhibitors 28F6 and 2E10 kept the level of luciferase activity as 
observed with the negative control compound. The value of IC50 for 3E4 was 
determined at 5.3 µM. Nearly complete suppression of marker gene expression was 
achieved at 25 µM of 3E4. It is remarkable that the inhibitor 3E4, that is active in the 
cell-based assay, has exhibited the most promising characteristics accompanied with the 
lowest IC50 and the highest selectivity in vitro. 
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Figure 18. Inhibitory activity of small molecule RT inhibitors in the self-inactivating HIV vector 
system. Percent luciferase activity of 293 target cells transduced in the presence of the indicated 
amounts of each molecules with the chimeric vector is shown. The luciferase activity is expressed as 
percentage of the luciferase activity of cells cultured in the absence of inhibitors. The compound 
28F6, 3E4, and 2E10 are the inhibitors identified from the screening, while the control corresponds 
to the compound 20H3 which was selected arbitrarily from the library. Positive control was 
performed with azidothymidine (AZT), one of the approved NRTIs. The mean and the standard 
deviation of duplicates are given. 
 
 
2.3.10. Action of the Identified Inhibitors on in vivo HIV-1 Replication 
 
Encouraged by the promising data for 3E4 from the study using the self-inactivating 
HIV system, further in vivo analysis of the inhibitors using HIV wild type was 
performed. The effects of the compounds to inhibit HIV-1 replication in vivo was 
investigated by the group of Prof. Dr. H.-G. Kraeusslich, University of Heidelberg, and 
the results are shown in Figure 19. 
TZM cells infected with HIV-1 NL43 exhibit luciferase gene expression under the 
control of the HIV-1 LTR promoter.[85] As described in Figure 19, luciferase expression 
was reduced in considerable extent with 3E4, in comparison to 28F6 and 2E10. The 
assay includes the same negative and positive controls used in self-inactivating HIV 
vector system described above (Figure 18). In this assay, the control 20H3 resulted in 
some reduction of HIV-1 replication at high concentration (75 µM). Although AZT 
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showed extremely enhanced reduction even at low µM concentrations, 3E4 was able to 
reach the approximately equivalent level of reduction at 30 µM, which was also 
comparable to the result obtained from Figure 18. 
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Figure 19. Effect on inhibition of HIV-1 replication by small molecule inhibitors. HIV-1 replication 
for TZM cells infected with HIV-1 NL43 wild-type virus in the presence of 28F6 (light blue 
diamonds), 3E4 (red-filled circles), 2E10 (dark blue triangles) or the negative control (gray crosses) 
and the positive control with the NRTI AZT (non-filled orange circle) was investigated by 
monitoring luciferase activity. The mean percentage of luciferase marker gene expression compared 
with untreated control cells from at least two replicate infections are shown. 
 
HIV-1 virus particles were produced in MT4 co-culture in the presence of different 
inhibitors and used to infect TZM cells, expressing β-galactosidase under the control of 
the HIV-1 LTR promoter, thus enabling colorimetric detection and enumeration of the 
HIV-1 infected cells. The infectivity of the HIV-1 was examined with those compounds 
tested above (Figure 20). The infectivity of intact HIV-1 NL43 virus was arbitrarily set 
at 100 %. As controls, 20H3 and AZT were included. Again, 3E4 reduced the number 
of infected cells distinguishably from 28F6, 2E10 and the negative control. The 
complete reduction was observed in the presence of 3E4 at 30 µM. 
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Figure 20. Effect on inhibition of HIV-1 infectivity. The supernatant from the MT4 co-culture with 
NL43 virus particles produced in the presence of inhibitors was used to infect TZM cells. The 
infected TZM cells were counted by staining with β-galactosidase substrate after 48 h. Values are 
expressed as percentage of the number of infected cells treated without inhibitors. The symbols for 
each compound are listed in the right. The mean of duplicates are given 
 
To evaluate the cell toxicity of the inhibitors, escalating doses of the compounds alone 
were applied to TZM cells, and the cell viability was measured using a standard MTT 
assay (Figure 21). The significant reduction in transduction efficiency and infectivity 
could not be attributed to cytotoxic effects of the compound. Figure 21 showed that 
TZM cell viability was not significantly affected by the addition of 3E4 up to 20 µM as 
observed with AZT. Unfortunately, the cell viability steeply dropped down to 50 % 
level, when the concentration reached to 30 µM. The complete reduction of HIV-1 
replication and infectivity showed before at the concentration more than 30 µM might 
have been caused in some extent by the effect of the cell toxicity of 3E4. However, 
employing 20 µM of 3E4 enables to reach more than half reduction of HIV-1 
replication as well as the infectivity with no cell toxicity. Hence, 3E4 is a highly 
potential lead structure for further anti-HIV drug development. The toxic effect in 
regard to 28F6 could be expected, because its possible metabolite o-aminoazotoluene is 
reasonably anticipated to be a human carcinogen.[86] 
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Figure 21. Cytotoxicity of small molecule inhibitors on TZM cells. To test for small molecule 
toxicity, 28F6, 3E4, 2E10, a negative control compound, and NRTI ATZ in concentrations ranging 
from 1-100 µM were added to TZM cells at 37°C for 24 hours, and the cell viabilities were 
monitored by MTT assay. Values are expressed as percentage of the values obtained from cultures 
without inhibitors. The symbols for each compound are listed in the right. The mean and the 
standard deviation of triplicates are given. 
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2.4. Discussion and Perspective 
 
2.4.1. Design and General Application of Reporter Ribozymes to HTS 
 
Despite the considerable number of functional allosteric ribozyme invention,[31, 87] and 
their great potentiality for multiple applications,[16, 48, 49, 88-92] there are only a few 
examples which have demonstrated applications of allosteric ribozymes to HTS 
formats.[45, 46] Hartig et al. screened antibiotics to identify HIV-1 Rev inhibitors using 
two rationally designed hammerhead allosteric ribozymes which can be regulated by 
Rev proteins. In one construct of the ribozyme, the anti-Rev aptamer sequence was 
inserted, and the conversely regulated ribozyme construct contains the Rev binding 
element (RBE).[46] Alternatively, using a combinatorial approach, Srinivasan et al. 
constructed an ADP-dependent allosteric ribozyme (RiboReporter) in a two step-in vitro 
selection, and applied it to screen protein kinase inhibitors.[45] Since these systems 
resulted in the identification of specific inhibitors, allosteric ribozymes should serve a 
useful basis to design multiple screening assays in a general way. The concept was 
further validated by the herein depicted work where employing an allosteric ribozyme 
(reporter ribozyme) as HTS assay format resulted in the identification of a highly 
promising HIV-1 RT inhibitor which suppresses HIV function both in vitro and in vivo. 
The design of the screening assay was based on the reporter ribozyme FK-1 investigated 
by Hartig et al..[32] The characteristic features of FK-1 are the highly selective detection 
of HIV-1 RT and the domain specific sensing of HIV-1 RT binding partners. These 
important properties are required for the highly sensitive performance of HTS to search 
for specific small molecule inhibitors of HIV-1 RT. Successfully, the FK-1 
ribozyme-based HTS assay was employed to identify three potential inhibitors (28F6, 
3E4, and 2E10) of HIV-1 RT with in vitro inhibitory concentration that gave 
half-maximal activity (IC50) of 2-5 µM on DNA-dependent DNA polymerase activity 
(Table 2). 
However, the evaluation of the primary screen resulted in relatively frequent false 
positive hit compounds. The reliability of the assay could be increased by decreasing 
the concentration of library compounds (< 50 µM), and further optimization of assay 
conditions and data normalization. 
Furthermore, the approach using a rationally engineered allosteric ribozymes (like 
FK-1) as the reporter basis holds the potential to be broadly applicable as screening 
format by constructing new fusion ribozymes. In addition to anti-RT aptamers, several 
aptamers targeting other components in the virus life cycles, e.g. protease, integrase, Tat, 
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and nucleocapsid, have been isolated via SELEX procedure.[68, 69] Some of them have 
shown effective suppression of HIV-1 replication in vivo. In principle, those aptamer 
sequences can be fused to ribozyme sequences in rational design approach to engineer 
new assay formats. 
 
 
2.4.2. Functional Conversion from Aptamer into Small Molecule 
 
One of the major tasks to use the assay based on the FK-1 ribozyme construct was to 
convert the aptamer inhibitory properties to the potential HIV-1 RT inhibitors. The 
pseudoknot aptamer sequence recognize the primer/template binding site of HIV-1 
RT.[76] Endogenous expression of this aptamer by generating a tRNAMeti/pseudoknot 
RNA chimera in the cell culture could suppress replication of HIV-1 by > 75%.[93] In 
another design of aptamer expression vector, in which the aptamer sequence was 
flanked by self-cleaving ribozymes, HIV infection and replication were strongly 
blocked again. In addition, replication of variety of drug resistant viruses as well as 
several subtypes of HIV were suppressed by this aptamer.[94] The results from different 
expression system support the pseudoknot aptamer as an efficacious agent in a gene 
therapy approach for anti-AIDS treatment. Like the pseudoknot aptamer, nucleic acid 
macromolecules such as ssDNA inhibitors seems to inhibit HIV-1 RT in the same way, 
that is to make extensive interacts with primer/template cleft of RT.[95] Considering 
those excellent inhibitory effect of nucleic acids aptamers, inhibitors that act with a 
primer/template competing mechanism might be able to suppress HIV superior to the 
mechanisms of NRTIs and NNRTIs, with respect to the drug resistance of RT, that 
always appears after drug administration.  
Specific small molecule inhibitors that interact with the primer/template binding site are 
not known yet. (-)-Epigallocatechin gallate, which was used to demonstrate the utility of 
the FK-1 ribozyme-based assay (Figure 8), has been reported to be a HIV-1 RT 
inhibitor by Nakane et al..[79]  The compound is suspected to inhibit DNA polymerase 
activity by interfering with binding of the primer/template, however, the detailed 
inhibitory mechanism and exact binding site are not yet elucidated. Later cell-based 
analysis of inhibitory effects of (-)-epigallocatechin gallate showed that anti-HIV 
activity of (-)-epigallocatechin gallate may result from an interaction with several steps 
in the HIV-1 life cycle.[96] Concerning only RT inhibition by (-)-epigallocatechin gallate, 
data from FK-1 ribozyme competition assay could support inhibitor binding to the 
primer/template site (Figure 8). 
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The pseudoknot aptamer can bind selectively to HIV-1 RT, with the closely related 
HIV-2 RT showing a binding affinity about 4 orders of magnitude lower.[75] In the in 
vitro selectivity assay of the identified compounds, 3E4 exhibited moderate selectivity 
to HIV-1 RT over HIV-2 RT (5-fold) with respect to DDDP inhibition (Figure 13, Table 
4). While the other two inhibitors, 28F6 and 2E10, gave approximately the same IC50 
for HIV-1 and HIV-2 RTs. The factor of the differentiation obtained for 3E4 was not as 
efficient as that for the pseudoknot aptamer, however, the result is logically adequate, 
presuming the possible huge interface of RT interacting with nucleic acids 
macromolecules. Nevertheless, the inhibitory properties of the pseudoknot aptamer 
could be acceptably converted to the small molecule 3E4 in terms of protein selectivity. 
However, a compound that inhibits viral RTs more effective, even in a promiscuous 
way, than human enzymes holds great potential for further developments. 
 
 
2.4.3. Inhibitory Mechanism of 3E4 on HIV-1 RT 
 
Due to the discovered in vitro specific inhibition of HIV-1 RT accompanied with in vivo 
suppression of HIV replication, 3E4 justifies further characterization to understand its 
inhibitory mechanism. 
SPR binding analysis to a dsDNA derivatized chip confirmed that HIV-1 RT was not 
inhibited by a mechanism, where 3E4 binds to the primer/template complex through 
intercalation or groove recognition (Figure 14). This results led to the hypothesis that 
3E4 (also 28F6 and 2E10) binds to HIV-1 RT or HIV-1 RT-primer/template ternary 
complex. Further characterization of 3E4 using HIV-1 RT derivatized chip in SPR 
supports the direct interaction between 3E4 and HIV-1 RT. 
To know the mode of inhibition is of equal interest. HIV-1 RT recognizes both 
primer/template and dNTP as its substrates. The mode of inhibition of the inhibitors 
could be further analyzed by kinetic studies in the presence of saturated concentration of 
one substrate and different concentrations of the other substrate. Double reciprocal plots 
of initial velocity versus substrate concentrations will give information about the type of 
inhibition: competitive, non-competitive, or mixed type.[97, 98] The gel mobility shift 
assay could test if the compounds interfere with RT-primer/template complex 
formation.[99, 100] The most direct interpretation will be accessible from a crystal 
structure of the RT in complex with 3E4. 
3E4 has been investigated for inhibitory effect on DDDP and RDDP. In terms of the 
three enzymatic functions of HIV-1 RT, it is not known yet if 3E4 inhibits the RNase H 
 
2. Reporter Ribozyme toward Screening of Small Molecule Inhibitors of Human Immunodeficiency Virus 
Type-1 Reverse Transcriptase with anti-Viral Activity 
43 
activity of HIV-1 RT. Specific inhibitors designed to target the RNase H domain of 
HIV-1 RT have been previously described.[101] 
Probably the most distinctive feature of 3E4 is to inhibit DDDP preferentially to RDDP 
with 70-fold lower IC50 value. Most of the HIV-1 RT inhibitors have been 
supplemented with approximately equivalent IC50 values for both DDDP and RDDP or 
with the lower IC50 of RDDP than that of DDDP. However, the amount of information 
is insufficient to conclude that this observation is a general tendency. Additionally, only 
the IC50 values for RDDP have been determined for several inhibitors. The origin of 
3E4 to specific inhibition of DDDP might derive from a novel inhibition mechanism. 
Crystal structures of HIV-1 RT in complex with DNA/DNA (primer/template)[71, 72] and 
DNA/RNA (primer/template)[102] have been determined. The authors who published the 
structure of HIV-1 RT-DNA/RNA complex made an effortful comparison with the 
RT-DNA/DNA complex. They observed very similar protein conformation as well as 
the nucleic acid helix conformation in both complexes. Slight differences were i) 
numerous interactions of RT with the 2’-OH groups of the RNA template in addition to 
sugar phosphate backbone interactions observed in common for both primer/template 
complexes and ii) increased involvement of the p51 subunit in binding the RNA/DNA 
relative to the DNA/DNA template/primer complex. It is difficult to interpret, however, 
3E4 might recognize subtle structural difference between the HIV-1 RT-DNA/DNA and 
HIV-1 RT-DNA/RNA complexes, and inhibits only DNA polymerization derived from 
the HIV-1 RT-DNA/DNA complex. Another biochemical study concerning the effects 
of mutations in HIV-1 RT that affect residues contacting the template/primer provide 
some insight into this specialized property. Fisher et al. identified the N265D 
substitution, adjusting in the minor groove-binding track and making hydrogen bonds 
with the template strand (DNA and RNA), which led to a loss of processive 
polymerization on DNA templates but not on RNA templates.[103] This differential 
template usage was accompanied by a rapid dissociation of the N265D variant from 
DNA but not RNA templates. 3E4 might cause similar structural disruption to RT, with 
affecting DNA template/primer binding but without affecting RNA template/primer 
binding. 
 
 
2.4.4. in vivo Inhibition Study of HIV by 3E4 
 
The different performances among the identified inhibitors in vitro and in vivo, 
regarding specificity and toxicity, illustrates the importance of a secondary evaluation of 
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the hits resulting from the initial screening. 
The cell-based assay employing the self-inactivating HIV vector system identified 3E4 
as an active inhibitor in an cellular environment (Figure 18). The effect of 3E4 was 
further confirmed with the similar reduction of HIV-1 replication in vivo using a HIV 
wild type strain (Figure 19, Figure 20). The results from both assays fully correlate. 
Again, it is notably to say that the cellular activity of the pseudoknot aptamer was 
maintained in 3E4. 
While the anti HIV drugs targeting HIV-1 RT currently used in therapy can suppress 
viral replication to undetectable level, the emergence of drug resistant variants is still a 
unsolved problem. To test whether the drug resistant strains could be suppressed with 
3E4, further in vivo analysis is currently under examination. 
As discussed above, 3E4 as a HIV-1 RT inhibitor may act at the primer/template 
binding site. Recently, Fisher et al. provided an interesting discussion concerning the 
emergence of resistance to template/primer competing inhibitors.[104] The authors 
discovered that the mutations caused by DNA aptamer treatment, that overlaps with the 
binding surface of the primer/template complex, result in replication defective HIV by 
affecting RT-primer/template interactions. In addition, the aptamer-resistant mutations 
retain wild-type susceptibilities to all NRTIs and NNRTIs tested in vitro.[105] If such a 
DNA aptamer-like (also pseudoknot aptamer-like) inhibitory mechanism would act in 
case of 3E4, this compound would be highly promising for further evaluations. A small 
molecule drug like 3E4 providing aptamer-like functions will not only supersede 
burdensome procedures such like the preparation of expression vectors but also 
overcome the instability of nucleic acid-derived drugs under cellular conditions. 
 
 
2.4.5. 3E4 as a Drug Lead Structure  
 
It is not yet elucidated which stereoisomer of 3E4 is active in the assay performed. Both 
isomers of 4 are commercially available, thus in future both antipodes of 3E4 should be 
synthesized by the same strategy shown in Scheme 2. First it has to be elucidated 
whether the configuration at 3E4 has an effect on its activity. If one isomer turns out to 
be more active on HIV, the architecture of the corresponding chiral 3E4 structure can be 
considered as a lead compound to synthesize a number of derivatives. Comprehensive 
analysis using structure-activity relationship (SAR) is important for the optimization 
and prioritization of compound series. The required profile for 3E4 is to find derivatives 
with enhanced selective inhibitory effect on HIV-1 RT as well as to improve the 
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intrinsic poor solubility of 3E4. Indeed, the low solubility of 3E4 was the major 
problem in the assays for in vitro and in vivo characterization with respect to the 
preparation of the samples or the administration to the cell culture. Specially the percent 
of DMSO, in which the compound is suspended, was reduced to 1 % in all the assays 
performed in vivo, compared to the 5 % DMSO used in the RT assays. It was confirmed 
that 5 % DMSO haves no interference to the activity of RT employing the in vitro RT 
assays. It implies that 3E4 might have a effect to suppress the replication of HIV-1 RT 
at less concentrations than those that observed. Additionally, cell toxicity has to be 
addressed in these endeavors. 
Several anti-HIV inhibitors which share structural similarity with 3E4 are listed in 
Figure 22. By determining the structural nucleus within the diphenylurea group as 
observed similarly in Figure 12, the following three compounds have been selected. 
LY30046[106] was discovered by rational investigations to find the minimum molecular 
architecture of the tetrahydro imidazobenzo diazepinthiones (TIBO),[107] providing a 
new class of potent NNRTIs series derived from 
N-(2-phenylethyl)-N’-(2-thiazolyl)thiourea (PETT).[108] One of the PETT series 
inhibitor shows, besides high potency against HIV-1, marked activity against HIV-2 in 
a noncompetitive manner with respect to dGTP and poly(rC)/oligo(dG) as substrates, 
respectively. A novel molecular mode of action and mechanism of PETT series have 
been implied with interaction close to he active site but distal to the putative 
NNRTI-binding site by mutational mapping. Another RT inhibitor called KM-1 was 
reported as NNRTI that binds at a unconventional site to HIV-1 RT.[109, 110] Interestingly, 
KM-1 is believed to bind to RT in both the absence and presence of dsDNA but 
weakens the affinity for dsDNA so that it favors DNA dissociation. The data suggests 
that KM-1 distorts RT conformation and misaligns the dsDNA at the active site. One 
CCR antagonist, CCR is utilized for chemokine receptors in the initial stage of the 
infection, showed inhibitory activity of the HIV-1 envelope mediated membrane fusion 
during HIV-1 cell entry with extremely low IC50.[111] 
Taking the intriguing characteristics observed with 3E4 together with the possible 
speculation from the structurally similar compounds, 3E4 has been discovered as a 
novel type of potent inhibitor for anti-HIV therapy.  
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Figure 22. Structural comparison of 3E4 in other anti-HIV-1 drugs. LY300046[106] and KM-1[109, 110] 
of HIV-1 RT inhibitor, and one CCR antagonist[111] are shown. 
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3. in vitro Selection of Small Molecule Binding Proteins using 
mRNA-Display 
 
 
3.1. Introduction 
 
3.1.1. Protein Engineering by in vitro Selection 
 
In the past decade, in vitro selection technologies have provided essential tools to 
evolve proteins (or peptides) with functional properties based on combinatorial 
chemistry. As discussed in chapter 2, engineering of proteins with new activities and 
rapid assignment of their functions are of fundamental interest from both biological and 
pharmaceutical point of views. Advances in molecular biology have made great 
enhancement to generate high complexity of protein variants at the DNA level. In 
general, the evolutional strategies applied consist of iterative rounds of selection and 
amplification to identify desirable members from the molecular ensembles (library). 
Since proteins can not be amplified directly like DNA, all selection approachs 
necessitate the linkage of genetic information to the phenotype (Figure 23).[5] To 
perform in vitro selection, the linkage should be tolerant to technical manipulations. The 
methods currently used for in vitro selections are either physical linkage or 
compartmentalization.[112-115] Specially, the techniques employing the generation of 
physical linkages are also referred as “display” systems.[116-119] 
 
 
 
Figure 23. General selection strategy for isolation of functional proteins. Gray dotted line represents 
RNA or DNA selection. The figure is modified from Lin et al..[5] 
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Phage display is one of the first methods, that introduced indirectly the physical linking 
of a protein with its DNA sequence (Figure 24).[120-122] The encoded proteins are 
expressed on the surface of bacteriophage. A major drawback of this technology is the 
limitation of library size by the transformation efficiency of bacteria (approximately 
1010). Another approach described is ribosome display, that can be prepared totally in 
vitro, and reduce biases due to expression, resulting in a library complexity of >1012 
(Figure 24).[123-125] By eliminating the stop codon in the template mRNA, the ribosome 
stalls on the template after translation and generates ribosome-mRNA-peptide ternary 
complex. However, this ternary complex needs to be stabilized against dissociation by 
low temperature and high salt concentrations. The inherent instability of the complex 
makes it difficult to keep it intact during the selection steps and restricts the choice of 
conditions. A more robust method of physical linkage is to introduce a covalent bond. 
The modern technology called mRNA-display forms the covalent mRNA-protein 
conjugate by using puromycin, an antibiotic that mimics the aminoacyl end of tRNA 
(Figure 24). The mRNA-display system is apparently the most attractive for directed 
evolution among the above mentioned methods for a number of reasons. First, an 
expanded range of conditions can be exploited for the selection step. Second, unnatural 
amino acids can be incorporated directly into the proteins through suppressor codons. 
Finally, libraries of much greater complexity and size can be generated in the range of 
1011-1013, depending on the transcription/translation scale. 
 
 
 
Figure 24. Illustration of representative methods for in vitro display technologies. The figure is 
reproduced from Lin et al..[5] 
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3.1.2. in vitro Selection using mRNA-Display  
 
Initial papers on the principle of mRNA-display were published by Szostak[126] and 
Yanagawa[127] independently. A Selection using mRNA-display system provides an 
alternative method that can be applied to ligand discovery. In this approach, an encoded 
protein library is covalently fused to their own mRNA (Figure 25). mRNA-protein 
conjugates are able to be synthesized by using mRNA molecules that act as both 
template and protein acceptor on the surface of the ribosome. For this purpose, the 
mRNA contains a puromycin molecule at its 3’ end. Puromycin is an antibiotics that 
serves as a chemically stable small molecule mimic of aminoacyl tRNA (Figure 25). 
Initially, the ribosome binds and transits the template in 5’→3’ direction. When the 
ribosome reaches the 3’ end of the mRNA template, puromycin enters the peptidyl 
transferase site to form a covalent mRNA-protein fusion. 
 
 
 
Figure 25. The formation of a mRNA-protein fusion. The ribosome reads the template in 5’→3’ 
direction. tRNA (light gray) and the ribosome P- (pink) and A- (yellow) sites are shown. Puromycin 
enters the ribosome, attaching the template to the C-terminus of the nascent protein. 
 
To perform in vitro selection cycles (Figure 26), a synthetic oligonucleotide containing 
a 3’ puromycin is ligated to the 3’ end of transcribed mRNA and the resulting product is 
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translated in vitro using rabbit reticulocyte lysate. The mRNA-protein fusions generated 
are then isolated by affinity chromatography based on the oligonucleotide tag and 
peptide tags. After reverse transcription, mRNA/DNA-protein fusions are selected 
against an immobilized antigen or ligand. Selected complexes can be PCR amplified to 
serve as the input material of next cycle. The functional proteins will be enriched in the 
fraction via successive cycles of selection and amplification. 
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Figure 26. Schematic of mRNA-display in vitro selection cycle. a) A library of dsDNA (black line) 
is transcribed to generate mRNA (dotted line). b) The mRNA is ligated to a puromycin linker (blue). 
c) In vitro translation yields mRNA-displayed proteins. d) The complex is purified from the lysate 
mixtures using affinity chromatography. e) Reverse transcription generates mRNA/DNA double 
helix. f) The fusion library is sieved using the target of interest in the selection step. g) PCR 
amplification of selected molecules serves dsDNA sequences for input of the subsequent cycle. 
 
 
3.1.3. Applications of mRNA-Display 
 
Since the emergence of the mRNA-display system in 1997,[126, 127] a variety of new 
peptides and proteins have been discovered via in vitro selection. The libraries derived 
from mRNA-display technologies have demonstrated their ability to target versatile 
molecules including small molecule, nucleic acid, and protein. Keefe et al. evolved ATP 
binding proteins from the library containing 80 contiguous random amino acids, as 
simulating the evolution of primordial protein in the prebiotic era.[128] The selected 
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proteins had conserved CXXC sequence and functioned in zinc ion-dependent fashion. 
The authors estimated the frequency of occurrence of functional proteins in totally 
random sequence libraries, that is roughly one in 1011 which is similar to that observed 
with random RNA libraries. The peptide sequences capable of the recognition of a 
particular RNA loop motif called boxBR RNA have been identified from a library  
which has a randomized construct based on the corresponding RNA-binding domain of 
a λ N protein.[129] The in vitro selection resulted in peptides with high affinity (Kd = 
0.5-5.0 nM) and better specificity than the wild-type sequence. The first protein as 
binding target for mRNA-displayed protein library was streptavidine reported by 
Wilson et al..[130] The isolated peptides contained a HPQ consensus sequence, showing 
nanomolar affinity. This strong and specific interaction permitted to apply them to use 
as peptide tag for the purification of recombinant proteins.[131] Raffler et al. exploited 
mRNA display to select human α-thrombin binders.[132] In addition, clot formation of 
human plasma was inhibited by the isolated peptides. Further approach has been 
performed to construct protein libraries engineered from an antibody mimic 
scaffold.[133] Three exposed loops of an immunoglobulin-like protein, the tenth 
fibronectin type III domain (10Fn3), were randomized and used for a selection against 
tumor necrosis factor-α (TNF-α). 
mRNA-display potentially facilitates proteomic analysis. Not only random sequence 
libraries but also cellular protein libraries can be generated by mRNA-display, and those 
cellular derived libraries have been selected for specific targets such as v-Abl tyrosine 
linase substrate,[134] anti-apoptotic protein Bcl-XL,[135] and Ca2+ sensor calmodulin 
(CaM).[136] The sequence characterization of the identified proteins enables to elucidate 
cellular interaction partners and protein-protein interaction networks. The mentioned 
proteome scanning using mRNA-display resulted in all three experiments in the finding 
of both known and previously unknown binding partners. 
Another application in the proteomic field is to establish addressable protein 
microarrays using mRNA-protein fusion. Weng et al. demonstrated that a standard 
DNA chip could be converted into a protein chip by hybridization of the informational 
content of the nucleic acid component of the mRNA-protein fusions.[137] The system 
was sensitive enough to detect sub-attomole quantities of the proteins. 
mRNA-display technologies are even compatible with unnatural amino acids 
incorporation via amber codon suppression[138, 139] or four-base anticodon.[140] 
Furthermore, by reprogramming the universal genetic code for 20 naturally occurring 
amino acids, the unnatural peptide library containing different unnatural amino acids are 
able to be generated.[141] This technique greatly expands chemical and functional 
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diversity. 
As discusssed above, various examples have demonstrated that mRNA-display is a 
powerful tool for both ligand discovery and interaction analysis. The major advantage 
of this technique is that manipulations occur in vitro starting from the generation of the 
library to selection, making it more tunable for desired investigations. 
 
 
3.1.4. Coenzymes and Small Molecule Dyes as Selection Targets 
 
Coenzymes are fundamental component in biology and are required for the function of 
many essential proteins common to all living organisms. At the same time, 
coenzyme-dependent proteins constitute a very large group of proteins that play central 
roles in the metabolism of the cell. The adenine binding motif shared among ATP-, 
coenzyme A (CoA)-, nicotinamide adenine dinucleotide (NAD)-, nicotinamide adenine 
dinucleotide phosphate (NADP)-, and flavine adenine dinucleotide (FAD)-dependent 
proteins indicates that these coenzyme-dependent proteins are likely to be “ancient 
proteins” in the evolutionary process.[142] The simple description for the requirement of 
common adenine-binding motifs are 1) backbone polar interactions that are not 
dependent on the protein sequence or particular properties of amino acid side chains, 
and 2) nonspecific hydrophobic interactions. 
Proteins that bind dinucleotides (NAD and NADP, Figure 27) function pivotally in 
energy production, exchange and consumption. The classical dinucleotide binding fold 
is referred as Rossmann fold that contains βαβαβ unit.[143, 144] The core topology locates 
in the first 30-35 amino acids, so-called “fingerprint” region and is characteristic for 1) 
a phosphate binding consensus sequence GXGXXG (where X is any other amino acids), 
2) six positions usually occupied by small hydrophobic amino acids, 3) a conserved 
negatively charged residue (Glu or Asp) at the end of the second β strand of the 
fingerprint, and 4) a conserved positively charged residue (Arg or Lys) at the beginning 
of the first β strand of the fingerprint. Although most of the dinucleotide binding 
proteins are thought to contain the classical Rossmann fold, still numerous nonclassical 
folding patterns, less observed than the classical fold, are used by proteins that bind 
NAD(P). 
CoA is involved in various essential pathways, such as fatty-acid degradation and the 
citric acid cycle (Figure 27). Acetyl-CoA is a central intermediate in the metabolism of 
almost all kinds of biological compounds, including amino acids, carbohydrates and fats. 
On the contrary to dinucleotide binding fold, the CoA-dependent proteins cover a wide 
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variety of different topologies, including Rossmann fold, TIM barrel, or four helical 
up-and-down bundle.[145, 146] 
Cibacron blue 3GA is a water-soluble triazine dye that binds to the nucleotide binding 
fold of many proteins. The similarity of its three dimensional structure with NAD(P) 
enables to purify NAD(P) binding proteins on affinity chromatography using 
immobilized cibacron blue 3GA[147, 148] as well as to analyze the structures of those 
proteins by co-crystallization.[149, 150] 
In vitro selections of protein libraries which target coenzyme binding allow comparison 
with known biological coenzyme-binding motifs and might bring insight to understand 
protein evolution, e.g. as proteins have evolved from relatively random sequence 
scrambles in the ancient period. 
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Figure 27. Structures of target molecules used for in vitro selections. 
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3.2. Aims of Study 
 
To isolate functional proteins with desired properties, a number of methods are 
available in current days. As discussed in chapter 3.1, mRNA-display has turned out to 
be an improved generic strategy for in vitro selection and holds extensive potential for 
future applications. The aim of this study is to establish a in vitro selection scheme 
using mRNA-display to identify the proteins that can bind to small molecule targets. 
There is only one report which has showed the in vitro selection against the small 
molecule ATP, compared to numerous reports that describe protein targets. To enhance 
the possibility for small molecule recognition with folding stability, the design of 
secondary structural patterning such as α-helix or β-strand should be introduced to the 
library construction. Coenzymes (NADP and coenzyme A) have been chosen as small 
molecule targets, because following sequence analysis of isolated proteins allows 
comparison to known coenzyme binding motifs. Additionally, it is of interest to 
investigate which type of folding or motif can be dominantly evolved from the random 
sequence library. The results might provide insight to understand protein evolution in 
ancient era. Cibacron blue 3GA have been chosen, because it is known that the dye can 
interact with variety of proteins by mimicking the NAD(P) structure. 
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3.3. Results 
 
3.3.1. Construction of a DNA Library of long ORFs for mRNA-Display 
 
Chemically synthesized DNA library to construct randomized protein library is always 
accompanied with the problem of deletions at the DNA level due to imperfect coupling 
and capping efficiency during solid phase DNA synthesis. These cause frameshifts and 
undesired stop codons during translation, resulting in premature termination at protein 
library level. Accordingly, the number of intended sequences in the protein library will 
be greatly reduced. To address these problems, a DNA library encoding polypeptides in 
total length of 117 amino acids for mRNA-display was constructed using a strategy 
reported by Cho et al..[151] As described in Figure 28, the final DNA library consists of 
four short cassettes. Each cassette is designed to encode constant regions (T7, TMV, 
and FLAG in 5’ as well as His6-tag and linker in 3’) and a 22 amino acids long random 
region. The random region is flanked by two different restriction sites, BbsI and BbvI. 
Using the short DNA cassettes which have been enriched for those sequences lacking 
stop codons and frameshifts through protein tag purifications, the assembly proceeded 
by dividing the dsDNA library into two aliquots, one of which was cut with BbsI and 
the other with BbvI. The purified fragments were then ligated together with T4 DNA 
ligase. Two successive restrictions and ligations yielded the final DNA library in which 
the random region is 88 amino acids long. 
Furthermore, not only a totally random (unpatterned: R) cassette but patterned cassettes 
(α, β), in which polar and nonpolar residues were arranged so as to have peptide 
domains with propensity for forming amphiphatic secondary structures like α-helices 
and β-strands, were incorporated into a final DNA library. Thus, 36% of the 
incorporated cassettes encode α-helices; 46% were β-strands; 18% were unpatterned 
random sequences in the full length DNA library. These patterning increases the 
fractions in the library with the ability of constituting a well-defined folding pattern. 
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Figure 28. The strategy to construct a DNA library of long ORFs for mRNA-display.[151] Four DNA 
short cassettes are assembled into the full-length library. BbsI and BbvI are the restriction enzymes, 
which divide each cassette into two aliquots by different restriction sites. The cleavage sites are 
shown with arrows. After two successive ligation steps the flanking regions for the constant 
sequences remain the same. T7: T7 promoter sequence, TMV: tobacco mosaic virus translation 
enhancer sequence, Flag: Flag-tag sequence, His6: His6-tag sequence, Linker: linker annealing site. 
 
The final full length DNA library resulted from the assembly of four cassettes was 
designed to encode a 88 amino acids long random sequence and several constant 
regions at both ends (Figure 29). At the 5’-end, the transcription promoter and 
translation enhancer sequences were located. The random sequence is flanked by two 
peptide tags for the purification of mRNA-displayed proteins: FLAG-tag at the 
N-terminal and His6-tag at the C-terminal position. A oligonucleotide sequence 
complementary to a linker used for photoligation[152, 153] was included at 3’-end. This 
DNA library was used to prepare mRNA-displayed protein library to perform in vitro 
selection against small molecule targets as shown in the following chapters. 
 
 
 
Figure 29. DNA library design for mRNA-display. Untranslated sequences are in gray color and 
translated sequences are in white and black. White boxes encode constant regions and black box 
encodes random amino acids sequence (88-aa). TMV: tobacco mosaic virus translation enhancer 
sequence. 
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3.3.2. Generation of m-RNA-Displayed Protein Library 
 
First, the DNA library was transcribed by T7 RNA polymerase and thereafter a 
photolinker oligonucleotide bearing the puromycin moiety was ligated at its 3’ end. The 
mRNA linked to puromycin was translated in vitro, yielding the proteins displaying 
their mRNA via the puromycin linkage. The resulting mRNA-protein fusion library was 
then purified on oligo-dT cellulose and peptide tag affinity chromatography, and reverse 
transcribed. One of the affinity chromatography Ni-NTA agarose captures the proteins 
expressing a His6-tag at the C-terminus, so that the mRNA-displayed proteins that 
include internal stop codons or frameshifts can be excluded. Optionally anti-FLAG 
affinity chromatography was introduced to avoid proteins translated by internal 
initiation. The generation of RNA/DNA heteroduplex by reverse transcription prevented 
enrichment of RNA aptamers. The formation of mRNA-protein fusions and reverse 
transcribed mRNA/DNA-protein fusions was monitored by SDS gel analysis during the 
cycles (Figure 30). The library used for the in vitro selections consisted of 1 × 1011 - 5 × 
1012 different displayed proteins (for details concerning affinity chromatography and the 
input diversity; see the following sections). 
 
 
Figure 30. SDS gel analysis of the formation of mRNA-protein fusions. The loaded samples are as 
follows; lane 1: after in vitro translation, lane 2: elution from oligo-dT affinity chromatography, lane 
3: elution from anti-FLAG affinity chromatography, lane 4: elution from Ni-NTA affinity 
chromatography, lane 5: before reverse transcription, lane 6: after reverse transcription. 
 
 
3.3.3. Selection against Cibacron Blue 3GA 
 
The random sequence library generated with 1 × 1011 different proteins was subjected to 
iterative cycles of in vitro selection and amplification. In each cycle the 
mRNA-displayed proteins were incubated with immobilized cibacron blue 3GA, 
washed and eluted with free NAD. The eluted fractions were collected and amplified by 
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polymerase chain reaction (PCR), and the resulting DNA was then used to generate new 
mRNA-displayed proteins for input into the next cycle of selection (Figure 26). The 
operations for each purification steps during the cycles are listed in  
Table 5. After nine cycles, raising percentage (30 %) of the mRNA-displayed proteins 
that retain on the column after elution was observed ( 
Table 5, Figure 31). However, the fractions eluted with NAD remained at low amounts 
of the proteins even after nine cycles. 
 
Cycle  
number 
1 2 3 4 5 6 7 8 9 
Oligo(dT)  ○ ○ ○ ○ ○ ○ ○ ○ ○ 
FLAG ○ ○ ○ ○ ○ ○ ○ ○ ○ 
Ni-NTA ○ ○ ○ ○ ○ ○ ○ ○ ○ 
Elution [%] 10.4 0.28 0.25 0.64 1.59 0.54 0.53 0.54 0.68 
Column [%] 37.7 27.6 8.3 4.5 20.7 15.0 28.1 24.0 31.0 
PCR cycle 20 22 22 16 13 13 17 10 11 
 
Table 5. The course of each cycle for cibacron blue 3GA selection using mRNA-displayed proteins. 
○: the purification step performed, -: not performed. The cycle numbers required for PCR 
amplification after selection are depicted. 
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Figure 31. Progress of the selection against Cibacron blue 3GA. The bars represent the percentage 
of radioactivity that eluted from the column matrix (white) and remained on the column (dark gray). 
 
Sixty-nine randomly chosen clones from the PCR product from ninth cycle were 
sequenced. Surprisingly 42 % of the analyzed sequences were frame-shifted from the 
intended frame (Figure 32). There were also sequences carrying internal stop codons 
(17 %), and even sequences which are composed of less or more numbers of cassettes 
than four (9 %). 32 % of the intact full length sequences were observed. In Figure 33, 
the percent of the appearance of the cassettes’ type is depicted. The most frequently 
identified type of cassette was αβαβ. The alignment of full length sequences resulted in 
three sequences in different cassette’ type which appeared to be duplicates with one 
point mutation. Other sequences exhibited to be broadly diverse. No conserved amino 
acids sequence motif was observed within these sequences. 
 
 
3. in vitro Selection of Small Molecule Binding Proteins using mRNA-Display 
60 
 
 
Figure 32. Analysis of cloned sequences from the elution fraction in ninth cycle. 
 
 
 
Figure 33. Percent of appeared sequences depending on the type of cassettes. 
 
To test whether the protein fractions remained on the column are nonspecific matrix 
binder, the mRNA-displayed proteins from ninth cycle were incubated on cibacron blue 
3GA agarose and then eluted from the column competitively by different elution 
conditions (Figure 34). By raising the NAD concentration to 50 mM (10-fold) in elution 
condition, ca. 3.0 % of the proteins were able to be eluted from the matrix. This DNA 
sequences were amplified by PCR and used for the subsequent selection (cycle 10). 50 
mM of NAD eluted again the approximately same percentage of the proteins (3.2 %) in 
the tenth cycle, which implies no enrichment of NAD binders. While elution conditions 
including 5 mM of cibacron blue 3GA could competitively elute most of the protein 
fractions stayed on the column (ca. 30%). These results indicate that the proteins 
retained on the column are no matrix binders, and the operated selection conditions 
seemed to force the protein library to bind more tightly to cibacron blue 3GA than 
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NAD. 
 
 
Figure 34. Different elution experiment with the mRNA-displayed proteins from ninth cycle. 
 
 
3.3.4. Selection against NADP 
 
The mRNA-displayed protein library which was composed of 5.0 × 1012 different 
sequences was generated for the input in the first selection cycle. This library was 
incubated with immobilized NADP, washed and eluted by free NADP. PCR 
amplification of these molecules yielded the starting material for the next round of 
selection. In the first cycle, a preselection against nonderivatized matrix (adipic acid 
hydrazide agarose) was introduced to eliminate possible matrix binders. The 
purification step using anti-FLAG-tag affinity chromatography was omitted. The details 
about the course of consecutive cycles are described in Table 6. As shown in Figure 35, 
no significant increase of protein amounts in both elution fractions and fractions 
retained on the column was observed even after seven cycles. The obtained result 
suggests that no enrichment of NADP binders was obtained. 
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Cycle  
number 
1 2 3 4 5 6 7 
Oligo(dT)  ○ ○ ○ ○ ○ ○ ○ 
FLAG - - - - - - - 
Ni-NTA ○ ○ ○ ○ ○ ○ ○ 
Elution [%] 0.77 2.21 0.10 0.30 0.56 0.23 0.42 
Column [%] 0.38 2.76 0.17 0.21 0.19 0.18 0.20 
PCR cycle 21 20 19 15 17 18 17 
 
Table 6. The course of each cycle for NADP selection using mRNA-displayed proteins. ○: the 
purification step performed, -: not performed. The cycle numbers required for PCR amplification 
after selection are depicted. 
 
 
Figure 35. Progress of the selection against NADP. The bars represent the percentage of 
radioactivity that eluted from the column matrix (white) and remained on the column (dark gray). 
 
 
3.3.5. Selection against CoA 
 
For the selection targeting CoA, the matrix derivatized with CoA was prepared from 
thiopropyl sepharose as described in Figure 36. The coupling of CoA via disulphide 
bond enables non-competitive but specific elution of the bound proteins by covalent 
bond cleavage with DTT treatment. This would allow to enrich tight binders which have 
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low dissociation constants.  
 
 
 
Figure 36. Affinity column preparation and selection strategy targeting CoA. 
 
Random sequence protein library generally tends to have a intrinsic poor solubility and 
low potentiality for stable folding. To improve such properties of mRNA-displayed 
proteins, a selection strategy was designed by the addition of a small amount of 
denaturant in the selection condition. In comparison to phage display or ribosome 
display, mRNA-display is uniquely suited for this purpose because it is an entirely in 
vitro selection system based on a covalent linkage between translated proteins and their 
encoding mRNA. Chaput et al. re-selected ATP binding proteins, which have been  
isolated by using mRNA-display, to optimize protein folding stability in the presence of 
increasing concentrations of guanidine hydrochloride.[154] One selected sequnence has 
shown a unique folded structure by circular dichroism, tryptophan fluorescence, and 
1H-15N correlation NMR studies. In the following selection against CoA, two selections 
are performed in parallel, one in physiological condition and the other in slightly 
denaturing condition, to examine the effects of the selection pressure for better folding 
using the same target molecule. 
Starting from 1.2 × 1012 unique protein sequences, several successive cycles of in vitro 
selection and amplification were performed under the respective condition. For the 
selection, mRNA-displayed proteins were incubated with CoA immobilized sepharose 
in the absence of GuHCl (physiological condition) and in the presence of 0.5 M GuHCl 
(slightly denaturing condition). After washing each column with the respective buffer, 
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the bound proteins were recovered specifically by liberating the CoA moiety from the 
matrix with DTT. The encoding DNA sequences were PCR amplified and used to 
generate a new library of mRNA-displayed proteins for input into the next selection 
cycle. Anti-FLAG affinity purification was skipped and after the sixth cycle under 
natural condition and fifth under denaturing condition, Ni-NTA purification was 
omitted to reduce any stringency. The details about the course of cycles are described in 
Table 7. As shown in Figure 37, no significant increase of protein amounts in elution 
fractions was observed under both physiological condition and slightly denaturing 
condition until the eighth and seventh cycle, respectively. The results suggest that no 
enrichment of CoA binders was obtained in both selections. 
 
A 
Cycle number 
1 2 3 4 5 6 7 8 
Oligo(dT)  ○ ○ ○ ○ ○ ○ ○ ○ 
FLAG - - - - - - - - 
Ni-NTA - ○ ○ ○ ○ - - - 
Elution [%] 0.04 1.84 3.11 0.33 0.27 0.55 0.34 0.57 
Column [%] 0.11 0.43 0.22 0.13 0.13 0.07 0.04 0.05 
PCR cycle 20 24 25 22 22 17 16 20 
 
B 
Cycle number 
1 2 3 4 5 6 7 
Oligo(dT)  ○ ○ ○ ○ ○ ○ ○ 
FLAG - - - - - - - 
Ni-NTA - ○ ○ ○ - - - 
Elution [%] 0.04 0.37 0.36 0.24 0.55 0.28 0.44 
Column [%] 0.10 0.21 0.10 0.08 0.08 0.05 0.04 
PCR cycle 20 25 22 26 17 16 18 
 
Table 7. The course of each cycle for Coenzyme A selection using mRNA-displayed proteins under 
physiological condition (A) and slightly denaturing condition (B). ○: the purification step performed, 
-: not performed. The cycle numbers required for PCR amplification after selection are depicted. 
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Figure 37. Progress of the selection against Coenzyme A. The bars represent the percentage of 
radioactivity that eluted from the column matrix under physiological condition (white) and slightly 
denaturing condition (dark gray). 
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3.4. Discussion and Perspective 
 
Three independent in vitro selections using mRNA-display have been performed to 
target coenzymes (NADP and CoA) and a small dye molecule (cibacron blue 3GA). The 
cibacron blue 3GA selection resulted in the enrichment of specific binders. However, 
the isolated sequences are not yet fully characterized. The sequence analysis of the 
fraction eluted by NAD from the ninth cycle showed unexpectedly a few numbers of 
full length proteins and abundant proteins derived from unintended reading frames. This 
argues the quality and the necessity of peptide-tag purification of the library before the 
selection process. A similar observation was described by Wilson et al..[130] The authors 
identified streptavidin binders from the patterned sequence protein library consisting of 
88 amino acids. They also applied the purification step using Ni-NTA affinity 
chromatography to exclude such frameshifted products. However, the sequence analysis 
of the selected proteins turned out that their initial design of pattern of polar and 
nonpolar residues was discarded by frameshifts, leaving an essentially random sequence. 
It was mentioned that this was caused due to the higher frequency of the conserved 
amino acids sequence motif (HPQ) in the shifted open reading frame. This finding leads 
to the idea to align the majority of frameshifted sequences to search for a new consensus 
motifs required for target binding. 
As discussed in §3.3.3, the alignment of full length sequences cloned from the ninth 
cycle by NAD elution showed no invariant amino acids motif and quite diverse 
sequences. However, the selection yielded the most frequent type of cassette for αβαβ, 
that include the part of important folding βαβ where the fingerprint region locates in the 
Rossmann fold. To characterize the cibacron blue 3GA specific binders, the fraction 
eluted by cibacron blue 3GA competitively (Figure 34) should be cloned and sequenced. 
This will provide a more detailed analysis of enriched proteins. 
No enrichment of binding proteins was observed with two selections against NADP and 
CoA unfortunately. Considering the number (1 out of 1011) for the frequency of 
functional proteins estimated for ATP binder,[128] the input diversity for each selection 
were in the same range like most other successful selections done. However, selection 
against ATP using mRNA-display remains the single report for selection against a small 
molecule target. In general, small molecule recognition by protein requires well defined 
binding pockets. The incidence of stably folded structures from a totally random 
sequence protein assembly can be easily imagined to be very low. In fact, Chaput et al. 
needed to improve the poor solubility and folding stability of ATP binders by 
re-selection under the denaturing condition.[154] Taking together, the rate of occurrence 
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estimated for the ATP binders might have been exaggerated for small molecule targets. 
Alternatively the problems arising from intrinsic poor solubility and folding instability 
might be addressed by the construction of scaffolded libraries. The lipocalin family[155] 
can be a considerably attractive candidate for such an endeavor. Lipocalins constitute a 
structural family of small functionally diverse proteins comprising 160-180 residues, 
with conserved β-barrels as their central folding motif. They exhibit great functional 
diversity including retinol transport, invertebrate cryptic coloration, olfaction and 
pheromone transport, and prostaglandin synthesis. The loop regions of the lipocalin 
family are remarkably dissimilar in length and conformation, reflecting the differing of 
shapes and chemical properties of their cognate ligands. Thus, the lipocalins show 
molecular recognition with the ability to bind a wide range of ligands including small 
hydrophobic molecules, specific cell-surface receptors, and macromolecules. The 
potential of small molecule binding by the lipocalins scaffold has been demonstrated by 
Beste et al..[156] The authors engineered the lipocalin protein by randomization in the 
loop region to resemble immunoglobulin. The resulting scaffold library was selected for 
fluorescein binding using phage display. Since it has been demonstrated with phage 
display, the lipocalin scaffold might be able to expand the ligand variety and property 
for usage in in vitro selections by mRNA-display due to stable folding. 
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4. Materials and Methods 
 
4.1. Materials 
 
4.1.1. Equipment 
 
Equipment; type Manufacturer 
Agarose gel chamber Cosmo Bio 
Autoclave Systec 
Automated liquid handling system; 
Freedom evo 
Tecan 
Balance; JL-200, 
BL1500S; BP 211D 
Chyo 
Sartorius 
Centrifuge Eppendorf 
Compact reagent grade water system,  
Easy pure UV/UF 
Barnstead 
Electrophoresis power supply Consort 
EI-MS; Finnigan MAT 95XL Thermo Finnigan 
FAB-MS; Concept 1H Kratos 
Fluoroskan Ascent FL Labsystem 
Geiger-Counter; LB122 Berthold 
Gel documentation system Bio-Rad 
Gel dryer Bio-Rad 
HPLC; 1100 series Agilent technologies 
Incubator shaker; 4430 Innova 
Magnetic stirrer IKA 
Micropipettes Eppendorf 
Microwave Bosch 
NMR; DPX300, DPX400, DPX500 Bruker 
Nucleic acid sequencing Electrophoresis 
apparatus 
Bio-Rad 
Oven WTBbinder 
PCR apparatus Eppendorf / Biometra 
pH meter Inolab 
PhosphorImager; FLA-3000 Fujifilm 
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Photometer; BioMate3 ThermoSpectronic 
Scintillation counter; winSpectral 1414 PerkinElmer 
Speed-Vac; Concentrator 5301 Eppendorf 
Surface plasmon resonance (SPR); 
Biacore 3000 
Biacore 
Thermo block Stuart Scientific 
Thermo mixer Eppendorf 
UV transilluminator Bachofer 
UV/VIS spectrometer; Lambda 2S PerkinElmer 
Vertical electrophoresis apparatus Bio-Rad 
Vortexer Neolab 
Water bath GFL 
 
 
4.1.2. Consumable 
 
Product Manufacturer 
Centrifuge tube (15 ml, 50 ml) Greiner 
Chromatography paper 3MM Whatman 
Disposable filter (0.2 µm) QualiLab 
Disposable syringe Henke Sass Wolf / Braun 
Glass wool Serva 
Micropipette tip Peske / Biozym 
MicroSpin column (Sephadex G-25) Amersham 
NAP-column (NAP-5, 10, 25) Pharmacia Biotech 
PolyPrep chromatography column Bio-Rad 
Prepacked micro spin column, P-30 Bio-Rad 
Reaction tube Eppendorf 
Sensor chip (CM5, SA) Biacore 
Steril filteration units Millipore 
Steril surgical blade Bayha 
Ultrafree-MC centrifugal filter device  Millipore 
96-well plate Costar 
384-well plate Greiner 
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4.1.3. Chemicals 
 
The water used for all biochemical experiment was deionized by compact reagent grade 
water system (Easy pure UV/UF), treated with diethylpyrocarbonate (DEPC), then 
autoclaved. 
 
Chemical Manufacturer 
Acetic acid Merck 
Agarose Invitrogen 
Agarose low melting point Sigma 
Ammonium acetate Merck 
Ammonium peroxydisulfate (APS) Roth 
Ammonium sulfate Merck 
Ampiciline Sigma 
Boric acid KMF 
5-Bromo-4-chloro-3-indolyl-β- 
galactopyranoside (D-Gal) 
Sigma 
Bromophenol blue Merck 
Chloroform Kraemer & Martin 
Cibacron blue 3GA Sigma 
Coenzyme A (CoA) Sigma 
Coomasssie brilliant blue G-250 Merck 
Diethyl pyrocarbonate (DEPC) Sigma 
Dimethylchlorosilane Fluka 
Dimethylformamide (DMF) Fluka 
Dimethylsulfoxide (DMSO) Fluka 
1,4-Dithiothreitol (DTT) Acros 
Ethanol Merck 
Ethidium bromide Roth 
Ethylenediaminetetraacetic acid (EDTA) Merck 
Formamide Fluka 
Glycerol AppliChem 
Glycine AppliChem 
Glycogen Roche 
Guanidine hydrochloride Sigma 
HEPES Roth 
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Hydrochloric acid min. 37 % Riedel-deHaean 
Imidazole Fluka 
Isopropanol Fisher Scientific 
Isopropyl-β-D-thiogalactopyranoside 
(IPTG) 
Roth 
Magnesium chloride Fluka 
β-Mercaptoethanol Sigma 
Methanol Fluka 
β-Nicotinamide adenine dinucleotide 
(NAD) 
ICN 
β-Nicotinamide adenine dinucleotide 
phosphate sodium salt (NADP) 
Fluka 
Potassium chloride Acros 
Potassium dihydrogen phosphate 
(KH2PO4) 
Merck 
Potassium hydroxide Acros 
Roti-phenol Roth 
Rotiphorese Gel 30 Roth 
Rotiphorese sequencing gel concentrate Roth 
Sodium acetate Merck 
Sodium chloride KMF 
Sodium dihydrogen phosphate dehydrate 
(NaH2PO4·2H2O) 
Riedel-deHaean 
Sodium dodecyl sulfate (SDS) Roth 
Disodium hydrogen phosphate dihydrate 
(Na2HPO4·2H2O) 
Merck 
Sodium hydroxide KMF 
Spermidine Sigma 
N,N,N',N'-Tetramethylendiamine 
(TEMED) 
Merck 
Tricin AppliChem 
Tris-(hydroxymethyl)-aminomethane 
(Tris) 
Roth 
Triton X-100 Merck 
Urea AppliChem 
Xylen cyanol Merck 
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4.1.4. Chromatography 
 
Chromatography Manufacturer 
Adipic acid hydrazide immobilized on 
cross-linked 4 % beaded agarose 
Sigma 
Anti-FLAG M2 affinity gel freezer-safe Sigma 
Cibacron blue 3GA immobilized on 
cross-linked 4 % beaded agarose 
Sigma 
Nicotinamide adenine dinucleotide- 
agarose 
ICN 
β-Nicotinamide adenine dinucleotide 
phosphate immobilized in cross-linked 
4 % beaded agarose 
Sigma 
Ni-NTA agarose Qiagen 
Oligo(dT) cellulose type 7 Amersham 
Thiopropyl sepharose 6B Amersham 
Ultro gel A4 Sigma 
 
 
4.1.5. Nucleotides and Radiochemicals 
 
Product Manufacturer 
Deoxyribonucleotides triphosphate 
(dNTPs) 
Roche 
Ribonucleotides triphosphate (NTPs) Roche 
[γ-32P]-ATP (3000 Ci/mmol) PerkinElmer 
[α-32P]-GTP (3000 Ci/mmol) PerkinElmer 
[α-32P]-TTP (3000 Ci/mmol) PerkinElmer 
[35S]-Methionine (1000 Ci/mmol) Amersham 
 
 
4.1.6. Enzymes and Proteins 
 
Product Manufacturer or Donor 
AMV (Avian Myeloblastosis Virus) 
reverse transcriptase 
Promega 
 
4. Materials and Methods 
73 
Bbs I New England Biolabs 
Bbv I New England Biolabs 
Bovin serum albumin (BSA) Sigma 
Calf intestinal alkaline phosphatase 
(CIAP) 
Stratagene 
DNase I (RNase-free) Roche 
FLAG peptide Sigma 
HIV-1 reverse transcriptase (HIV-1 RT) Prof. Restle, University of Luebeck 
HIV-2 reverse transcriptase (HIV-2 RT) Prof. Restle, University of Luebeck 
Human DNA polymerase β Prof. Marx, University of Konstanz 
Inorganic pyrophosphatase Roche 
Klenow fragment exo- New England Biolabs 
M-MLV (Moloney Murine Leukemia 
Virus) reverse transcriptase 
Promega 
Pfu DNA polymerase Prof. Famulok 
RNasin ribonuclease inhibitor Promega 
Superscript II reverse transcriptase Invitrogen 
T4 DNA ligase New England Biolabs 
T4 polynucleotide kinease (T4 PNK) New England Biolabs 
T7 RNA polymerase Prof. Famulok 
Taq DNA polymerase Prof. Famulok 
 
 
4.1.7. Standards and Kits 
 
Product Manufacturer 
Amine coupling kit Biacore 
100-bp DNA ladder PeqLab 
High Range Rainbow Marker RPN756 Amersham 
Low Range Rainbow Marker RPN755 Amersham 
NucleoSpin Extract II Kit Macherey-Nagel 
NucleoTrap Kit Macherey-Nagel 
QIAprep spin miniprep kit Qiagen 
Rabbit Reticulocyte Lysate Novagen 
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4.1.8. Plasmid and Bacterial Strains 
 
Product Manufacturer 
pGEM-T vector system Promega 
E. coli DH10B Qiagen 
 
 
4.1.9. Oligonucleotides 
 
The synthetic DNA oligonucleotides were purchased from MWG or Metabion. The 
FRET-labeled RNA substrate was purchased from IBA. Other RNAs were transcribed 
from dsDNA synthesized by PCR using following appropriate DNA templates and 
primers. T7 promoter sequences are italicized in primer and template sequences. 
 
The following oligonucleotides were used for the experiments in chapter 2. 
 
FK-1 (RNA):  
5’-GGG UCC UCU GAU GAG CUU CCG UUU UCA GUC GGG AAA AAC UGA AGC GAA ACU 
CGU-3’ 
FK-1 template: 
5’-TCT AAT ACG ACT CAC TAT AGG GTC CTC TGA TGA GCT TCC GTT TTC AGT CGG 
GAA AAA CTG AAG CGA AAC TCG T-3’ 
T7 promoter primer19: 
5’-TCT AAT ACG ACT CAC TAT A-3’ 
3’primer_FK-1: 
5’-ACG AGT TTC GCT TCA GTT TTT CC-3’ 
HHRz-FRET-substrate (RNA): 
5’-FAM-ACG AGU CAG GAU U–TAMRA-3’ 
 
anti–HIV-1 RT aptamer (RNA): 
5’-GGG AGC UUC CGU UUU CAG UCG GGA AAA ACU GAA-3’ 
anti-HIV-1 RT aptamer template: 
5’-TAA TAC GAC TCA CTA TAG GGA GCT TCC GTT TTC AGT CGG GAA AAA CTG AA-3’ 
T7 promoter primer17: 
5’-TAA TAC GAC TCA CTA TA-3’ 
3’primer_anti-HIV RT aptamer: 
 
4. Materials and Methods 
75 
5’-TTC AGT TTT TCC CGA CTG-3’ 
 
RT-assay template: 
5’-GTG CGT CTG TCA TGT CTG TCA GAA ATT TCG CAC CAC-3’ 
RT-assay primer: 
5’-GTG GTG CGA AAT TTC TGA C-3’ 
PCR_template for RT-assay template: 
5’-TCT AAT ACG ACT CAC TAT AGT GCG TCT GTC ATG TCT GTC AGA AAT TTC GCA 
CCA C-3’ 
 
Biotin-P12II: 
5’-Biotin-CAC ACC CCG CGC-3’ 
RT18II: 
5’-GCG CGG GGT GTG GTG GTA-3’ 
 
The following oligonucleotides were used for the experiments in chapter 3. The 
sequences designed for protein tag, restriction enzyme recognition, and translation 
initiation were underlined with their explanation. The sequences for start and stop 
codons were shown in bold letters. The two sequences for proralen insertion were in 
italicized bold letters. XYZ indicates one codon with randomized nucleotide sequences. 
 
mRNA-display library: 
5’-TTC TAA TAC GAC TCA CTA TA GGG ACA ATT ACT ATT TAC AAT TAC A  
             T7                                     TMV 
ATG  GAC TAC AAG GAC GAC GAC GAC AAG  GGA AGA CTG AGT GGA (XYZ)17 CCA 
start                    FLAG tag                          Bbs I                   random 
GGG AGT AGT (XYZ)21 AGT (XYZ)21   AGT GGA (XYZ)17 CCA GGG AGT AGT 
                  random           random                 random 
GCT AGC GTA GCT  GCA  CAT CAC CAC CAC CAC CAT GGC AGC GGC GCT ATT TAA  
out of frame stop      Bbv I                 His tag                                 psoralen    stop 
AA-3’ 
 
5’primer: 
5’-TTC TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT AC-3’ 
3’primer: 
5’-TTT TAA ATA GCG CCG CTG CCA TGG TG-3’ 
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5’short primer: 
5’-TTC TAA TAC GAC TCA CTA TAG GGA C-3’ 
3’short primer: 
5’-TTT CAA ATA GCG CCG CTG CCA TG-3’RT primer: 
5’-GCC ATG GTG GTG GT-3’ 
 
Photo linker: 
5’-(Ps)-UAGCGCCGCU-(dA)21-(18)(18)-dCdC-(Pu)-3’ 
(Ps: psoralen C-6, Pu: puromycin CPG, 18: Spacer C 18 PEG, N: 2’-OMe modified 
RNA nucleotide) 
 
 
4.2. General Methods for Manipulation of Nucleic Acids 
 
All buffers and solutions for RNA manipulation were prepared with ultra pure water 
treated with diethylpyrocarbonate (DEPC). To prepare DEPC-treated water, 1L of ultra 
pure water was mixed with 2 ml of DEPC and incubated overnight at room temperature, 
then autoclaved. 
 
 
4.2.1. Phenol/Chloroform Extraction 
 
Phenol/chloroform extraction was used to remove proteins from nucleic acid solutions. 
An equal volume of phenol was added to the aqueous nucleic acid solution, vortexed for 
1 min, and centrifuged for 3 min at 14,000 rpm to separate the phases. The upper 
aqueous phase was transferred into to a new tube. To remove residual phenol from the 
nucleic acid containing aqueous solution, double volume of chloroform was added to 
this solution, vortexed, and centrifuged for 3 min at 14,000 rpm. After separation of the 
upper phase, DNA/RNA was precipitated as described in §4.2.2. 
 
 
4.2.2. Ethanol Precipitation 
 
Ethanol precipitation is performed to remove salts or reaction products. RNA or DNA 
was precipitated by adding 0.1 volume 3.0 M sodium acetate (NaOAc) pH 5.4, and 3.0 
volumes of ice-cold absolute ethanol. After shaking thoroughly the samples were 
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incubated for 10 min at -80°C (for 15 ml tubes this time was elongated to 30 min) or 
overnight at -20°C. RNA or DNA was recovered by centrifugation for 15 min at 4°C at 
14,000 rpm (30 min for 15 ml tubes). The supernatant was discarded. The resulting 
pellet was washed with 100 µL of 70 % (v/v) ethanol, centrifuged for 5 min at 14,000 
rpm, the supernatant was taken off. After drying at room temperature, the pellet was 
resuspended in DEPC-treated water. To precipitate short oligonucleotides, or tiny 
amount of nucleic acids, 1 µL of solution of glycogen (20 mg / mL) was added to 
ethanol mixture. 
 
 
4.2.3. Photometric Concentration Determination of Nucleic acids 
 
The concentration of aqueous nucleic acid solutions was determined by UV absorbance 
at a wavelength of 260 nm. An optical density of 1 corresponds to a concentration of 
approx. 50 µg/ml of double stranded DNA, 33 µg/mL of single stranded DNA, 40 
µg/ml of single stranded RNA, or 25 µg/mL of oligonucleotide under 40 bases. The 
concentration was determined by following equation: 
 
c [mM] = (f · A · OD1) / (n · Mr) 
 
f = dilution factor 
A = measured absorption value 
OD1 = concentration by an optical density of 1 
n = number of nucleotides 
Mr = average molecular weight of each nucleotide 
     (dNTP: 330 g/mol, NTP: 345 g/mol) 
 
The concentration of short oligonucleotides (up to 40 nucleotides) which sequences 
were known was determined using the sum of the absorption coefficient ε (Table 8) of 
each nucleotide and the following equation: 
 
 
4. Materials and Methods 
78 
c [mM] = (f · A) / ∑ε 
 
 dNTP ε [mM-1 · cm-1]  NTP  ε [mM-1 · cm-1] 
 dATP 15.4   ATP  15.2 
 dCTP 9.0   CTP  7.05 
 dGTP 13.7   GTP  12.1 
 dTTP 10.0   UTP  8.4 
 
Table 8. Absorption coefficients of dNTPs and NTPs. 
 
 
4.3. General Methods for Gel Electrophoresis 
 
Nucleic acids were analyzed on agarose gels (non-denaturing condition) or 
polyacrylamide gels (denaturing condition). Proteins or fusion proteins for 
mRNA-display were analyzed on tricine SDS gels. 
 
 
4.3.1. Agarose Gel Electrophoresis 
 
Linear dsDNA was separated and identified using non-denaturing agarose gels at 
concentrations ranging from 0.7 to 2.5 % (w/v). The location of the nucleic acid within 
the gel was determined by ethidium bromide staining. Agarose gels were cast by 
melting the agarose in 0.5 x TBE buffer in a microwave. Subsequently the liquid was 
poured into a horizontal mold and left to harden after adding ethidium bromide solution 
(1 µL/10 mL). The gel well was loaded with 7 µL probes resuspended in agarose 
loading buffer at a 2:1 ratio. The molecular size of DNA probes was estimated using a 
DNA mix size marker (PeqLab) containing xylene cyanol and bromophenol blue. To 
achieve maximum resolution, gels were run at 170 V in 0.5 x TBE buffer. The lanes 
were visualized using a 366 nm UV-transilluminator. 
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Agarose gel loading buffer: 
reagent MW concentration required for10 mL 
Glycerol 92.09 50% (v/v) 5 mL 
1 M Tris/HCl 121.14 50 mM 500 µL 
0.5 M EDTA, pH 8.0 372.2 50 mM 1 mL 
Bromophenol blue 691.94 0.05% (w/v) 5 mg 
 
 
4.3.2. Isolation of Nucleic Acids from Agarose Gel 
 
DNA was separated using low melting point agarose gel from 0.7 - 2 % at 70 V in TAE 
buffer. The bands of DNA fragment were detected by UV shadowing and excised using 
sterile surgical blade. DNA fragments were purified using gel the extraction kit from 
Macherey-Nagel (e.g. NucleoSpin Kit) by following the instructions supplied by the 
manufacturer. 
 
 
4.3.3. Denaturing Polyacrylamide Gel Electrophoresis (PAGE) 
 
For the purification and/or analysis of single-stranded DNA or RNA, denaturing 
polyacrylamide gels were used. Gels 6-20 % (v/v) were performed under denaturing 
conditions using 8.3 M urea. The gel mixture was prepared from appropriate amounts of 
stock solutions B, C, and D. The polymerization was initiated with 800 µL 10% APS 
(ammonium peroxodisulfate) and 40 µL of TEMED (N,N,N',N'-tetramethylendiamine) 
per 100 mL of gel mixture. The gel mixture was poured between two glass plates (ca. 
18 x 20 cm) held apart by spacers of 1-1.5 mm (1 mm for analytical use, and 1.5 mm for 
preparative use) and sealed with clamps after insertion of the comb. After 
polymerization (60-90 min), the vertical gels were pre-run for 20 - 30 min at 370 V in 1 
x TBE, and the samples were loaded on the gel in loading buffer (1:1 ratio) after a short 
denaturation (1-3 min at 95ºC). The gels were then run at 370 V for the appropriate time 
(usually 90 min). The course of electrophoresis was monitored with a control lane 
containing 0.25% of bromophenol blue and xylene cyanol in loading buffer. For 
analytical purposes, the radioactive RNA or DNA bands were detected after exposure to 
a PhosphorImager screen. For preparative purposes, the RNA or DNA was visualized 
using film exposure or UV shadowing. 
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Stock solution B: 10 x TBE in 8.3 M urea 
Stock solution C: 25 % acrylamide solution in 8.3 M urea 
 2 % N,N’-methylene bis acrylamide 
Stock solution D: 8.3 M urea 
 
PAGE loading buffer: 
reagent MW concentration required for 10 mL 
Urea 60.1 9 M 5.4 g 
0.5 M EDTA, pH 8.0 372.2 50 mM 1 mL 
Bromophenol blue 691.94 0.05 % (w/v) 5 mg 
Xylene cyanol 538.62 0.05 % (w/v) 5 mg 
 
 
4.3.4. Isolation of Nucleic Acids from Denaturing Polyacrylamide Gels 
 
After electrophoretic separation, bands were visualized by UV-shadowing at 254 nm. 
The band of the desired size was excised using a sterile scalpel, and the gel slice was 
crushed and soaked in one volume 0.3 M sodium acetate solution (pH 5.4). To allow 
passive elution, the suspension was incubated at 65°C for 1.5 h or overnight by room 
temperature with strong agitation. To separate the nucleic acid containing liquid phase 
from the gel fragments, the sample was filtered through a syringe which was pre-packed 
with silanized glass wool. Finally, the nucleic acid was ethanol precipitated and 
collected by centrifugation as described in previous section (§4.2.2). Optionally the 
resuspended aqueous RNA solution was filtered through Ultrafree-MC centrifugal filter 
device (Millipore) to remove remaining small gel pieces. 
 
 
4.3.5. Sequencing Gel Electrophoresis 
 
For analysis of kinetic studies, 15 % sequencing gels were used (gel size 30 x 50 cm, 
gel thickness 0.4 mm, glass plates from Bio-Rad). 150 ml of gel mixture was prepared 
as described in §4.3.3. The surfaces of glass plates were silanized with 5 % of 
dimethylchlorosilane in dichloromethane before pouring the gel mixture. After 
polymerization (60 – 90 min), the vertical gels were pre-run for 30 min at 2000 V in 1 x 
TBE. The samples were denatured by adding two volume of STOP solution and 
treatment for 5 min at 95 ºC, then cooled down on ice immediately before loading. The 
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gels were then run at 2000 V for the appropriate time. The course of electrophoresis was 
monitored with a control lane containing 0.25 % of bromophenol blue and xylene 
cyanol in STOP solution. To visualize the radioactive nucleic acids bands the gel was 
transferred to a sheet of Whatman paper, dried for 40 min at 80 ºC on a gel drying 
apparatus (Bio-Rad) and then exposed to PhosphorImager screen. 
 
STOP solution: 
reagent MW concentration required for 50 mL 
Formamide 45.04 80 % 40 mL 
0.5 M EDTA, pH 8.0 372.2 20 mM 2 mL 
 
 
4.3.6. Tricine SDS Polyacrylamide Gel Electrophoresis 
 
Tricine SDS polyacrylamide gels were used to separate proteins or analyze in vitro 
translated mRNA-displayed fusion proteins. They have a higher resolution than glycine 
SDS polyacrylamide gels, especially for lower weight peptides. The percentage of the 
gel was adjusted to 12 % or 8 % according to molecular weight of the proteins. The gel 
mixture was prepared from appropriate amount of stock solutions, and then the 
polymerization was initiated by addition of a 10% APS solution and TEMED. The 
solution was poured between two glass plates held apart by spacers of 1 mm, and the 
polymerization usually completed in 30 min. After the gel was placed into a gel 
chamber, the inner buffer tank was filled with 1 x tricine SDS electrophoresis buffer, 
and the outer tank was filled with 1 x tricine SDS anode buffer. The samples (up to 15 
µL) with 5 µL of loading buffer were loaded into wells without heating. The gel was 
run at 125 V for ca. 1 h. The course of electrophoresis was monitored with a control 
lane containing protein markers (Amersham). The gel was removed from glass plates, 
placed into fixing solution for 10 min with agitation, exchanged into water for another 
10 min while shaking. The gel was transferred onto a piece of Whatman paper and dried 
for 30 min at 80 ºC on the gel dryer. The radioactive protein samples were visualized by 
exposure of a dried gel to a phosphor imager screen. 
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Tricine SDS polyacrylamide gel (12 %): 
reagent  concentration required for 6 mL 
3 x Tricine SDS gel buffer 1 x 2000 µL 
Water   900 µL 
30 % Bis-acrylamide (Roth) 12 % 2500 µL 
Glycerol  10 % 600 µL 
10 % APS   60 µL 
TEMED   6 µL 
 
Tricine SDS loading buffer: 
reagent MW concentration required for 10 mL 
1 M Tris/HCl, pH 6.8 121.14 50 mM  500 µL 
10% SDS 288 4 % (w/v) 4 mL 
1 M DTT 154.2 0.1 M 1 mL 
Glycerol 92.09 12 % (v/v) 1.2 mL 
Water   3.3 mL 
 
3 x Tricine SDS gel buffer: 
reagent MW concentration required for 100 mL 
Tris 121.14 3 M  36.34 g 
SDS 288 0.3 % (w/v) 300 mg 
pH value was adjusted to 8.45 with HCl. 
 
10 x Tricine SDS electrophoresis buffer: 
reagent MW concentration required for 1000 mL 
Tris 121.14 1 M 121.14 g 
Tricin 178.2 1 M 178.2 g  
SDS 288 1 % (w/v) 10 g 
pH value was adjusted to 8.25 with NaOH/HCl. 
 
10 x Tricine SDS anode buffer: 
reagent MW concentration required for 1000 mL 
Tris 121.14 2 M 242.28 g 
pH value was adjusted to 8.9 with NaOH/HCl. 
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Fixing solution: 
reagent MW concentration required for 1000 mL 
Methanol 32.04 40 % (v/v) 400 mL 
Acetic acid 60.05 10 % (v/v) 100 mL 
Water  50 % (v/v) 500 mL 
 
 
4.3.7. Coomassie Staining of SDS Gels 
 
To stain the protein bands, the gels were soaked in coomassie solution for 30 min, and 
then transferred into destaining solution for 30 – 120 min until the protein bands 
became distinct. The gel was placed onto a piece of Whatman paper and dried for 30 
min at 80ºC on a gel dryer. 
 
Coomassie solution: 
reagent MW concentration required for 1000 mL 
Acetic acid 60.05 10 % (v/v) 100 mL 
Methanol 32.04 45 % (v/v) 450 mL 
Water  45 % (v/v) 450 mL 
Coomassie brilliant blue 0.0125 % (w/v) 125 mg 
 
Destaining solution: 
reagent MW concentration required for 1000 mL 
Acetic acid 60.05 10 % (v/v) 100 mL 
n-Butanol 74.12 30 % (v/v) 300 mL 
Water  60 % (v/v) 600 mL 
 
 
4.4. Enzymatic Reactions 
 
4.4.1. Polymerase Chain Reaction (PCR) 
 
dsDNA constructs encoding reporter ribozymes, aptamers, and DNA library sequences 
were generated and amplified by the polymerase chain reaction (PCR) using Taq DNA 
polymerase. Reactions in 100 µL final volume were performed in a PCR thermocycler. 
Standard conditions were programmed as follows; 
 
4. Materials and Methods 
84 
 
operation  time  temperatur 
Denaturing  50 s  94°C 
Annealing  60 s  55°C 
Extension  60 s  72°C 
Heated lid    110°C 
 
PCR mixture (100 µL): 
reagent amont stock resultant 
PCR buffer 10 µL 10 x 1 x 
MgCl2 6 µL 25 mM 1.5 mM 
5' primer 1 µL 100 µM 1 µM 
3' primer 1 µL 100 µM 1 µM 
dNTP mix (ACTG) 0.8 µL 25 mM 0.2 mM 
DNA template x µL  1-10 nM 
Taq DNA Polymerase 0.5 µL 5 U/µL 0.025 U/µL 
Water y µL 
 
To monitor the amplification of desired DNA product, aliquots (5 µL) from different 
cycles were taken, mixed with agarose loading buffer (2.5 µL), then loaded on agarose 
gel as described in §4.3.1. One reaction mixture without DNA template as negative 
control was also operated equally to check the unspecific amplification of primers or 
DNA contamination.  
PCR was performed with optimized cycle numbers, in large scale, if necessary. The 
PCR product was finally isolated and purified by phenol/chloroform extraction as 
written in section §4.2.1 and the dsDNA was ethanol precipitated by the method 
described in §4.2.2. 
 
 
4.4.2. in vitro Transcription 
 
For in vitro synthesis of RNA, DNA-dependent RNA polymerase from bacteriophage 
T7 was used. The DNA templates are required to contain a double stranded T7 promoter 
sequence. The reaction mixtures were prepared as follows, and incubated at 37°C for 4 
h to overnight. When the resulting RNA needed to be body-labeled, α-32P GTP was 
added to the mixture before T7 RNA polymerase addition. 
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Transcription reaction mixture (100 µL): 
reagent amount stock resultant 
Transcription buffer 20 µL 5 x 1 x 
NTP mix (ACUG) 10 µL 25 mM 2.5 mM 
IPP 0.2 µL 0.2 U/µL 0.0004 U/µL 
[α-32P]-GTP 1 µL 10 µCi/µL 0.1 µCi/µL 
RNasin 1.25 µL 40 U/µL 0.5 U/µL 
DNA template x µL  1-3 µM 
T7 RNA polymerase 2 µL 50 U/µL 1 U/µL 
Water y µL 
 
To digest DNA templates, 0.5 µL DNase I (5 U/µL) was added to the mixture and 
incubated at 37°C for at least 10 min. One equivalent volume of PAGE loading buffer 
was added to the mixture, and subsequently heated to 95°C for 1 min. The desired RNA 
was purified on PAGE (see §4.3.3 and §4.3.4). 
 
 
4.4.3. 5’-Dephosphorylation of RNA 
 
Prior to labeling, the transcribed RNA was dephosphorylated at the 5´-end using calf 
intestine alkaline phosphatase (CIAP). The reaction mixture was composed as follows; 
 
5’-Dephosphorylation reaction mixture (50 µL): 
reagent amount stock resultant 
CIAP buffer 5 µL 10 x 1 x 
RNA 150 pmol 10 µM 3 µM 
BSA 0.5 µL 100 x 1 x 
CIAP 0.3 µL 57 U/µL 0.34 U/µL 
RNasin 0.5 µL 40 U/µL 0.4 U/µL 
Water y µL 
 
The reaction mix was then adjusted to a final volume of 50 µL and incubated for 15 min 
at 37°C. After addition of 0.15 µL CIAP the reaction was incubated at 55°C for an 
additional 15 min. The reaction was stopped by adding 0.5 µL 0.5 M EDTA solution 
and the enzyme inactivated for 10 min at 75°C. The volume was adjusted to 200 µL by 
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addition of water and the reaction mixture was extracted with chloroform and phenol 
(see §4.2.1). The RNA was recovered after ethanol precipitation (see §4.2.2) and the 
pellet was resuspended in 20 µL of DEPC treated water. 3 µL of this sample per 20 µL 
reaction volume can be used for 5’-radioactive end labeling. 
 
 
4.4.4. 5’-Phosphorylation of Nucleic Acids 
 
Radioactive 5’-end labeling of DNA or RNA was performed using T4 polynucleotide 
kinase (T4 PNK) with [α-32P]-ATP. Nucleic acids synthesized on solid phase can be 
phosphorylated directly, while RNA transcribed in vitro should be dephosphorylated as 
described in §4.4.3 prior to labeling. The reaction mixture was incubated for 1 h at 37°C. 
After heat denaturation at 100°C for 2 min, the sample was immediately cooled down 
on ice. Unincorporated radioactive dNTP was removed by gel filtration (G-25 column). 
To generate a 3 µM solution of radioactive DNA primer, 20 µL of 10 µM cold primer 
was added to 50 µL of labeled DNA primer. 
 
5’-Phosphorylation reaction mixture (50 µL): 
reagent amount stock resultant 
RNA/DNA template (20 pmol) 2 µL 10 µM 0.4 µM 
T4 PNK buffer 5 µL 10 x 1 x 
[α-32P]-ATP 5 µL 10 µCi/µL 1 µCi/µL 
RNasin (added for RNA template) 0.75 µL 40 U/µL 0.6 U/µL 
T4 polynucleotide kinase 5 µL 10 U/µL 1 U/µL 
Water y µL  
 
 
4.4.5. RNase Test 
 
All buffers required for RNA manipulation were examined for RNase contamination. 
For this purpose, radioactive labeled RNA in 25 µL of each buffer was incubated at 
least for 4 h at room temperature. After addition of PAGE loading buffer, the RNA 
degradation of each sample was analyzed on PAGE. The radioactive bands were 
visualized by exposure of the gel to a phosphor imager screen.  
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4.4.6. Restriction Digestion of dsDNA 
 
The digestion of dsDNA was done by restriction enzymes to construct DNA libraries of 
long ORFs used for mRNA display. Each DNA cassette was restricted by either Bbs I 
or Bbv I in the supplied buffer under the recommended condition (at 37°C overnight). 
Usually approximately 1 µL of restriction enzyme per 25µL of reaction volume 
including up to 300 pmol of dsDNA was used. The digested fragments were purified 
from low melting point agarose gels (§4.3.2). 
 
 
4.4.7. Ligation of DNA Fragments 
 
The digested DNA fragments by the restriction enzymes were ligated by T4 DNA ligase 
using the conditions recommended by the supplier. Ligation was completed at 16°C 
overnight. After phenol/chloroform extraction and ethanol precipitation, the ligated 
DNA could be amplified using appropriate primers and PCR. 
 
 
4.5. DNA Sequencing 
 
For DNA sequencing, the plasmids were sent to Qiagen for sequencing service. 
Otherwise, dideoxy (Sanger) sequencing method was used. 
 
 
4.5.1. Ligation of PCR Product into Plasmids 
 
For preparation of the plasmid to be transformed into E. coli, pGEM-T Vector System 
from Promega was used. This system represents a convenient system for cloning of 
PCR products into vectors which carry single 3’-T overhangs at the insertion sites. The 
ligation reactions including positive and negative controls were performed by the 
following protocols described in the technical instruction from the kit. 
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Ligation reactions (10 µL): 
reagent standard positive negative 
2 x Rapid ligation buffer 5 µL 5 µL 5 µL 
pGEM-T Vector (50 ng) 1 µL 1 µL 1 µL 
PCR product x µL - - 
Control insert DNA - 2 µL - 
T4 DNA ligase 1 µL 1 µL 1 µL 
Water y µL y µL y µL 
 
 
4.5.2. Transformation 
 
The appropriate high efficiency competent cells (DH10B) were transformed with the 
ligation products using the protocols provided by Promega with some modifications. 
For transformation, 5 µL of the respective ligation reaction was gently mixed with 100 
µL of freshly thawed competent cells. After 20 min incubation on ice, the cells were 
warmed at 37°C for 40-45 sec, and immediately returned on ice for 2 min. Then, 750 
µL SOC medium (room temperature) was added to the cells, and incubated for 1 h at 
37°C with shaking (~300 rpm). 100 -250 µL of transformation culture was plated onto 
LB/ampicillin/IPTG/X-Gal plates. The plates were incubated overnight at 37°C. 
 
 
4.5.3. Isolation of Plasmid DNA 
 
Purification of high copy plasmid DNA from overnight cultures of E. coli was done 
using the QIAprep spin miniprep kit from Qiagen. All procedures were followed using 
the handbook of the supplier. 
 
 
4.5.4. DNA Sequence Analysis 
 
The isolated plasmids were added to sequencing reaction mixture with an appropriate 
primer described as follows. Primer extension using fluorescent dye-labeled terminators 
produced chain terminated products, which were analyzed by an automated DNA 
sequencer. 
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Sequencing reaction mixture (10 µL): 
reagent amount stock resultant 
Premix 2 µL 
DNA-template 380 ng 
Primer 10 pmol 100 µM 1 µM 
Water y µL 
 
operation  time  temperatur 
Initial denaturing  2 min  96°C 
Denaturing  10 s  96°C 
Annealing  10 s  53°C 
Extension  4 min  60°C 
Steps 2-4 were repeated 25 times. 
 
 
4.6. Reporter Ribozyme-Based Screening Assay 
 
4.6.1. Screening Procedure using Reporter Ribozyme 
 
Screening to identify small molecule inhibitors of HIV-1 RT was performed in 384-well 
plates. Each reaction in total volume of 25 µL was carried out under multiple turnover 
condition with excess FRET-substrate (200 nM) over the reporter ribozyme FK-1 (10 
nM) in HH buffer (50 mM Tris/HCl, pH 7.9, 25 mM NaCl) at 37°C in the presence of 
HIV-1 RT (200 nM) and a small molecule entity (100 µM) from the library. The library 
compounds and the reaction mixture were combined into 384-well plates by using an 
automated liquid handling system (Tecan). It was necessary to use ceramic tips and to 
prepare the enzyme mixture in Pyrex glass vials for robotic operation. After the plates 
were pre-incubated for 15 min at 37°C in Ascent Fluoroskan apparatus, the ribozyme 
reaction was initiated by adding MgCl2 to a final concentration of 8 mM. The cleavage 
reaction was monitored in real-time by measuring FAM-dye fluorescent emission (520 
nm) for 15 min at 60 seconds intervals at a fixed excitation wavelength (492 nm). 
Negative control without HIV-1 RT was included for each compound. Each plate also 
contained standard ribozyme reaction without compound as a positive control. Every 
reaction was duplicated. 
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4.6.2. Identification of Hit Compounds 
 
The initial velocity (fluorescence/min) was determined by plotting the increment of 
fluorescence intensity, multiplied by factor 10000, versus time. For each compound, 
relative ribozyme activity (Arel) was calculated by following equation; 
 
Arel =  VRT+ / VRT- 
 
Arel = relative activity 
VRT+ = averaged number of initial velocity of ribozyme in the presence of HIV-1 RT 
VRT- = averaged number of initial velocity of ribozyme in the absence of HIV-1 RT 
 
Standard reaction without compound usually gave the Arel value of 0.2-0.3 depending 
on the plate. The compounds which showed the value of Arel > 0.4 were identified as hit 
compounds. 
 
 
4.7. Reverse Transcriptase (RT) Assay 
 
The RNA-dependent DNA polymerase activity was assayed by monitoring the RNA 
template/DNA primer-directed incorporation of dNTPs, while the DNA-dependent 
DNA polymerase activity was assayed by DNA template/DNA primer-directed 
incorporation of dNTPs. As an example, the assay to examine the inhibition on 
DNA-dependent DNA polymerase activity of HIV-1 RT by a certain compound is 
described in the following. 
After heat denaturing at 95°C for 5 min (RNA template/DNA primer denaturing at 
70°C), the DNA template (10 µM) was annealed to a 5’-[32P]-end labeled 
complementary DNA primer (3 µM) (see §4.4.4) by slow cooling to room temperature 
over 1 h. The small molecule inhibitors were pre-incubated at 37°C for 5 min at various 
concentrations in the enzyme mixture containing 14 nM HIV-1 RT and 50 µM dNTP. 
Polymerase reactions were carried out in 20 µL volumes, containing 50 mM Tris/HCl, 
pH 8.0, 50 mM KCl, and 10 mM MgCl2. The reactions were initiated by the addition of 
DNA template/5’-[32P]-DNA primer complex and incubated at 37°C for 15 min. The 
polymerase activity was deactivated by addition of 40 µL of STOP solution (80 % 
formamide, 20 mM EDTA) and denatured by heating at 95°C for 5 min prior to gel 
analysis (15 % sequencing gel). The gel was visualized by autoradiography and the 
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amount of DNA synthesized was quantified by phosphor imaging analysis. IC50 values 
were caluculated from the inhibition dose-dependent curves using Origin software. 
Assays of HIV-2 RT, AMV, MMLV, Klenow fragment, human DNA polymerase β 
were carried out in the buffers supplied from the manufacturers. The reaction time was 
elongated to 1 h for the Klenow fragment and human DNA polymerase β. Optionally 
the concentration of dNTP was raised to 200 µM. 
 
 
4.8. Surface Plasmon Resonance (SPR) 
 
To elucidate the inhibition mechanism of HIV-1 RT by small molecule inhibitors, the 
possible interaction between double stranded DNA and a small molecule was analyzed 
via surface plasmon resonance (SPR) using Biacore instrumentation.  
The Biacore equipment enables to monitor biomolecular interactions in real time, using 
a non-invasive optical detection principle based on SPR. The SPR response reflects a 
change in mass concentration at the detector surface as molecules bind or dissociate. 
SPR is an optical phenomenon arising in thin metal films under conditions of total 
internal reflection. The phenomenon produces a sharp dip in the intensity of reflected 
light at a specific angle, the resonance angle. The position of this resonance angle 
depends on refractive index of the medium when other factors kept constant. The 
refractive index is directly correlated to the concentration of dissolved material in the 
medium. Therefore, SPR enables to measure changes in the concentration of molecules 
in a surface layer of a solution in contact with the sensor surface. 
The surface immobilized with dsDNA was prepared as follows. While, HIV-1 RT 
immobilization was done by using amino coupling kit onto CM5 chip. 
 
4.8.1. Immobilization of Oligonucleotides on the Sensor Surface 
 
Oligonucleotides were synthesized with a biotinylated 5’-end (Biotin-P12II). Sensor 
chip SA was activated with three consecutive 1 min injections of 1 M NaCl in 50 mM 
NaOH prior to the immobilization. The oligonucleotide solution was prepared in a 1:1 
mixture of 1 M NaCl and HBS-EP buffer supplied by the manufacturer, with a final 
concentration of 50 nM. Typically, 330 - 350 resonance units (RU) of oligonucleotide 
were immobilized on a flow cell at a flow rate of 5 µL/min. 
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4.8.2. Binding of Small Molecules to dsDNA 
 
The running buffer contained 50 mM Tris/HCl pH 8.0, 50 mM KCl, 10 mM MgCl2, and 
0.5 % DMSO. The RT18II template sample was suspended in the running buffer by 
adding 1 µL of a 100 µM template solution into 199 µL of running buffer. The double 
stranded oligonucleotide construct (P12II/RT18II) was formed by injecting 35 µL of a 
500 nM solution of RT18II at a flow rate of 5 µL/min. This annealing step usually 
resulted in an increase of 500 RU. The stock solutions for the small molecules were a 
200-fold concentrate in 100 % DMSO. Dilutions were prepared in running buffer such 
that 1 µL of a respective compound was added to 199 µL of running buffer to give a 
final DMSO concentration of 0.5 % (v/v) in each sample. The flow rate was set to 30 
µL/min and 60 µL of the dilution sample (50 pM – 5 µM) was injected simultaneously 
over the surfaces including the reference cell (program: KINJECT). For each 
experiment, a calibration for bulk differences between flow cells and buffer jump was 
performed. Between the sample injections, the needle and IFC were washed to ensure 
no contamination with compounds from the previous injection. Regeneration of the 
surfaces were successfully done by either 60 - 90 µL injection of running buffer 
containing 0.5-2.5 % DMSO, or by 5 µL injection of up to 20 mM of NaOH containing 
0.5-5 % DMSO. The latter condition caused slight dissociation of the template from the 
surface in some experiments. 
 
 
4.9. Inhibition Study of HIV-1 Replication in vivo 
 
The study of the inhibition of HIV-1 replication by small molecules in vivo was done by 
usage of an assay setup termed “self-inactivating HIV vector system” in collaboration 
with the group of Prof. Restle at University of Luebeck. Other in vivo assays were 
performed in collaboration with the group of Prof. Klaeusslich at University of 
Heidelberg. 
 
 
4.9.1. Self-Inactivating HIV Vector System[84] 
 
A self-inactivating replication-defective plasmid (pGJ3) was constructed from the 
proviral plasmid pHXB2D by the method reported by Jármy et al.[84] 1 x 106 293T cells 
were co-transfected with 8 µg of plasmid VSV-G and pGJ3-Luci, using the calcium 
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phosphate method. After 40 h of incubation in the presence of 10 mM sodium butyrate, 
cell culture supernatants containing viral particles were harvested and stored at -80°C 
until infection. 
The compounds in 100 % DMSO were diluted in PBS buffer to give a final 
concentration of 1 % DMSO, and then pre-incubated on 2 x 104 293 cells for 30 min in 
a 96-well plate. Subsequently, infection with equal amounts (50 µl) of vector-containing 
supernatants was performed, and luciferase activity was determined after 24 h 
incubation. Normalization in relation to cell viability was done with 10 µM fluorescein 
diacetate (FDA), which is a marker for esterase activity of living cells. 
As a positive control, the assay was carried out with 10 µM AZT to see complete 
inhibition.  
 
 
4.9.2. HIV-1 Replication Assay 
 
2 x 104 TZM cells were grown in 48well plate. Different concentrations of compounds 
dissolved in 2 µL of 100 % DMSO were diluted in 150 µL of cell culture medium 
(DMEM), then 50 µL virus containing solution (= 10000 infectious units) was added to 
give a final concentration of 1 % DMSO. TZM cells were infected with 200 µL of 
DMEM containing virus and inhibitor after removal of old medium. After incubation 
for 2 days at 37°C under 5 % CO2 atmosphere, the luciferase marker gene expression, 
under the control of the HIV-1 LTR promoter, was measured (Steady-Glo luciferase 
assay from Promega). NL43 which has been produced in a co-culture with C8166 cells 
was used as virus. 
 
 
4.9.3. HIV Infectivity Assay 
 
Fresh co-culture was prepared by dilution of co-culture of NL43 virus with uninfected 
MT4 cells in the ratio of 1:10 (1 x 106 MT4/mL). After 4 h incubation at 37°C under 
5 % of CO2 atmosphere, 500 µL of co-culture and 5 µL of different concentration of 
inhibitors were added to each 48 well. After 2 days at 37°C under 5 % of CO2, cell-free 
supernatant of the MT4 co-culture was used to infect TZM cells, which enables to 
determine amount of infectious particles which have been produced in the presence of 
inhibitor. After 2 days postinfection, cells were fixed with 3% PFA for 30min, washed 
with PBS. The infected TZM cells were stained with β-galactosidase substrate (TZM 
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cells also contain a β-Galactosidase reporter gene under the control of HIV-1 LTR). 
After 2-3 hours incubation at 37°C, infected cells turned blue and could be counted 
under the microscope. 
 
 
4.9.4. MTT Cell Toxicity Assay 
 
The MTT-assay was performed to determine cell viability by quantifying its metabolite. 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazoliumbromid) is up taken by 
living cells. Mitochondrial dehydrogenases convert it to a violet formazan that cannot 
diffuse through cell membranes and crystallizes in vital cells. The crystals can be 
solubilized with organic solvents and than be measured with a colorimetric assay. Only 
living cells with an active metabolism, as well as cells which are in an early apoptotic 
phase can convert MTT. Cells in a late apoptotic phase and dead cells cannot.  
1 x 104 TZM cells were seeded in 96-well plate. 100 µL of medium containing 1µL of 
different concentrations of inhibitors were added, and incubated for 24 h at 37°C under 
5% CO2 atmosphere. The medium was removed, and 100µl of MTT-solution (1:10 
dilution of 5mg/mL MTT-stock solution in PBS into DMEM) was added to 96-well 
plate. After incubation for 3-4 h at 37°C, the medium was removed carefully, then 100 
µL of DMSO:ethanol (1:1) was added. Absorbance both at 550-570nm (L1) and at 
620-650nm (L2) was measured to determine the value of L1-L2. 
 
 
4.10. Preparation and Purification of mRNA-Displayed Proteins 
 
mRNA templates are prepared from appropriate DNA library by in vitro transcription. 
The following sections describe the preparation of mRNA display templates with DNA 
linker 3’-terminated with puromycin, the use of the mRNA display template to yield 
mRNA-displayed proteins and their subsequent purifications. In order to separate the 
mRNA displayed proteins from both mRNA templates which don’t carry the proteins 
and free proteins, it is necessary to perform a purification step based on a protein 
affinity tag. In the initial cycles of in vitro selection, all the enzymatic reactions were 
scaled up to keep the library diversity. 
The FLAG tag affinity chromatography was optionally used only in the selection 
against cibacron blue 3GA. 
 
4. Materials and Methods 
95 
4.10.1. Photoligation of RNA to Psoralen-Photolinker 
 
To form a covalent bond between transcribed RNA and the linker carrying puromycin at 
3’-end, photoligation was conducted by usage of psoralen.[152, 153] The photolinker was 
designed to contain a psoralen-C6, 2’-O-methyl RNA, oligo(dA), spacer, and 
puromycin from 5’- to 3’-end. The ligation reaction mixture was prepared on ice, and 
operated as follows in a PCR cycler; 
 
Photoligation reaction mixture (50 µL): 
reagent amount stock resultant 
RNA x µL x µM 2.5 µM 
Ligation buffer 5 µL 10 x  1 x 
Photolinker 2.5 µL 100 µM 5 µM 
Water y µL 
 
operation  time  temperature 
Denaturing  150 s  85°C 
Annealing  20 min  4°C 
Lid temperature    110°C 
 
The solution was transferred into disposable cuvette, and irradiated with 366 nm light 
by a UV transilluminator for 15 min. The sample was precipitated with ethanol, and 
then resuspended in water. 
 
10 x Photoligation buffer: 
reagent MW concentration required for 50 mL 
1 M Tris/HCl, pH7.2  250 mM 12.5 mL 
NaCl 58.44 1.5 M 4.38 g 
 
 
4.10.2. in vitro Translation 
 
In vitro translation of photoligated mRNA in rabbit reticulocyte lysate produced 
mRNA-displayed proteins via covalent bond formation promoted by puromycin. 
Radioactive [35S]-methionine labeling of translated proteins enables to detect fusion 
products and free proteins on tricine SDS gels. Translation mixtures were made up as 
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follows by adding the lysate last; 
 
in vitro Translation mixture (100 µL): 
reagent amount stock resultant 
mRNA display template x µL x µM 400 nM 
Amino acid mix without Met 8 µL 12.5 x 1 x 
[35S]-Methionine 8 µL 10 µM 800 nM 
KCl 4 µL 2.5 M 100 mM 
Mg(OAc)2 5 µL 25 mM 1.25 mM 
RNasin 2.5 µL 40 U/µL 1 U/µL  
Rabbit reticulocyte lysate 35 µL 100 % 35 % (v/v) 
Water  y µL  
 
After incubation at 30°C for 1 h, KCl (4 M) and MgCl2 (1 M) were added to the final 
concentration of 340 mM and 100 mM, respectively. The sample was incubated for 
additional 10 min at room temperature. To release the fusion proteins from the ribosome, 
EDTA was added to a final concentration of 100 mM, and incubated for 10 min at room 
temperature. Both the concentrations of KCl and Mg(OAc)2 in the translation mixture 
and the later addition of KCl and MgCl2 after incubation were optimized for every 
library template used. 
 
 
4.10.3. Oligo(dT) Affinity Chromatography 
 
Oligo(dT) affinity chromatography was used for isolation of mRNA-protein fusions 
from the translation mixture. The cellulose resin has oligo(dT) covalently attached to it, 
which can form specific Watson-Crick base pairs with the target oligo(dA) tag. For this 
purpose, the photolinker contains oligo(dT) sequences. mRNA-protein fusions and 
photolinker could be purified by the column, while other proteins which lack mRNA 
(free proteins) were discarded. Typically, the binding capacity for the Pharmacia type 7 
oligo(dT) cellulose is around 200 nmol/g of resin. 
The translation mixture was diluted 1:15 or 1:20 with oligo(dT) binding buffer. The 
appropriate amount of oligo(dT) cellulose (2 mg per mL of diluted sample) was 
weighted out (up to 20 mg for PolyPrep chromatography column from Bio-Rad), 
washed 3 times with 1 mL of water, then equilibrated with 1 mL of oligo(dT) binding 
buffer. The diluted lysate was incubated with oligo(dT) cellulose at 4°C for 1 h while 
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shaking. Optionally, washing of cellulose and the incubation steps could be performed 
in 15 or 50 mL of centrifuge tubes. The mixture was filtered through the column, and 
the flow through was poured again into the column to collect all the remaining cellulose. 
The resin was washed 3 times with 1 mL of oligo(dT) binding buffer, subsequently with 
1 mL of oligo(dT) wash buffer. The bound molecules were eluted with 2 times of 250 
µL water at 4°C for 30 min while shaking to denature DNA hybridization. Small 
aliquots (1–2 % of each fraction) from wash and elution samples were used to measure 
the containing radioactivity by a scintillation counter.  
 
Oligo(dT) binding buffer: 
reagent MW concentration required for 100 mL 
KCl 74.6 1 M 7.46 g 
Tris 121.14 100 mM 1.21 g 
Triton X-100 643.37 0.25% (v/v) 250 µL 
pH was adjusted to 8.0 with NaOH/HCl. 
 
Oligo(dT) wash buffer: 
reagent MW concentration required for 100 mL 
KCl 74.6 100 mM 746 mg 
Tris 121.14 10 mM 121 mg 
Triton X-100 643.37 0.25% (v/v) 250 µL 
pH was adjusted to 8.0 with NaOH/HCl. 
 
The amount of mRNA displayed proteins in the oligo(dT) elution was calculated with 
the following equation; 
 
mRNA-displayed proteins [mol] = (CMet · V · P) / N 
 
CMet = total concentration of hot and cold methionine in the translation reaction mixture 
V = the translation reaction volume 
P = the counts in the oligo(dT) elution / the counts in the translation mixture 
N = the average number of methionine in a single displayed protein 
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4.10.4. Ni-NTA Chromatography 
 
Ni-NTA affinity chromatography was used to isolate mRNA-protein fusions carrying 
His-6 tag. Ni2+ ions immobilized on agarose can form the complexes with the histidine 
residues of the proteins. Because His-6 tag was placed at C-terminus of protein library, 
those proteins that do not carry a His-6 tag e.g. through the presence of internal stop 
codons or immature translation were not captured on Ni-NTA agarose. The bound 
proteins were competitively eluted with the buffer including imidazol. 
100–200 µL of Ni-NTA agarose was washed 3 times with 1 mL of water, and once with 
1 mL of 1 x Ni-NTA binding buffer on PolyPrep chromatography column from Bio-Rad. 
The sample was diluted with 2 x Ni-NTA binding buffer, incubated for 60 min at 4°C, 
and filtered through the column membrane. The flow through was discarded. The resin 
was washed with following wash buffers; 
 
2 times with 500 µL of Ni-NTA first wash buffer 
1 times with 500 µL of Ni-NTA first wash buffer : Ni-NTA second wash buffer = 4 : 1 
1 times with 500 µL of Ni-NTA first wash buffer : Ni-NTA second wash buffer = 3 : 2 
1 times with 500 µL of Ni-NTA first wash buffer : Ni-NTA second wash buffer = 2 : 3 
1 times with 500 µL of Ni-NTA first wash buffer : Ni-NTA second wash buffer = 1 : 4 
 
Elution was done by incubating the agarose in 2 times with 250 µL of Ni-NTA elution 
buffer at 4°C for 30 min each while shaking. Finally 0.5 M of EDTA was added to a 
final concentration of 5 mM to chelate eluted Ni2+ ions. The eluate was desalted on 
NAP column twice to remove denaturant. 1–2 % samples of each fraction were 
analyzed by tricine SDS PAGE and scintillation counting for radioactivity. 
 
Denaturing 2 x Ni-NTA binding buffer: 
reagent MW concentration required for 100 mL 
Guanidine HCl 95.5 6 M 57.4 g 
NaCl 58.4 1 M 5.86 g 
Na2HPO4·2H2O 177.99 200 mM 3.56 g 
Tris 121.14 20 mM 242 mg 
Triton X-100 643.37 0.5 % (v/v) 500 µL 
β-Mercaptoethanol 78.1 200 mM 1402 µL 
pH was adjusted to 8.0 with NaOH/HCl. 
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Denaturing 1 x Ni-NTA binding buffer: 
reagent MW concentration required for 100 mL 
Guanidine HCl 95.5 3 M 28.7 g 
NaCl 58.4 500 mM 2.93 g 
Na2HPO4·2H2O 177.99 100 mM 1.78 g 
Tris 121.14 10 mM 121 mg 
Triton X-100 643.37 0.25 % (v/v) 250 µL 
β-Mercaptoethanol 78.1 100 mM 701 µL 
pH was adjusted to 8.0 with NaOH/HCl. 
 
Denaturing Ni-NTA first wash buffer: 
reagent MW concentration required for 100 mL 
Guanidine HCl 95.5 3 M 28.7 g 
Urea 60.1 8 M  48.1 g 
NaCl 58.4 500 mM 2.93 g 
NaH2PO4·2H2O 156.01 100 mM 1.56 g 
Tris 121.14 10 mM 121 mg 
Triton X-100 643.37 0.25 % (v/v) 250 µL 
β-Mercaptoethanol 78.1 100 mM 701 µL 
pH was adjusted to 6.3 with NaOH/HCl. 
 
Ni-NTA second wash buffer: 
reagent MW concentration required for 100 mL 
Guanidine HCl 95.5 3 M 28.7 g 
NaCl 58.4 500 mM 2.93 g 
Tris 121.14 10 mM 121 mg 
Triton X-100 643.37 0.25 % (v/v) 250 µL 
β-Mercaptoethanol 78.1 100 mM 701 µL 
pH was adjusted to 8.0 with NaOH/HCl. 
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Ni-NTA elution buffer: 
reagent MW concentration required for 100 mL 
Guanidine HCl 95.5 3 M 28.7 g 
NaCl 58.4 500 mM 2.93 g 
Tris 121.14 10 mM 121 mg 
Triton X-100 643.37 0.25 % (v/v) 250 µL 
Imidazol 68.1 250 mM 1.70 g 
β-Mercaptoethanol 78.1 100 mM 701 µL 
pH was adjusted to 8.0 with NaOH/HCl. 
 
 
4.10.5. FLAG Tag Chromatography 
 
The anti-FLAG M2 antibody immobilized on agarose binds with high affinity to the 
FLAG octapeptide sequences (DYKDDDDK). This amino acid sequences are encoded 
in N-terminus of protein library sequences, thus mRNA-protein fusion molecules with 
full length proteins were isolated by FLAG tag purification after Ni-NTA purification. 
Proteins resulting from internal translation initiation were discarded due to the lack of 
FLAG peptide. 
100 µL of anti-FLAG M2 agarose was washed with 3 times with 1 mL of FLAG tag 
clean buffer, then equilibrated 2 times with 1 mL of 1 x FLAG binding buffer on a 
PolyPrep chromatography column from Bio-Rad. The elution from Ni-NTA purification 
was diluted with 2 x FLAG tag binding buffer, added to the resin, and incubated at 4°C 
for 1 h while shaking. The resin was washed 3 times with 1 mL of 1 x FLAG binding 
buffer. The bound proteins were eluted 2 times of 500 µL FLAG tag binding buffer 
containing 10 µM FLAG peptide at 4°C for 30 min each while shaking. 1–2 % samples 
of each fraction were analyzed by tricine SDS PAGE and scintillation counting for 
radioactivity. Eluates were desalted on NAP columns (Pharmacia) to exchange the 
buffer into water. 
 
FLAG tag clean buffer: 
reagent MW concentration required for 100 mL 
Glycine 75.1 100 mM 751 mg 
Triton X-100 643.37 0.25 % (v/v) 250 µL 
pH was adjusted to 3.5 with NaOH/HCl. 
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2 x FLAG tag binding buffer: 
reagent MW concentration required for 100 mL 
NaCl 75.1 300 mM 1.75 g 
HEPES 238 100 mM 2.38 g 
Triton X-100  0.5 % (v/v) 500 µL 
pH was adjusted to 8.0 with NaOH/HCl. 
 
 
4.10.6. Desalting on NAP Column 
 
For desalting or buffer exchange of the samples, NAP columns (NAP-5, 10, 25) from 
Pharmacia were used. The samples can be eluted from the pre-equilibrated columns 
with water or desired buffer. According to the principle of gel filtration, small 
molecules and salts tend to stay longer on the column, while the larger molecules like 
proteins or nucleic acids flow through the column. Particularly, the NAP column was 
blocked with salmon sperm DNA und BSA prior to desalting of mRNA-displayed 
proteins. 
As an example, to a NAP-5 column 10 mL of water, 1 mL of salmon sperm DNA and 
BSA solutions, and further 10 mL of water were added. 0.5 mL of the sample solution 
was loaded on the top of the column. Finally the sample was eluted with 1 mL of water. 
 
Salmon sperm DNA und BSA: 
reagent  concentration required for 1 mL 
Salmon sperm DNA (10 mg/mL) 1 mg/mL 100 µL 
BSA (10 mg/mL)  0.1 mg/mL 10 µL 
H2O   890 µL 
 
 
4.10.7. Reverse Transcription 
 
Reverse transcription creates a DNA/RNA-hybrid from a single strand RNA template 
and a RT primer which is necessary to give a starting double stranded region. 
DNA/RNA double strand formation also prevents the formation of tertiary RNA 
structures to avoid the selection of RNA aptamers. 
The following mix I and II were prepared on ice. Mix I was incubated for 10 min at 
42°C prior to addition of mix II. Mix I and II were mixed, and incubated for 50 min at 
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42°C. 2 % of samples before and after the reaction were analyzed by tricine SDS PAGE 
to confirm the DNA/mRNA-protein fusion formation. The sample was desalted on 
pre-equilibrated NAP column. 
 
Reverse transcription reaction mix I (50 µL): 
reagent amount stock resultant 
RT buffer 20 µL 5 x 1 x 
DTT 10 µL 100 mM 10 mM 
dNTP mix 0.8 µL 25 mM 0.2 mM 
Superscript II RT 2 µL 200 U/µL 4 U/µL 
Water 17.2 µL 
 
Reverse transcription reaction mix II (50 µL): 
reagent amount stock resultant 
RT primer 2 µL 100 µM 2 µM 
RNA template x µL x µM 1 µM 
Water y µL 
 
 
4.11. in vitro Selection using mRNA displayed proteins 
 
The approaches for three different selections targeted the small molecules, cibacron blue 
3GA, NADP, and CoA, are depicted in succeeding sections. The former two selections 
applied competitive elution to obtain bound species, while the latter used 
non-competitive elution and cleaving the target molecule from a resin. The percentage 
of bound proteins to the input library proteins were determined from the number of the 
radioactive counts measured by scintillation counting. Theoretically, cycles of selection 
and amplification should be repeated until the proportion of the resultant 
mRNA-displayed proteins in the selected fraction is no longer increasing. 
Approximate input library diversity for the initial selection was estimated from the 
amount of mRNA-displayed proteins after oligo(dT) purification and the yield of 
protein tag affinity chromatography. 
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4.11.1. Selection against Cibacron Blue 3GA 
 
The desalted samples of DNA/mRNA-protein fusion library were diluted at the ratio of 
1:1 with 2 x cibacron blue selection buffer. In the first cycle of the selection, 200 µL of 
cibacron blue 3GA agarose was used. In the subsequent selections, 100 µL of cibacron 
blue 3GA agarose was washed 3 times with 500 µL of 1 x cibacron blue selection buffer, 
and then incubated with mRNA displayed proteins for 1 h at 4°C while shaking. After 
drain for flow through, the remaining agarose was washed with 3 to 30 column volumes 
of cibacron blue selection buffer. The bound molecules were eluted 4 times with 250 µL 
of cibacron blue elution buffer including NAD+ at 4°C for 15 min each while shaking. 
Elution fractions were pooled, and desalted on pre-equilibrated NAP column. 2 % of 
samples from every fraction were analyzed by scintillation counter. 
Desalted samples (through employment of NAP columns) were ethanol precipitated, 
and the resulting pellet was resuspended in 100 µL of water. 20 µL aliquots of this 
solution were used for test PCR (100 µL) to optimize the cycle number for 
amplification of the corresponding DNA fragment. 
 
2 x Cibacron blue selection buffer: 
reagent MW concentration required for 1 L 
Tris 121.14 40 mM 4.84 g 
NaCl 58.44 100 mM 5.84 g 
KCl 74.54 100 mM 7.46 g 
MgCl2 203.30 20 mM 4.06 g 
0.5 M EDTA, pH 8.0  800 µM 1600 µL 
pH was adjusted to 7.5 with NaOH/HCl. 
 
Cibacron blue elution buffer: 
reagent MW concentration required for 200 mL 
Tris 121.14 20 mM 484 mg 
NaCl 58.44 50 mM 584 mg 
KCl 74.54 50 mM 746 mg 
MgCl2 203.30 10 mM 406 mg 
0.5 M EDTA, pH 8.0  400 µM 160 µL 
NAD 663.4 5 mM 665.4 mg 
pH was adjusted to 7.5 with NaOH/HCl. 
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4.11.2. Selection against NADP 
 
The desalted samples of DNA/mRNA-protein fusion library were diluted at the ratio of 
1:1 with 2 x NADP selection buffer. In the first cycle of the selection, pre-selection 
using 200 µL of adipicacid dihydrazide agarose was done to exclude the matrix binders, 
prior to the incubation with 200 µL of NADP agarose. In the subsequent cycles, 100 µL 
of NADP agarose was washed 3 times with 1 mL of 1 x NADP selection buffer, then 
incubated with mRNA displayed proteins for 1 h at 4°C while shaking. After drain for 
flow through, the remaining agarose was washed with 10 to 30 column volumes of 
NADP selection buffer. The bound molecules were eluted 4 times with 250 µL of 
NADP elution buffer including 5 mM of NADP at 4°C for 15 min each while shaking. 
Elution fractions were pooled, and desalted on pre-equilibrated NAP column. 2 % of 
samples from every fraction were analyzed by scintillation counting. 
Desalted samples (through employment of NAP columns) were ethanol precipitated, 
and the resulting pellet was resuspended in 100 µL of water. 20 µL aliquots of this 
solution were used for test PCR (100 µL) to optimize the cycle number for 
amplification of the corresponding DNA fragment. 
 
5 x NADP selection buffer: 
reagent MW concentration required for 1 L 
HEPES 121.14 100 mM 23.83 g 
NaCl 58.44 250 mM 14.61 g 
KCl 74.54 250 mM 18.64 g 
MgCl2 203.30 50 mM 10.17 g 
0.5 M EDTA, pH 8.0  2000 µM 4 mM 
Triton X-100  0.5 % 5 mL 
pH was adjusted to 7.5 with NaOH/HCl. 
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NADP elution buffer: 
reagent MW concentration required for 50 mL 
HEPES 121.14 20 mM 238.3 mg 
NaCl 58.44 50 mM 146.1 mg 
KCl 74.54 50 mM 186.4 mg 
MgCl2 203.30 10 mM 101.7 mg 
0.5 M EDTA, pH 8.0  400 µM 40 µM 
Triton X-100  0.1 % 50 µL 
NADP 787.38 5 mM 196.8 mg 
pH was adjusted to 7.5 with NaOH/HCl. 
 
2 x NADP elution buffer: 
reagent MW concentration required for 20 mL 
5 x NADP selection buffer  8 mL 
NADP 787.38 10 mM 157.5 mg 
 
 
4.11.3. Immobilization of Coenzyme A to Thiopropyl Sepharose 
 
Coenzyme A was coupled to the sepharose via the thiol group. Thiopropyl sepharose 6B 
purchased from Amersham contains reactive 2-thiopyridyl disulphide group attached to 
sepharose through a chemically stable ether linkage. The thiopropyl sepharose reacts 
with thiol groups under mild conditions to form mixed disulphides, and release 
2-thiopyridone which can be detected by its absorbance (absorbance coefficient at 343 
nm = 8.08 x 103 M-1cm-1, this value is approximately equivalent at 260 nm). 
The gel slurry was prepared by recommended procedure from supplier. 500 µL of the 
gel (1000 µL of the slurry) was incubated in 500 µL of TPS buffer containing 0.01 M 
CoA at 4°C overnight. After drain, the gel was washed with TPS buffer until no 
absorbance at 343 nm was observed. Approximate amounts of released 2-thiopyridone 
and non-coupled CoA (absorbance coefficient at 260 nm = 16.4 x 103 M-1cm-1) were 
quantified by spectro-photometrical measuring of absorbance. The non-reacted 
thiopyridyl group on sepharose was removed by incubation at 4°C for 30 min in TPS 
buffer containing 2-mercaptoehtanol. The concentration of 2-mercaptoethanol was 
adjusted to the amount of the remaining thiopyridyl group. The sepharose was then 
intensively washed with TPS buffer to equilibrate the gel, and the column was stored in 
1:1 ratio in TPS buffer. Additionally, the amount of CoA coupled to the sepharose was 
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quantified by eluting CoA from the small amount of the prepared gel (50 µL) with 50 
mM 2-mercaptoethanol in TPS buffer. 
 
TPS buffer: 
reagent MW concentration required for 500 mL 
Tris 121.14 0.1 M 6.06 g 
NaCl 58.44 0.5 M 14.61 g 
0.5 M EDTA, pH 8.0  1 mM 1 mL 
pH was adjusted to 7.5 with NaOH/HCl. 
 
 
4.11.4. Selection against Coenzyme A 
 
The selections targeted coenzyme A were operated in two fashions in parallel; one in 
the absence of guanidine hydrochloride, and the other in the presence of guanidine 
hydrochloride. The aim to make a slightly denaturing condition by adding 0.5 M of 
guanidine hydrochloride in the selection buffer and elution buffer was not only to confer 
better solubility on the proteins but to force to select proteins which are folded stably.  
The desalted samples of DNA/mRNA-protein fusion library were diluted at the ratio of 
1:1 with 2 x CoA selection buffer. In first cycle of the selection, pre-selection using 100 
µL of 2-mercaptoehanol-blocked thiopropyl sepharose was done to exclude matrix 
binders, prior to the incubation with 100 µL of CoA immobilized sepharose. In the 
subsequent cycles, 20 µL of CoA sepharose was washed 3 times with 1 mL of 1 x CoA 
selection buffer, and then incubated with mRNA displayed proteins for 1 h at 4°C while 
shaking. After drain for flow through, the remaining sepharose was washed with 8 
column volumes of CoA selection buffer. The bound molecules were eluted 6 times 
with 500 µL of CoA elution buffer including DTT by cleaving disulfide bond. Elution 
fractions were pooled, and desalted on pre-equilibrated NAP column. 1 % of samples 
from every fraction were analyzed by scintillation counting. 
Desalted samples (through employment of NAP columns) were ethanol precipitated, 
and the resulting pellet was resuspended in 200 µL of water. 5 µL aliquots of this 
solution were used for test PCR (100 µL) to optimize the cycle number for 
amplification of the corresponding DNA fragment. 
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5 x CoA selection buffer: 
reagent MW concentration required for 1 L 
HEPES 121.14 100 mM 23.83 g 
NaCl 58.44 250 mM 14.61 g 
KCl 74.54 250 mM 18.64 g 
MgCl2 203.30 50 mM 10.17 g 
0.5 M EDTA, pH 8.0  2000 µM 4 mM 
Triton X-100  0.5 % 5 mL 
pH was adjusted to 7.5 with NaOH/HCl. 
 
Denaturing CoA selection buffer: 
reagent MW concentration required for 50 mL 
5 x CoA selection buffer  10 mL 
Guanidine HCl 95.33 0.5 M 2.39 g 
 
CoA elution buffer: 
reagent MW concentration required for 50 mL 
5 x CoA selection buffer  10 mL 
DTT 154.3 50 mM 385.8 mg 
 
Denaturing CoA elution buffer: 
reagent MW concentration required for 50 mL 
5 x CoA selection buffer  10 mL 
Guanidine HCl 95.33 0.5 M 2.39 g 
DTT 154.3 50 mM 385.8 mg 
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4.12. Synthesis 
 
All reagents are commercially available and used without further purification. Solvents 
are purchased over molecular sieves (Fluka) and used directly without further 
purification unless otherwise noted. All reactions were conducted under rigorous 
exclusion of air and moisture. Chemical shift (δ) are given in ppm with 
tetramethylsilane as an internal standard, and coupling constants (J) are given in hertz 
(Hz). 
NMR spectra: Bruker (DPX 300, DPX 400 und DPX 500) with the solvent peak as 
internal standard. 
EI-MS: Finningan MAT 95XL. 
FAB MS: Concept 1H using 3-nitrobenzyl alcohol (NBA) as a matrix.  
Flash chromatography: Merck silica gel G60 (230–400 mesh).  
Thin-layer chromatography: Merck precoated plates (silica gel 60 F254).  
 
 
4.12.1. Synthesis of 28F6 
 
(E)-2-(4-p-Nitrobenzamido-3-methylphenyl)-1-o-tolyldiazene (28F6) 
N+
H
N
N N
O-
O
O
CH3
CH3
 
To a solution of o-aminoazotoluene (1) (50 mg, 0.222 mmol) in CH2Cl2 (1 mL), dried 
triethylamine (46.2 µL, 0333 mmol) was added at 0°C. Then, 4-nitrobenzoylchloride (2) 
(45.3 mg, 0.244 mmol) in CH2Cl2 (1 mL) was added to this mixture dropwise at 0°C. 
After stirring at 0°C for 15 min, the reaction mixture was subsequently allowed to warm 
to room temperature, and continued to stir for 4 h. The reaction was quenched with 
saturated NaHCO3 solution, and extracted. The organic phase was washed with brine, 
dried over MgSO4, concentrated, and purified by flash column chromatography (ethyl 
acetate/cyclohexane 1:19 → 1:3) to yield 28F6 (15 mg, 18 %) as a orange solid. 
Rf = 0.54 (ethyl acetate/cyclohexane 1:3); 1H-NMR (400 MHz, DMSO-d6): δ 2.39 (s, 
3H), 2.69 (s, 3H), 7.30-7.45 (m, 1H), 7.43-7.45 (m, 2H), 7.57 (d, J = 7.83 Hz, 1H), 7.66 
(d, J = 8.46 Hz, 1H),  7.78 (dd, J = 8.46, 2.15 Hz, 1H), 7.84 (d, J = 1.77 Hz, 1H), 
8.21-8.23 (m, 2H), 8.37-8.40 (m, 2H), 10.3 (s, 1H); 13C-NMR (100 MHz, DMSO-d6): δ 
 
4. Materials and Methods 
109 
17.1, 18.0, 115.0, 120.2, 123.6, 124.8, 126.6, 126.7, 129.3, 131.2, 131.4, 134.3, 137.5, 
138.8, 140.0, 149.3, 150.0, 150.1, 163.9; MS (EI): 374.1 [M]+ 
 
 
4.12.2. Synthesis of 3E4 
 
2-Chloro-5-nitro-N-(1-phenylethyl)benzamide (5) 
HN
O2N O
CH3
Cl  
To a stirred solution of 1-chloro-5-nitrobenzoic acid (3) (1.01 g, 5.0 mmol) and 
N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.15 g, 6.0 mmol) in 
DMF (10 mL) was added (±)-α-methylbenzylamine (4) (645 µL, 5.0 mmol), and the 
mixture wasstirred at room temperature for 19 h. After the mixture was concentrated in 
vacuo, the residue was diluted in CH2Cl2, extracted with saturated NaHCO3 solution. 
The combined extracts were washed with brine, dried over MgSO4, concentrated and 
purified by column chromatography on silica gel (ethyl acetate/cyclohexane 1:3 → 4:1) 
to yield 5 (526 mg, 35 %) as a white solid. 
Rf = 0.38 (ethyl acetate/cyclohexane 1:3); 1H-NMR (400 MHz, CD3OD): δ 1.57 (d, J = 
6.19 Hz, 3H), 5.26 (m, 1H), 6.40 (d, J = 6.44 Hz, 1H), 7.19-7.34 (m, 5H), 7.49 (d, J = 
8.84 Hz, 1H), 8.10 (dd, J = 8.72, 2.78 Hz, 1H), 8.39 (d, J = 2.78 Hz, 1H); 13C-NMR 
(100 MHz, CD3OD): δ 21.7, 50.2, 125.4, 125.8, 126.5, 128.0, 129.1, 131.6, 136.7, 137.7, 
142.3, 146.8, 163.5; MS (EI): 304.1 [M]+ 
 
5-Nitro-N-(1-phenylethyl)-2-(piperidin-1-yl)benzamide (6)[157] 
HN
N
O2N O
CH3
 
A mixture of 5 (506 mg, 1.66 mmol) and piperidine (197 µL, 1.99 mmol) in dry 
pyridine (5 mL) was refluxed for 24 h. Solvent was removed from the reaction mixture 
by evaporation, and the residue was diluted in CH2Cl2, extracted, and washed with 0.5 
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M HCl (40 mL). The combined extracts were dried over MgSO4, concentrated and 
purified by column chromatography on silica gel (CH2Cl2/ethyl acetate 50:1 → 10:1) to 
yield 6 (518 mg, 88 %) as a yellow solid. 
Rf = 0.25 (CH2Cl2/ethyl acetate 50:1); 1H-NMR (400 MHz, CD3OD): δ 1.32-1.52 (m, 
6H), 1.57 (d, J = 6.82 Hz, 3H), 2.87-2.90 (m, 4H), 5.22-5.29 (m, 1H), 7.15 (d, J = 8.97 
Hz, 1H), 7.22 (tt, J = 7.05, 1.66 Hz, 1H), 7.27-7.35 (m, 4H), 8.13 (dd, J = 8.97, 2.91 Hz, 
1H), 8.81 (d, J = 2.91 Hz, 1H), 9.00 (d, J = 6.57 Hz, 1H); 13C-NMR (100 MHz, 
CD3OD): δ 22.0, 23.6, 25.8, 49.9, 54.6, 120.4, 126.7, 126.8, 127.5, 127.9, 128.8, 129.1, 
143.1, 143.6, 157.4, 164.2; MS (EI): 353.1 [M]+ 
 
5-Amino-N-(1-phenylethyl)-2-(piperidin-1-yl)benzamide (7) 
HN
N
H2N O
CH3
 
6 (493 mg, 1.40 mmol) was dissolved in methanol (7 mL) under an argon atmosphere 
and 10% Pd-C (250 mg) was added. The reaction mixture was subsequently floated 
with hydrogen applying a balloon. After stirring under a hydrogen atmosphere for 24 h, 
the reaction mixture was filtered through celite, and the celite was washed with ethanol, 
methanol, and CH2Cl2. The collected filtrate was evaporated and purified by column 
chromatography on silica gel (CH2Cl2/methanol 30:1 →25:1) to yield 7 (403 mg, 89 %) 
as a yellow solid. 
Rf = 0.29 (CH2Cl2/methanol 25:1); 1H-NMR (400 MHz, CD3OD): δ 1.36 (bs, 4H), 
1.46-1.51 (m, 2H), 1.54 (d, J = 6.95 Hz, 3H), 2.70 (bs, 4H), 3.62 (bs, 2H), 5.23 (tq, J = 
7.07, 6.95 Hz, 1H), 6.63 (dd, J = 8.46, 2.91 Hz, 1H), 6.99 (d, J = 8.46 Hz, 1H), 
7.14-7.34 (m, 5H), 7.53 (d, J = 2.91 Hz, 1H), 11.2 (d, J = 6.44 Hz, 1H); 13C-NMR (100 
MHz, CD3OD): δ 22.2, 23.8, 26.4, 49.2, 55.1, 117.3, 117.9, 118.1, 122.9, 126.5, 127.1, 
128.6, 144.0, 144.1, 144.1, 165.4; MS (EI): 323.2 [M]+ 
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1-(3-(1-Phenylethylcarbamoyl)-4-(piperidin-1-yl)phenyl)-3-(3-chloro-4-fluoro- 
phenyl)urea (3E4)[158] 
HN
N
H
N
H
N O
O
Cl
F
CH3
 
3-Chloro-4-fluorophenylisocyanate (160 µL, 1.29 mmol) and 7 (398 mg, 1.23 mmol) 
were dissolved in dry THF, and stirred at room temperature for 18 h. The mixture was 
concentrated and purified by 2 times of column chromatography on silica gel 
(CH2Cl2/methanol 1:0 →50:1, then ethyl acetate/cyclohexane 0:1 →2:1) to yield 3E4 
(397 mg, 65 %) as a yellow solid. 
Rf = 0.20 (CH2Cl2/methanol 25:1); 1H-NMR (400 MHz, CD3OD): δ 1.35-1.50 (m, 6H), 
1.53 (d, J = 6.95 Hz, 3H), 2.72-2.75 (m, 4H), 5.15 (dq, J = 7.33, 7.01 Hz, 1H), 6.85 (t, J 
= 8.84 Hz, 1H), 7.01-7.05 (m, 1H), 7.15-7.24 (m, 6H), 7.41 (dd, J = 6.57, 2.65 Hz, 1H), 
7.80 (d, J = 2.65 Hz, 1H), 7.95 (dd, J = 8.72, 2.65 Hz, 1H), 8.42 (d, J = 9.09 Hz, 2H), 
11.64 (d, J = 7.33 Hz, 1H); 13C-NMR (100 MHz, CD3OD): δ 22.6, 23.7, 26.3, 49.9, 55.1, 
116.3 (d, 6J = 21.97 Hz), 119.3, 119.4, 120.7 (d, 2J = 18.37 Hz), 121.7 (d, 5J = 5.79 Hz), 
123.1, 125.1, 126.1, 127.0, 127.6, 128.8, 135.9 (d, 4J = 3.00 Hz), 136.6, 142.6, 147.8, 
153.6, 153.9 (d, 1J = 243.86 Hz), 166.3; MS (FAB): 495.2 [M+H]+ 
 
 
4.12.3. Synthesis of 2E10 
 
1-(4-(4-Nitrophenyl)piperazin-1-yl)-2-o-tolylethanone (10)[159] 
N
N
NO2
O
CH3  
To a mixture of o-tolylacetic acid (8) (751 mg, 5.0 mmol) and N-hydroxybenzotriazole 
(1.36 g, 10.1 mmol) in DMF (7 mL) was added a solution of 
N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide hydrochloride (958 mg, 5.0 mmol) in 
DMF (6 mL). The mixture was stirred at room temperature for 2 h, and a solution of 
1-(4-nitrophenyl)piperazine (9) (1.04 g, 5.0 mmol) in CH2Cl2 (4 mL) was added. Then, 
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the resulting mixture was stirred at room temperature for 24 h, and concentrated under 
reduced pressure. The residue was distributed between CH2Cl2 and saturated NaHCO3 
solution. Phases were separated, washed with NaCl, dried over MgSO4, and 
concentrated. The residue was purified by column chromatography on silica gel 
(CH2Cl2/methanol 1:0 →40:1) to yield 10 (1.38 g, 82 %) as a orange solid. 
Rf = 0.23 (CH2Cl2/methanol 50:1); 1H-NMR (300 MHz, CD3OD): δ 2.23 (s, 3H), 
3.24-3.78 (m, 8H), 3.66 (s, 2H), 6.69-6.74 (m, 2H), 7.04-7.13 (m, 4H), 8.02-8.07 (m, 
2H); 13C-NMR (75 MHz, CD3OD): δ 19.9, 38.8, 41.3, 45.3, 47.1, 113.2, 126.1, 126.6, 
127.4, 128.8, 130.7, 133.4, 136.5, 139.3, 154.5, 170.0; MS (EI): 339.1 [M]+ 
 
1-(4-(4-Aminophenyl)piperazin-1-yl)-2-o-tolylethanone (11) 
N
N
NH2
O
CH3  
A mixture of 10 (1.02 g, 3.0 mmol) and 10% Pd-C (500 mg) in ethanol (10 mL) was 
stirred at room temperature for 18 h under a hydrogen atmosphere. Then, the mixture 
was filtered through celite, and the celite was washed with ethanol, methanol, and 
CH2Cl2. The collected filtrate was concentrated and purified by column chromatography 
on silica gel (ethyl acetate/cyclohexane 3:1 →1:0) to yield 11 (796 mg, 86 %) as a 
brawn solid. 
Rf = 0.23 (ethyl acetate); 1H-NMR (400 MHz, CD3OD): δ 2.22 (s, 3H), 2.81 (t, J = 5.12 
Hz, 2H), 2.93 (t, J = 4.93 Hz, 2H), 3.30 (bs, 2H), 3.64 (s, 2H), 3.75 (t, J = 5.24 Hz, 2H), 
6.54-6.58 (m, 2H), 6.68-6.72 (m, 2H), 7.06-7.11 (m, 4H); 13C-NMR (100 MHz, 
CD3OD): δ 19.9, 38.7, 42.1, 46.3, 51.3, 51.6, 116.4, 119.4, 126.4, 127.2, 128.9, 130.5, 
133.8, 136.4, 141.1, 144.0, 169.0; MS (EI): 309.2 [M]+ 
 
1-(4-Nitrophenyl)-3-(4-(4-(2-o-tolylacetyl)piperazin-1-yl)phenyl)urea (2E10)[158] 
N+
N
N
H
N
H
N
O-
OO
O
CH3
2E10
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11 (808 mg, 2.61 mmol) and 4-nitrophenyl isocyanate (450 mg, 2.74 mmol) were 
dissolved in THF/DMSO (28 mL/1.5 mL), and stirred at room temperature for 18 h. 
After removal of THF under reduced pressure, the product was precipitated by addition 
of CH2Cl2, filtered off, washed with CH2Cl2 and ethyl acetate. Column chromatography 
on silica gel (CH2Cl2/methanol 1:0 →30:1) to yield 2E10 (1.01 g, 82 %) as a colorless 
solid. 
Rf = 0.42 (CH2Cl2/methanol 25:1); 1H-NMR (400 MHz, DMSO-d6): δ 2.20 (s, 3H), 3.04 
(t, J = 5.24 Hz, 4H), 3.61-3.64 (m, 4H), 3.72 (s, 2H), 6.90-6.93 (m, 2H), 7.06-7.16 (m, 
4H), 7.31-7.35 (m, 2H), 7.65-7.69 (m, 2H), 8.15-8.18 (m, 2H), 8.65 (s, 1H), 9.31 (s, 
1H); 13C-NMR (100 MHz, DMSO-d6): δ 19.2, 37.4, 41.1, 45.2, 49.0, 49.4, 116.6, 117.2, 
120.0, 125.1, 125.6, 126.4, 129.3, 129.7, 131.1, 134.7, 136.6, 140.7, 146.6, 146.6, 152.0, 
168.6; MS (EI): 473.2 [M]+, 474.2 [M+H]+ 
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6. Appendix 
 
6.1. Abbreviations 
 
AA amino acid 
AIDS acquired immunodeficiency syndrome 
AMV avian myeloblastosis virus 
APS ammonium peroxydisulfate 
ATM ataxia-talengiectasia-mutated 
ATP adenosine 5’-triphosphate 
AZT azidothymidine, zidovudine 
bp base pair(s) 
BSA bovine serum albumine 
cDNA complementary DNA 
Ci curie 
CIAP calf intestine alkaline phosphatase 
CMVp cytomegalovirus promoter 
CoA coenzyme A 
cpm counts per minute 
CTP cytosine 5’-triphosphate 
dATP 2’-deoxyadenosine-5’-triphosphate 
dCTP 2’-deoxycytosine-5’-triphosphate 
DDDP DNA-dependent DNA polymerase 
DEPC diethyl pyrocarbonate 
dGTP 2’-deoxyguanosine-5’-triphosphate 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTP deoxynucleotide triphosphate 
dsDNA double stranded DNA 
DTT dithiothreitol 
E. coli Escherichia coli 
EDAC N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide 
hydrochloride 
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EDTA ethylenediaminetetraacetic acid 
EI electron impact ionization 
FAB fast atom bombardment 
FAD flavine adenine dinucleotide 
FAM 6-carboxyfluorescein 
FRET fluorescence resonance energy transfer 
g gram 
GTP guanosine 5’-triphosphate 
HAART highly active antiretroviral therapy 
HEPES N-(2-hydroxyethyl)-piperazine-N’-2-ethanesulfonic 
acid 
HIV-1 human immunodeficiency virus type-1 
HIV-2 human immunodeficiency virus type-2 
HTS high throughput screening 
kDa kilodaltons 
KF klenow fragment 
L liter 
LTR long terminal repeat 
M molar 
min minutes 
MMLV moloney murine leukemia virus 
mRNA messenger RNA 
MW molecular weight 
NAD nicotinamide adenine dinucleotide 
NADP nicotinamide adenine dinucleotide phosphate 
NMR nuclear magnetic resonance 
NNRTI non-nucleoside RT inhibitor 
NRTI nucleoside analogue RT inhibitor 
NTP nucleotide triphosphate 
OD optical density 
ORF open reading frame 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PNK polynucleotide kinase 
pol β human DNA polymerase β 
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PR protease 
RBE Rev binding element 
RDDP RNA-dependent DNA polymerase 
RNA ribonucleic acid 
RNase ribonuclease 
RNase H Ribonuclease H 
rpm revolutions per minute 
rt room temperature 
RT reverse transcriptase 
SDS sodium dodecyl sulfate 
SELEX systematic evolution of ligands by exponential 
enrichment 
SFFV Spleen focus-forming virus 
SPR surface plasmon resonance 
ssDNA single stranded DNA 
TAMRA 6-carboxytetramethylrhodamine 
Taq thermus aquaticus 
TBE Tris borate EDTA 
TEMED N,N,N’,N’-tetramethylethylendiamine 
THF tetrahydrofuran 
TMV tobacco mosaic virus 
Tris tris-(hydroxymethyl)-aminomethane 
tRNA transfer RNA 
TTP thymidine-5’-triphosphate 
U unit 
UTR untranslated region 
UV ultraviolet 
VSV-G vesicular stomatitis virus G glycoprotein 
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6.2. Amino Acid Codes 
 
Single letter code Three letter code Amino acid 
A Ala alanine 
C Cys cysteine 
D Asp aspartic acid 
E Glu glutamic acid 
F Phe phenylalanine 
G Gly glysine 
H His histidine 
I Ile isoleucine 
K Lys lysine 
L Leu leucine 
M Met methionine 
N Asn asparagine 
P Pro proline 
Q Gln glutamine 
R Arg arginine 
S Ser serine 
T Thr threonine 
V Val valine 
W Trp tryptophane 
Y Tyr tyrosine 
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6.3. Vektor pGEM-T 
 
6.3.1. pGEM-T Vector Circle Map 
 
 
 
 
6.3.2. pGEM-T Vector Sequence 
 
   1  GGGCGAATTG GGCCCGACGT CGCATGCTCC CGGCCGCCAT GGCCGCGGGA 
  51  T*ATCACTAGT GCGGCCGCCT GCAGGTCGAC CATATGGGAG AGCTCCCAAC 
 101  GCGTTGGATG CATAGCTTGA GTATTCTATA GTGTCACCTA AATAGCTTGG 
 151  CGTAATCATG GTCATAGCTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA 
 201  ATTCCACACA ACATACGAGC CGGAAGCATA AAGTGTAAAG CCTGGGGTGC 
 251  CTAATGAGTG AGCTAACTCA CATTAATTGC GTTGCGCTCA CTGCCCGCTT 
 301  TCCAGTCGGG AAACCTGTCG TGCCAGCTGC ATTAATGAAT CGGCCAACGC 
 351  GCGGGGAGAG GCGGTTTGCG TATTGGGCGC TCTTCCGCTT CCTCGCTCAC 
 401  TGACTCGCTG CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT 
 451  CAAAGGCGGT AATACGGTTA TCCACAGAAT CAGGGGATAA CGCAGGAAAG 
 501  AACATGTGAG CAAAAGGCCA GCAAAAGGCC AGGAACCGTA AAAAGGCCGC 
 551  GTTGCTGGCG TTTTTCCATA GGCTCCGCCC CCCTGACGAG CATCACAAAA 
 601  ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC 
 651  CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT 
 701  GCCGCTTACC GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC 
 751  TTTCTCATAG CTCACGCTGT AGGTATCTCA GTTCGGTGTA GGTCGTTCGC 
 801  TCCAAGCTGG GCTGTGTGCA CGAACCCCCC GTTCAGCCCG ACCGCTGCGC 
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 851  CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA CACGACTTAT 
 901  CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA 
 951  GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG 
 1001 AAGAACAGTA TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA 
 1051 AAAGAGTTGG TAGCTCTTGA TCCGGCAAAC AAACCACCGC TGGTAGCGGT 
 1101 GGTTTTTTTG TTTGCAAGCA GCAGATTACG CGCAGAAAAA AAGGATCTCA 
 1151 AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG TGGAACGAAA 
 1201 ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC 
 1251 TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA 
 1301 TGAGTAAACT TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA 
 1351 TCTCAGCGAT CTGTCTATTT CGTTCATCCA TAGTTGCCTG ACTCCCCGTC 
 1401 GTGTAGATAA CTACGATACG GGAGGGCTTA CCATCTGGCC CCAGTGCTGC 
 1451 AATGATACCG CGAGACCCAC GCTCACCGGC TCCAGATTTA TCAGCAATAA 
 1501 ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC 
 1551 GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC 
 1601 GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG 
 1651 TGTCACGCTC GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA 
 1701 TCAAGGCGAG TTACATGATC CCCCATGTTG TGCAAAAAAG CGGTTAGCTC 
 1751 CTTCGGTCCT CCGATCGTTG TCAGAAGTAA GTTGGCCGCA GTGTTATCAC 
 1801 TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT GCCATCCGTA 
 1851 AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA 
 1901 GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA 
 1951 CCGCGCCACA TAGCAGAACT TTAAAAGTGC TCATCATTGG AAAACGTTCT 
 2001 TCGGGGCGAA AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT 
 2051 GTAACCCACT CGTGCACCCA ACTGATCTTC AGCATCTTTT ACTTTCACCA 
 2101 GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA 
 2151 ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCAATA 
 2201 TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG 
 2251 AATGTATTTA GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA 
 2301 AAAGTGCCAC CTGATGCGGT GTGAAATACC GCACAGATGC GTAAGGAGAA 
 2351 AATACCGCAT CAGGAAATTG TAAGCGTTAA TATTTTGTTA AAATTCGCGT 
 2401 TAAATTTTTG TTAAATCAGC TCATTTTTTA ACCAATAGGC CGAAATCGGC 
 2451 AAAATCCCTT ATAAATCAAA AGAATAGACC GAGATAGGGT TGAGTGTTGT 
 2501 TCCAGTTTGG AACAAGAGTC CACTATTAAA GAACGTGGAC TCCAACGTCA 
 2551 AAGGGCGAAA AACCGTCTAT CAGGGCGATG GCCCACTACG TGAACCATCA 
 2601 CCCTAATCAA GTTTTTTGGG GTCGAGGTGC CGTAAAGCAC TAAATCGGAA 
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 2651 CCCTAAAGGG AGCCCCCGAT TTAGAGCTTG ACGGGGAAAG CCGGCGAACG 
 2701 TGGCGAGAAA GGAAGGGAAG AAAGCGAAAG GAGCGGGCGC TAGGGCGCTG 
 2751 GCAAGTGTAG CGGTCACGCT GCGCGTAACC ACCACACCCG CCGCGCTTAA 
 2801 TGCGCCGCTA CAGGGCGCGT CCATTCGCCA TTCAGGCTGC GCAACTGTTG 
 2851 GGAAGGGCGA TCGGTGCGGG CCTCTTCGCT ATTACGCCAG CTGGCGAAAG 
 2901 GGGGATGTGC TGCAAGGCGA TTAAGTTGGG TAACGCCAGG GTTTTCCCAG 
 2951 TCACGACGTT GTAAAACGAC GGCCAGTGAA TTGTAATACG ACTCACTATA 
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6.4. Sequences of Selected Clones from the Ninth Cycle of Cibacron 
Blue Selection 
 
The following shows amino acid sequences cloned after ninth cycle of selection, which 
possessed intact ORFs. (M: the position for possible internal initiation, *: internal stop 
codon) 
 
Type No Amino acid sequence 
αβαβ: 5 SGECFFKNIHSSSYNTVRIPGG SENLNLSLNLNIDVKITVAPGS  
  SGNNPINNLKNISSGLLKVPGS SEEFEINLSIYSTIGLKFGLKPGS 
 8 SGNRALLRLNNSANDLSATPGS SECSSITLDIPIAVAMNMYPES 
  SGNRITKDTKNIIKDSIGSPGS SEEHKIHFEIKLCIKLNMKPGS 
 20 SGNDIMRNMYDLVHETFKIPGS SENLNNALELYFRLSFTIYPGS 
  SGKGLSKDIEELLGKLVVAPGS SEYTYFEIKFK*TLGFNLWPGS 
 21 SGQKILRRVKRTTRRVLDLPGT SEELYLTLQLNLTFNLTLWPGS 
  SGHKILDGFNNSSNCLSSAPGS SEELSFEIKLDITITINFTPGS 
 29 SGNKSIGSMNDIIRYFTNAPGS SEYVELGFKIKFEINFDKAPGS 
  SGNRMVRRFKDMTGWTIDVPGS SEDINFAIDFNLDVDLKMEPGS 
 34 SGNDIVRNMYDLVHETFKIPGS SENLNNALELYFRLSFTIYPGS 
  SGKGLSKDIEELLRKLVGAPGS SEYTYFEIKFKYTLGFNLWPGS 
 37 SGKGSHEYLNGSLNEIFRTPGS SEWLNTCLTLAFAFGVCVTPGS 
  SGNHFSDNTGNIFQDVAGTPGS SEKVTVKSDLTVSIELKLEPGS 
 40 SGNQITDESDQSAGKILLLPGS SEDLGLTFYLNLKLSMEFSPGG 
  SGHSLLNKLDDALESTFGLPGS SEDITIHIHLKFEINVRIEPGS 
 45 SRHGILEESDRFIGHSLNIPGS SEESYLKFEINIDMTLHLNPGS 
  SGQNFIKDASNFIKDTLRTPGS SENLRVNLKL*IALYKHLSPGS 
  49 SGNHTLENAKRLTESIIDPPGS SESIEVALDFEIKFKFTLDPGS 
  SGKHLINKLSDTLSEFINLPGS SEKLPFKLEIDIHLEMSLRPGS 
 50 SGNNMLDNTSWTTHQLISLPGS SEKLYFYLRMKFEINFNLKSGS 
  SGSYTLKNVDETMSNSFRLPGS SETVSINITVKFG*NVSI*PGS 
 52 SGKDSLGRSKKTIKELIDAPGS SECLSITLDIPIAVAMNMYPES 
  SGNSVSKGLYNTSSRLTCIPGS SDRITIKFEINFKLYLTIHPGS 
 53 SGRSSIERLEKLTLMTLNLPGS IEAF*LKLYITVNVHFYITPGS 
  TGQNTMRKARGVLHEI*GMPGS SENLMISI*IMFRLDLYLNPGS 
 68 SGKDVSKNFQDTVDNVSDSPGS SEPLNFSFEIKLNLKFSLSPGS 
  SGQELSGNIQNTVETTLQLPGS SEYRAIDLHFNLNFNLNLEPGS 
 
6. Appendix 
134 
 70 SGNHASKDINRFTRRSFRLPGS SEYINLDAKLYIDVTMRMNPGS 
  SGQDLANNSWNSASRLLDSPGS SGTLTITLASRFTFETNVNPGS 
 72 SGRQLLRSINSTSYNFVVIPGS SENMEFEINFTITINLSLYPGS 
  SGNEITDNLNNLTDNMTRCQRV VSI*PSIYTYG*TSV*I*RQGV 
 77 SGNRIFGDFKQATRSTSGLPGS SEELTMHLDVEITYNKSVAPGS 
  SGHKLLHGINNTLNKSMGTPGS SEYLDLEIPLLFEMRLKLKPGS 
 79 SEQTSGGIKRMFKNSTDSPAS SEHIDVNFEIKLNINLAFGPGS 
  SGQDLINRTRSVSKGTSRLPGS SETLTFYFAFSLGLKLKLPPGS 
βRαβ: 3 SEEIEVGFEIKLNLNIELKPGS SVIALYVKDNSNVIKRKAIMML 
  GGHEITDEISSALSNILSLPGS SEYLHLNFRLQISFTLDFEPGS 
 6 SEAIKLWFEINLELNVGFNSGG SEDGTMMIMEK*VNLSQTQNTR 
  SGNSSVNNSKKAFNKLSRVPGS SEHITLELQINVGLNVAMPPGS 
 10 SEEIEVGFEIKLNLNIELKPGS SVIALYVKDNSNVIKRKAIMML 
  SGHEITDEISSALSNILSLPGS SEYLHLNFRLQISFTLDFEPGS 
 15 SENFSFEIKPRFEMTFWIHPGS SEYFLD*DRLSCILDLNVTASL 
  SGQRSSEEFGNLINRVTELPGS SEYIDPQLTLCFNVKMNFEPGS 
 36 SEYLNLSINFSFEIKLDMDLES S*AEHE*LMFINHLLVHKEIKI 
  SGNKLADNLRQITGYTINLPGS SENLSLTFEINVNIKLYLKPGS 
ααββ: 1 SGRKSSNEVKNMFEELTNLPGS SGQDSLRKTRYSSKNIINLPGS 
  SDDIDISLNFQINMDLKFWPES SEKLTVTFEINIQLNFEVSPGS 
 4 SGQGSLGRIEDLIRNTINLPGS SGNETINRSWNTSNKATDMPGS 
  SEKFHVGIDIRFEINLNFGLGS SEELALALKLRLTLNPPVSPGS 
 42 SGRNALKKTHNTSQNSLNVPGS SGKDATNGVDNAVSKILSLPGS 
  SEKLKISVEITFRFSIELGPGS SEGLTLNIKLNLNVKLTIKPGS 
 62 SGRNALKKTHNTSQNSLNVPGS SGKDATNGVDNVVGKILSLPGS 
  SEKLKISVEITFRFSIELGPGS SEGLTLNIKLNLNVKLTIKPGS 
 65 SGNNSSGEIYHVSSELINSPGS SVHYSVGDSRDMI*STTGSPGS 
  SENLALYFEIKFKLNIDLSPGS SENINLSISVTLSLSLKITPGS 
 69 SGNHMMNETDKTSDSIVKIPGS IGQGLIKNISDTISSLISAPGS 
  SEYFSLSITFSVDVEIGLKPGG SENIKLNFEIKFNLKFRLGPGS 
ββββ: 22 SENINLYFWFYFNISFSLAPGS SEKFYLALELSFEIKFSQKPGS 
  SDRLEMEISMKVYLSISFNPGS SENLKIKIKIAIEMNLNLRPGS 
 33 S*TITLSLKLRFEINLKLNPGS SENLHMEIDIKIKIDMPINPGS 
  SEHLWLNICLSIRLDLALSPGS SECFDFKLDLKLRMTLTLTPGS 
 58 SEALKTTLRIGIHVDMGIELGS SEAEHE*LMFINHLLVHKEIKI 
  SGNKLADNLRQITGYTINLPGS SVELSFEIKLNFNLAIKVNPGS 
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αααα: 35 SGDNFTQYFKSFSNEILEIPGS SGNNIGNDSDKSSLQLIK*PGS 
  SGKNTTHNANDILSSAIWVPRS SGNDSMNNLQNTSERAMPGS 
βRRα: 39 SETSWFEINLKFQLRLDLSPGS SVKRNLIDDR*DGDKNPIQKVM 
  SAAPQVSIRGVPRYVGEKHTTV SGKGFSSEVEGSTDRLINSPGS 
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